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inTroducTion
endocrine disruption - causes for concern
In 1996, with the publication of Our Stolen Future by Theo Colborn and co-authors, many 
people heard for the first time about the existence of endocrine disruptors and that these 
chemicals could affect health of humans and wildlife. Since then public concerns regarding 
the possible harmful effects posed by endocrine-disrupting chemicals (EDCs) has grown. As 
a consequence, the U.S. Congress passed two laws affecting the regulation of pesticides and 
other chemicals in 1996. Both of these laws, the Food Quality Protection Act 1 and the Safe 
Drinking Water Act, 2 mandated that the Environmental Protection Agency (EPA) implements 
the Endocrine Disruptor Screening Program (EDSP) to test the possible endocrine disruptive 
effects of approximately 87,000 individual chemical substances. The mandate mainly dealt 
with compounds exhibiting estrogenic activity, although other hormone disrupting effects 
(e.g., disruption of androgen or thyroid hormone activity) were considered as well.
An endocrine-disrupting compound was defined by the U.S. EPA as “an exogenous 
agent that interferes with the production, release, transport, metabolism, binding, 
action, or elimination of natural hormones in the body responsible for the maintenance 
of homeostasis and the regulation of developmental processes”. The group of molecules 
identified as endocrine disruptors is highly heterogeneous and includes pharmaceuticals 
like diethylstilbestrol (DES), industrial by-products and pollutants like dioxins and 
polychlorinated biphenyls (PCBs), dichlorodiphenyltrichloroethane (DDT) and other 
pesticides, fungicides like vinclozolin and plasticizers such as bisphenol A. Although most 
of the endocrine-disrupting chemicals identified to date have a weak activity compared with 
their endogenous counterparts, they can be present in significant concentrations in human 
and animal food or in the environment. In addition, most of these chemicals have a strong 
tendency to bioaccumulate in different organisms. Exposure to chemicals that can act as 
hormones is not confined to those of industrial origin: some natural compounds can mimic 
the effects of estrogens and thus might act as EDCs too. Phytoestrogens (e.g., genistein and 
coumestrol), generally thought to have relatively low binding affinity to estrogen receptors 
(ERs), are widely consumed and are components of infant formula. 3, 4 A recent study reported 
that urinary concentrations of the phytoestrogens genistein and daidzein were about 500-fold 
higher in infants fed soy formula compared with those fed cow’s milk formula. 5 Therefore, 
the potential adverse health effects of phytoestrogens need to be considered. Fungi can also 
produce estrogenic substances, e.g., zearalenone and its derivatives, which are found in a 
number of cereal crops and food products derived from them. 6, 7 The natural estrogens, 
17ß-estradiol (E2), estrone (E1) and estriol (E3) and the synthetic estrogen used as main 
active ingredient in oral contraceptive pills 17α-ethinyl estradiol (EE2), have also been shown 
to contaminate the aquatic environment. 8, 9 As these substances are not completely removed 
with conventional wastewater treatment processes, there is increasing pressure to further 
develop and apply advanced methods for municipal wastewater treatment, such as ozonation 
and activated carbon treatment. 10, 11 Many of the substances listed above have estrogenic, 
androgenic, antiestrogenic, antiandrogenic or thyroid hormone-like activities. Moreover, 
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the same substance often has more than one of these properties. For example, bisphenol 
A may act both as an estrogen receptor agonist and an androgen receptor antagonist, 12-14 
while dioxin-like chemicals appear to have even more complicated effects, i.e., not only by 
the aryl hydrocarbon receptor (AhR), but also on the function of steroid hormones and 
thyroid hormones. 15-17 Furthermore, some substances are broken down or converted into 
metabolites that are even more potent than the parent compound, or into substances with 
other disturbing properties. For instance, the estrogen agonist DDT is metabolized into the 
androgen antagonist DDE, both in rodents and humans. 18, 19
In recent years, our understanding of the mechanisms by which endocrine disruptors exert 
their effect has increased. EDCs were originally thought to exert their actions primarily through 
activation of nuclear hormone receptors, including estrogen receptors (ERs), androgen receptors 
(ARs), thyroid receptors (TRs), progesterone receptors (PRs), glucocorticoid receptors (GRs), 
and retinoic acid receptors (RARs), among others. Today, basic endocrinology studies show 
that the mechanisms are much broader than originally recognized, as EDCs also act via e.g. 
membrane receptors, neurotransmitter receptors (such as the serotonin receptor, dopamine 
receptor and norepinephrine receptor), the enzymatic pathways involved in steroid biosynthesis 
and/or metabolism, and numerous other mechanisms that may affect endocrine and 
reproductive systems. 16, 20 EDCs thus encompass agents that cause alterations in reproduction 
or development through direct or indirect effects on the vertebrate hypothalamic–pituitary–
thyroidal (HPT) or hypothalamic–pituitary–gonadal (HPG) axes.
A great number of laboratory and field studies have shown that the exposure to EDCs can 
cause developmental, reproductive, neural, immune, and other problems in a range of animals, 
and these compounds have been hypothesized to elicit similar responses in humans and 
wildlife. 21 These effects include feminization, altered sex ratios and intersex gonads in frog and 
fish, 22, 23 egg-shell thinning in birds induced by DDT, 18 increased tumor formation in rats, 24 and 
impairment of immune function in seals caused by PCBs. 25 There is also evidence that exposure 
to EDCs can decrease sperm quality and semen volume, increase the number of testicular germ 
cells and the incidence of hormone-dependent cancers. 16 However, considerable scientific 
uncertainty remains regarding the causes of these reported effects. EDCs may not only affect the 
exposed individual, but also the children and even subsequent generations. Diethylstilbestrol 
(DES) is a good example, showing clear effects both during embryonic development and in 
adult life of exposed offspring. DES is an orally active synthetic estrogen that was frequently 
prescribed to pregnant women in the 1940s to 1960s to prevent spontaneous abortion. 
However, later, better-controlled studies showed no benefit, 26 and in 1971 in utero exposure 
was found to be associated with a greatly increased risk of clear cell carcinoma of the vagina 
and cervix in first generation female offspring, known worldwide as the problem with the DES 
daughters. 27 Subsequently, DES treatment was found to be associated with an increased risk of 
breast cancer in women who took the drug, namely the mothers, 28 and the latest results suggest 
that DES daughters also have an increased risk of breast cancer after the age of 40 years. 29 
Even the fertility of men exposed to DES before birth has been investigated and several studies 
have shown a misplaced opening of the penis (hypospadias), epididymal cysts (non-cancerous 
growth on the testicle), and undescended testicles (cryptorchidism) in first generation male 
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offspring. 30, 31 In adult men taking DES, the drug has been shown to cause gynaecomastia. 32, 33 
In view of these overt adverse effects of EDCs, it is necessary to consider EDCs as substances of 
concern equivalent to carcinogens, mutagens and reproductive toxicants, as well as persistent 
and bioaccumulative toxic chemicals. 34
current edc screening programs and strategies
Due to the possible adverse effects of EDCs, national governments and international 
regulatory authorities are in the process of establishing testing programs and strategies 
to assess the safety of currently used chemicals. One of the leading and the first national, 
legally-binding programs is the EDSP of the U.S. EPA, which employs a two-tier screening 
program consisting of a battery of in vitro and in vivo screening assays to gather information 
needed to identify endocrine-active substances. The Tier 1 battery assesses the potential of a 
chemical to interact with the endocrine system via estrogen- and androgen-mediated effects, 
i.e., receptor binding, transcriptional activation, steroidogenesis, and HPG axis feedback 
(Table 1). In addition, in vivo rodent pubertal and amphibian metamorphosis assays were 
included to detect direct and indirect effects on the HPT axis. These in vitro and in vivo 
assays are designed to complement one another, therefore the robustness and specificity 
of the current Tier 1 battery is based on the strengths of each individual assay and their 
complementary nature. However, conducting all of the 11 EDSP Tier 1 tests would require 
a minimum of 520 animals and the current costs are reported to range between $335,100 
and $964,250 per chemical. 35, 36 Once a chemical is identified as a potential EDC in Tier 
1 screening, EPA will require further testing in the Tier 2 screening, e.g., a reproductive 
toxicity test in rodents encompassing one or more generations. However, to date, no definite 
decisions have been made regarding the specific tests to be included into the Tier 2 testing 
stage. With the vast number of chemicals potentially targeted for testing under the current 
five-year time horizon of the EDSP Comprehensive Management Plan, 37 prioritization of 
chemicals to enter Tier 1 screening and replacing validated in vivo Tier 1 assays with effect-
based validated in vitro high-throughput assays are essential. Furthermore, EPA also works 
together with the Organisation for Economic Co-operation and Development (OECD) 
to set international standards on the safety of chemicals, and issues OECD guidelines for 
the testing of chemicals. They have defined test guidelines (TG) e.g., the Uterotrophic 
Bioassay for testing estrogenic properties (TG 440), the Hershberger Bioassay for testing 
(anti-)androgenic properties (TG 441) and the in vitro H295R assay for testing effects on 
steroidogenesis (TG 456). The OECD has also amended and validated its test guideline for 
repeated-dose 28-day oral toxicity studies in rodents (TG 407) to include endpoints relevant 
to the thyroid system, including histopathology of the pituitary and thyroid, and thyroid 
weight. However, the TG 407 in most cases failed to identify endocrine active substances that 
weakly affect estrogen or androgen receptors. Thus, characterization of potential endocrine 
activity of a substance should not be based on this TG alone, but its results should be used in 
a weight of evidence approach incorporating all existing data.
To date, no mandatory testing programs for endocrine disruption such as U.S. EPA’s EDSP 
exist in Europe. However three pieces of European Community legislation deal explicitly with 
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endocrine disrupters: The Plant Protection Product Regulation 1107/2009; 38 The Biocidal 
Products Directive 98/8/EC, 39 and most importantly, the European Community regulation: 
Registration, Evaluation, Authorization and Restriction of Chemical substances (REACH; EC 
1907/2006) and their safe use. 40 Specifically, REACH requires all substances that are marketed 
in the European Union (EU) at more than one tonne per year to be registered by presenting an 
extensive dossier to the European Chemical Agency (ECHA). A recent report by Rovida and 
Hartung claims that the total number of animals and costs to accomplish REACH legislation 
requirements for reproductive toxicity testing can increase up to 48.6 million experimental 
animals and 6.9 billion euro, respectively, if growth of the EU and its chemical industry is taken 
into account, and the current test guidelines are strictly followed. 41 One way to reduce the use of 
laboratory animals could obviously be replacing in vivo tests with in vitro alternative methods. 
So far, the EU has invested more than 200 million dollars into the development of alternative 
methods by funding respective research, 42 apart from the funding at the national level by the 
Member States themselves. In addition, The U.S. Interagency Coordinating Committee on the 
Validation of Alternative Methods (ICCVAM), the National Toxicology Program Interagency 
Center for the Evaluation of Alternative Toxicological Methods (NICEATM), and the European 
Commission for the Validation of Alternative Methods (ECVAM) are also concerned about 
possible effects of known and yet unknown EDCs, and have closely cooperated and conducted 
studies to develop and validate new test methods for EDC testing. Moreover, to undertake the 
investigation of high production volume (HPV) chemicals in a co-operative way, the OECD 
Cooperative Chemicals Assessment Programme was established, addressing challenges such 
as: assessing more chemicals in a shorter time period, addressing all chemicals on the market 
and avoiding duplication with work going on in other countries. In order to meet these goals 
and fulfil the 3R principle of Refinement, Reduction and Replacement of animal testing, OECD 
expert panels on non-animal testing have set up and approved the validation of the in vitro 
ERα-HeLa-9903 (TG 455) and BG1Luc ER (TG 457) transcriptional activation (TA) assays for 
estrogenicity testing. 43, 44 The present thesis focusses on developing an in vitro integrated test 
system (ITS) for estrogenicity. In the next sections, the in vivo uterotrophic bioassay and in 
vitro assays based on different steps in the estrogen receptor-dependent signal transduction 
pathway, will be discussed in some more detail.
uterotrophic Bioassay
Presently, the standard test for disruption of normal estrogen function is the Allen and Doisy 
test, an uterotrophic assay in immature or ovariectomised rodents with uterus weight as a 
crucial read-out parameter. 45, 46 The uterotrophic assay is a short-term screening test that 
originated in the 1930’s 47, 48 and was validated through a 4-year international validation 
program starting from July 2009 under the auspices of the OECD. 49 The biological and 
scientific basis for the uterotrophic assay is the central role of endogenous estrogens in 
the natural estrous cycle. The endogenous steroidal estrogens control cell division for the 
tissues of the female reproductive tract, i.e., the uterus, cervix, and vagina, resulting in easily 
measurable levels of tissue growth. In rodents like mice and rats, this tissue growth response 
takes place within a period of approximately two days and the entire cycle of growth and 
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regression is complete in 4-5 days. The time-frame for conducting the uterotrophic assay 
roughly corresponds to this time, and the assay measures increases in uterine tissue weight 
after 3 consecutive days of test substance administration. The uterotrophic assay relies for its 
sensitivity on an animal test system in which the hypothalamic-pituitary-ovarian axis is not 
functional, leading to low homeostatic regulation against exogenous estrogenic stimuli. 50 
When the animal is immature or ovariectomised, it lacks its main natural source of estrogens 
and also the feed-back response upon the administration of exogenous estrogenic compounds 
through the HPG axis is absent (when ovariectomised) or has little effect (when immature). 
As a result, the uterus becomes sensitive to external sources of estrogens. Subsequently, when 
exposed to an estrogenic substance the animals’ uterus will increase in weight as a result 
of the absorption of fluid and cell proliferation induced by the administered estrogen. For 
animal welfare reasons preference should be given to the method using immature rodents, 
avoiding surgical pre-treatment of the animals. The uterotrophic assay also presents the 
opportunity to assay estrogen antagonists, however, its use for antagonist detection is much 
less common than for agonists. To detect estrogen antagonists, a potent reference estrogen 
(e.g., EE2) in a dose causing a submaximal response is co-administered with the test 
substance and the response is compared to a control group given reference estrogen-only. 
The mean uterine weight of the test substance groups relative to the reference estrogen-only 
group is assessed for a statistically significant alteration. A statistically significant decrease in 
uterine weight indicates that the test substance has an ability to reduce or block the action of 
portent estrogens, and, therefore, is considered to be a potential antiestrogen. 51
The main advantage of the in vivo uterotrophic assay is, that it determines an overall 
biological effect by allowing for interactions between cells and between different components 
of the endocrine system, thereby being able to detect complex modes of action that may 
occur only in the intact animal. In addition, it takes account of the absorption, distribution, 
metabolism and elimination (ADME) parameters of the test chemicals. The uterotrophic 
assay has been extensively employed in pharmaceutical research within the drug discovery 
process for over 60 years. However, the current intended application of the uterotrophic 
assay is shifting from potent pharmacological substances to the identification of far less 
potent estrogen agonists and antagonists for large-scale regulatory chemical screening 
programs, e.g., REACH. Due to the fact that the in vivo methods are in general expensive, 
labour-intensive, time-consuming, and for obvious ethical reasons, this animal test is not 
suitable for routine high-throughput screening purposes. Several in vitro assays have been 
developed to determine the potential estrogenic activities of compounds corresponding 
to the different steps in the estrogen receptor-dependent signal transduction pathway. The 
cellular mechanism of action of estrogens is discussed in the next section.
cellular mechanism of action of estrogens
Estrogens are steroid hormones that are primarily biosynthesized in the female ovaries. 
Estrogens influence the growth, differentiation and function of many target organs, such as 
mammary gland, uterus, ovary, vagina, as well as testis and prostate. 52, 53 They also play a role 
in bone maintenance, the central nervous system and the cardiovascular system. 54 Estrogens 
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exert their physiological effects mainly through activation of the nuclear ER in target cells, 
exerting its effect through upregulation of the transcription of estrogen-responsive element 
(ERE)-controlled genes. Part of the effects of estrogens is also thought to be mediated by 
plasma membrane-associated ERs. Although two main forms of the ER exist, ERα and ERβ, 
in (reproduction) toxicology the main attention goes out to the nuclear ERα, as activation of 
nuclear ERα is the driving force behind the uterus response in the uterotrophic assay and ERα 
knockout animals have an irresponsive uterus. 52 Moreover, the focus on ERα, with respect to 
regulatory purposes, is because in contrast to ERβ, binding and activation of ERα is implicated 
as a key molecular initiating event (MIE) in estrogenicity-related adverse endpoints. 44
ERs consist of several distinct functional regions (A-F; Figure 1). The A/B region located 
in the N-terminal part of the protein encompasses the activation function 1 (AF-1) domain 
responsible for ligand-independent transactivation. The most conserved domain among ERs 
is the DNA-binding domain (DBD) corresponding to the C region, which is responsible for 
binding to a specific DNA sequence, called ERE, in gene promoter regions. The C-terminal 
protein part (E/F region) includes the ligand-binding domain (LBD) together with the ligand-
dependent transactivation domain AF-2. 53 The nuclear ERα and ERβ, like all members of 
the nuclear receptor (NR) super-family, are ligand-dependent transcription factors that 
work in concert with transcriptional coregulators to control target gene transcription. The 
unoccupied ER is found in the cytoplasm (Figure 2). Upon ligand binding, the LBD undergoes 
a conformational change that leads to receptor dimerization, translocation of the ER from the 
cytoplasm into the nucleus, and binding to estrogen-responsive elements. Moreover, as a result 
of the intramolecular conformational changes induced by ligand binding, the affinity of the 
Figure 1. Schematic representation of the domain structure of the estrogen receptors, ERα and ERβ. 
The percentage of amino acid homology between regions A-F in ERα and ERβ is indicated by the 
numbers. Adapted from: Klinge, 2000. 55
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ER for coregulator proteins is changed resulting in recruitment or release of transcriptional 
coactivator or corepressor proteins, respectively, that enhance or repress interaction of 
RNA polymerase II with estrogen-responsive gene promoters needed to actually induce or 
repress transcription of target genes. 55, 56 However, it is also possible that chemicals elicit 
their estrogenic effects through mechanisms that are not directly mediated by the ER, e.g., 
alteration of the hormonal steroidogenic pathway or cross-talk between ER and growth factor 
signaling, such as insulin-like growth factor-1 and epidermal growth factor. 53
in vitro bioassays for the detection of estrogen (ant)agonist
Due to the great variety of chemicals with estrogenic properties, both immunochemical and 
analytical chemical methods have the drawback that they are only able to detect structurally 
related compounds or target compounds already identified to be estrogenic and are not 
able to detect biological activity of unknown compounds and their metabolites. This is in 
contrast to biological assays which are based on the molecular or cellular mechanism of 
action of estrogens, and thus can detect unknown compounds with estrogenic activity. 
Many in vitro assays have been developed to determine the potential estrogenic activities of 
compounds corresponding to the different steps in the estrogen receptor-dependent signal 
transduction pathway, e.g., ER binding, ER-controlled reporter gene expression or other 
downstream events such as estrogen receptor-mediated cell proliferation. These in vitro 
assays were recently reviewed by Bovee and Pikkemaat, showing that every assay type has 
its own specific advantages and disadvantages. 57
In vitro ER competitive binding assays have been well established and extensively used to 
investigate ER-ligand interactions. ER competitive binding assays measure the displacement 
Figure 2. Schematic representation of the mechanism of action of estrogens. 
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of a receptor-bound probe molecule by a test compound, allowing to determine the relative 
binding affinity of the test compound as a ligand of the ER. Conventional ER binding assays 
are rapid and easy to perform. However, one of the main drawbacks is that these assays 
are unable to distinguish receptor agonists from receptor antagonists. Moreover, the rat 
uterine cytosol ER binding assay, currently listed as part of the Environmental Protection 
Agency (EPA) Endocrine Disruptor Screening Program Tier 1 screening battery, still 
requires the use of animals as a source of ERs. Although studies using a surface plasmon 
resonance biosensor technology-based receptor binding assay have shown that agonists and 
antagonists exhibited very different association kinetics for the ER, 58 the use of such a 
binding assay to detect estrogen antagonists, still has to be proven and validated using a 
larger set of compounds.
Reporter gene assays (or transcriptional activation assays), based on stably transfected 
cells (either mammalian or yeast cells), provide a more specific endpoint measurement, 
i.e., are based on the estrogen receptor-mediated mechanism of gene transcription 
activation. 59 These reporter-gene assays measure the induction of a reporter gene, the 
expression of which is easy to quantify and is put under transcriptional control of one or 
more EREs and therefore depends on the level of activation of the estrogen receptor. To 
date, two reporter gene assays have been validated by OECD and are being proposed for 
screening and prioritization purposes, i.e., the ERa-HeLa-9903 cell line, derived from a 
human cervical tumor, and the BG1Luc ER TA assay using the human ovarian BG1Luc-
4E2 cell line. 43, 44 These reporter gene assays are used to identify chemicals that activate 
the ER following ligand binding, after which the receptor-ligand complex binds to EREs 
and activates the expression of the reporter gene, resulting in increased cellular expression 
of a marker enzyme (e.g. luciferase). In the presence of the substrate luciferin, the enzyme 
luciferase will use the energy from ATP to oxidize luciferin and release photons. The emitted 
light can be quantitatively measured with a luminometer. In addition to the OECD-validated 
reporter gene assays, several other reporter gene assays have been developed and applied 
as screening tools to determine the estrogenic/anti-estrogenic activities of compounds and 
have been shown to produce relevant and reliable outcomes. 60-62
Proliferation assays have also been shown to provide valuable tools for estrogenicity 
testing. The E-screen is a proliferative assay based on the human MCF-7/BOS breast cancer 
cell line and is widely used as a screening tool to detect environmental and xenobiotic 
estrogens. 63, 64 However, crosstalk can occur due to the fact that MCF-7/BOS cells also 
express androgen, progesterone, glucocorticoid and retinoid receptors, which are also 
known regulators of cell proliferation. 65
As discussed above, the estrogenic effect of a chemical can be due to direct activation 
of ER but can be also due to alteration of normal hormone levels by affecting hormone 
biosynthesis, transport, or metabolism. The H295R steroidogenesis assay recently validated 
by the OECD provides an in vitro methodology to evaluate the potential interference of 
exogenous compounds with endogenous steroid hormone synthesis. 66 Compared to in vivo 
testing, the H295R steroidogenesis assay is one of the most complete and simple in vitro assays, 
since it is based on the human H295R adrenocarcinoma cell line which expresses all key 
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enzymes and can synthesize all steroid hormone precursors involved in adrenal and gonadal 
steroidogenesis. Moreover, regulation of steroidogenesis and hormone secretion patterns in 
H295R cells highly reflect those of freshly isolated adrenal cells.67, 68 However, the current 
OECD-approved protocol of the H295R steroidogenesis assay only measures testosterone (T) 
and estradiol (E2) levels after exposure to a test chemical and results of the assay are expressed 
as relative changes in hormone production compared with the solvent controls. Thus, this 
assay can only provide a YES/NO answer with regard to the potential of a chemical to induce 
or inhibit the production of T and E2 and does not provide specific mechanistic information 
concerning the interaction of the test substance with the endocrine system. 66
ouTline of TheSiS
To date, more than one hundred different in vitro assays have been described for the screening 
of estrogenic compounds. 69 However, there is as yet no single standalone or a panel of in 
vitro assay defined for replacement of the in vivo uterotrophic assay for estrogenicity testing. 
The aim of the research described in this thesis was to develop an integrated testing strategy 
(ITS) based on existing and newly developed in vitro assays for estrogenicity, allowing 
easy high-throughput screening and prioritization of chemicals, thereby contributing to 
reduction and ultimately replacement of current animal testing for estrogenic effects.
To reach this aim, several presently available and newly developed in vitro bioassays were 
selected and evaluated for optimal representation of the (anti)estrogenic effects occurring 
in the uterus/endometrium in vivo. These assays cover a broad range of endpoints and 
measure different steps in the estrogen-signaling pathways (i.e., receptor binding, receptor-
coregulator binding, reporter-gene transcriptional activation, targeted gene expression, 
and cell proliferation). Chapter 2 presents studies investigating the predictive value of ER-
controlled cell proliferation assays for the in vivo uterotrophic effect. Four cell lines derived 
from three different estrogen-sensitive female tissues, i.e., breast (MCF-7/BOS and T47D), 
endometrial (ECC-1) and ovarian (BG-1) cells, were investigated using a series of reference 
compounds in order to select a possible candidate for the in vitro test battery that shows 
the best correlation with in vivo outcomes. In chapter 3, the suitability of reporter gene 
assays for being part of an integrated in vitro testing strategy for the detection of estrogenic 
activity was studied. To this end, a set of reference compounds was chosen and tested in a 
battery of reporter gene assays in order to determine which assay most accurately predicts 
the uterotrophic effect observed in vivo. In chapter 4, a newly developed low-density DNA 
microchip, which contains probes for 11 different estrogen-responsive marker genes, was 
evaluated for the detection of estrogenic compounds and their relative potencies. Chapter 5 
presents the results of a 155-plex high-throughput in vitro coregulator binding assay for 
estrogenicity testing. Using this coregulator binding assay the ligand-modulated interaction 
of coregulators with ERα was assessed for a series of selected reference compounds and 
results obtained were correlated with results obtained in the OECD validated BG1Luc ER 
TA assay and in vivo uterotrophic assay. In chapter 6, the reproducibility and robustness 
of the coregulator binding assay was investigated by assessing the binding profiles of a set 
18
1IN
TRO
D
U
C
TIO
N
of model compounds, listed in the U.S. EPA endocrine disruptor screening program test 
guideline (OPPTS 890.1300). Chapter 7 describes an integrated in vitro testing panel for 
estrogenicity. This panel contains assays selected from previous chapters, but also includes 
in vitro assay for testing antiandrogenic properties and effects on steroidogenesis that 
might potentially also result in estrogenic or estrogen-like effects in vivo. Finally, chapter 8 
summarizes and discusses the results of the present thesis and provides future perspectives 
on endocrine disruption testing.
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ABSTrAcT
Proliferation assays based on human cell lines are the most used in vitro tests to 
determine estrogenic properties of compounds. Our objective was to characterise to 
what extent these in vitro tests provide alternatives for the in vivo Allen and Doisy 
test, a uterotrophic assay in immature or ovariectomised rodents with uterus weight 
as a crucial read-out parameter. In the present study four different human cell lines 
derived from three different female estrogen-sensitive tissues, i.e. breast (MCF-7/
BOS and T47D), endometrial (ECC-1) and ovarian (BG-1) cells, were characterised 
by investigating their relative ERα and ERβ amounts, as the ERα/ERβ ratio is a 
dominant factor determining their estrogen-dependent proliferative responses. All 
four cell lines clearly expressed the ERα type and a very low but detectable amount 
of ERβ on both the mRNA and protein level, with the T47D cell line expressing the 
highest level of the ERβ type. Subsequently, a set of reference compounds representing 
different modes of estrogen action and estrogenic potency were used to investigate 
the proliferative response in the four cell lines, to determine which cell line most 
accurately predicts the effect observed in vivo. All four cell lines revealed a reasonable 
to good correlation with the in vivo uterotrophic effect, with the correlation being 
highest for the MCF-7/BOS cell line (R2 = 0.85). The main differences between the 
in vivo uterotrophic assay and the in vitro proliferation assays were observed for 
tamoxifen and testosterone. The proliferative response of the MCF-7/BOS cells to 
testosterone was partially caused by its conversion to estradiol by aromatase or via 
androstenedione to estrone. It is concluded that of the four cell lines tested, the 
best assay to include in an integrated testing strategy for replacement of the in vivo 
uterotrophic assay is the human MCF-7/BOS breast cancer cell line.
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inTroducTion
Reproduction toxicology is an important field of chemical hazard characterisation and 
management and in the light of REACH many compounds need to be investigated. Presently, 
the standard test for disruption of normal estrogen function is the Allen and Doisy test, a 
uterotrophic assay in immature or ovariectomised rodents with uterus weight as a crucial 
read-out parameter. 1, 2 The main advantage of the Allen and Doisy test is that it determines 
an overall biological effect by allowing for interactions between cells and between different 
components of the endocrine system thereby being able to detect complex modes of action 
that may occur only in the intact animal. However, this assay is labour-intensive, expensive 
and use of laboratory animals may raise ethical concerns. There are many alternative in 
vitro assays to determine the potential hormonal activities of compounds. These alternative 
in vitro assays were recently reviewed by Bovee and Pikkemaat, 3 showing that every assay 
type has its own specific advantages and disadvantages. From the cell-based assays, reporter 
gene assays based on either mammalian or yeast cells and proliferation assays based on 
human cell lines are among the most used. The E-screen is a proliferative assay based 
on the human MCF-7/BOS breast cancer cell line and has been used to determine the 
estrogenic characteristics of pesticides and alkyl phenols. 4, 5 However, the E-screen has 
certain drawbacks due to the fact that the MCF-7 cells also express androgen, progesterone, 
glucocorticoid and retinoid receptors. This may compromise drawing straightforward 
conclusions from the assay results when testing compounds for anti-estrogenicity or when 
testing complex mixtures or sample extracts for estrogenicity, which are able to activate 
these receptors, as it has been shown that androgens, progestins, and glucocorticoids can 
antagonise estradiol induced cell proliferation. 3, 6 In addition, breast cancer cell lines often 
respond differently to estrogens and anti-estrogens compared to endometrial cell lines, and 
even between different breast cancer cell lines the response to estrogens and anti-estrogens 
may be different. 3 A well-known example of a compound that displays different estrogen 
signaling activities in different cell models is the selective estrogen receptor modulator 
(SERM) tamoxifen. This compound is mainly known from its anti-proliferative effect on 
human breast cancer cells and its estrogenic effect in the in vivo uterotrophic assay, which 
is considered the gold standard for estrogenicity testing. Tamoxifen not only suppresses the 
growth of estrogen sensitive breast cancer cells, e.g. MCF-7 and MDA-MB-134, but is also 
able to induce proliferation in the E-screen, however, not in the MDA-MB-134 cell line. 7, 8
In the present study a set of reference compounds was chosen and tested in a battery of 
in vitro proliferative assays in order to determine which cell line most accurately predicts 
the uterotrophic effect observed in vivo. Outcomes were therefore compared with the 
outcomes of the in vivo uterotrophic assay. Twelve reference compounds were chosen, 
including 17β-estradiol (E2), 17α-ethinylestradiol (EE2) and dienestrol as positive controls 
and corticosterone, progesterone and 17β-testosterone as negative controls. Dienestrol was 
added because this compound is only known as an estrogen receptor (ER) agonist, while 
EE2 is not only an ER agonist but also an androgen receptor (AR) antagonist and E2 is 
not only an ER agonist but also a partial AR agonist and AR antagonist. 9 Tamoxifen was 
chosen as a model compound for the selective estrogen receptor modulators (SERMs), 
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i.e. compounds displaying both ER agonistic and antagonistic properties, depending on 
the physiological context. Carbon tetrachloride (CCl4) was chosen as a compound that 
not directly acts via the ER itself, but displays an in vivo estrogenic effect by elevating the 
endogenous E2 level, as it inhibits the metabolism of E2. 6 Epidermal growth factor (EGF) 
also displays an indirect mode of action. It activates a membrane receptor that eventually 
increases the phosphorylation of the ER, by which the latter becomes more active. 10 Besides 
the MCF-7/BOS cell line, used for the E-screen, another breast cancer cell line, T47D, was 
included in the study. The T47D cell line is not often used for proliferative assays, but it is 
the host cell in many developed transcriptional activation assays. 11-13 The ECC-1 cell line 
is an endometrium cell line that also proliferates under the influence of estrogens and was 
included because it is derived from a target tissue, which is actually examined in the in vivo 
uterotrophic assay. 14 In addition, the BG-1 cell line was included because it represents the 
ovary, another main female estrogen-sensitive tissue. 15
mATeriAlS And meThodS
chemicals
Estradiol (E2), dienestrol, zearalenone, corticosterone, tamoxifen, 4-hydroxytamoxifen, 
EGF and β-mercaptoethanol were obtained from Sigma-Aldrich Chemie B.V. (Zwijndrecht, 
The Netherlands). Ethynyl estradiol (EE2), progesterone and testosterone were purchased 
from Steraloids (Newport, RI, USA), while genistein was obtained from Apin Chemicals 
(Abingdon, Oxon, UK). 4,4’-(octahydro-4,7-methano-5h-inden-5-ylidene)bisphenol from 
Acros Organics (Fisher Emergo B.V., Landsmeer, The Netherlands), carbon tetrachloride 
from Supelco Inc. (Bellefonte, PA, USA). Dimethylsulfoxide (DMSO), sodium chloride, 
Tween 20 and glycine were purchased from Merck (Darmstadt, Germany). Fetal bovine 
serum (FBS), charcoal-stripped fetal bovine serum (csFBS), ultrapure Tris, Dulbecco’s 
modified Eagle’s medium nutrient mixture F-12 HAM (DMEM/F12) with L-glutamine and 
15 mM HEPES and DMEM/F-12 with L-glutamine and 15 mM HEPES (without phenol 
red) were obtained from Gibco/Invitrogen (Breda, The Netherlands). Dulbecco’s modified 
Eagle’s medium (DMEM) was purchased from Lonza (Breda, The Netherlands). Methanol 
was from Biosolve (Valkenswaard, The Netherlands).
cell lines and cell culture conditions
MCF-7/BOS human breast cancer cells were kindly provided by Dr. Ana M. Soto (Tufts 
University, Boston, MA, USA) and maintained in DMEM supplemented with 10% FBS. 
T47D human breast cancer cells were purchased from the American Type Culture Collection 
(Manassas, VA, USA) and cultured in DMEM/F-12 with glutamine and 15 mM HEPES 
supplemented with 10% FBS. ECC-1 human endometrial cancer cells were kindly provided 
by Dr. Leen J. Blok (Erasmus Medical Center, Rotterdam, The Netherlands) and cultured in 
DMEM/F12 medium with glutamine and 15 mM HEPES, without phenol red supplemented 
with 5% FBS. BG-1 human ovarian cancer cells were kindly provided by Dr. Kenneth S. 
Korach (NIEHS, National Institute of Health, Research Triangle Park, NC, USA) and 
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cultured in DMEM/F-12 with glutamine and 15 mM HEPES supplemented with 10% FBS. 
All cell lines are routinely maintained in 75 cm2 canted-neck tissue culture flasks (Greiner, 
Gloucestershire, UK) in a humidified incubator at 37 °C and 5% CO2. Cells were sub-cultured 
at approximately 80% confluence and regularly tested negative for mycoplasma.
cell proliferation assays
Proliferation of the human MCF-7/BOS breast cancer cells for testing the estrogenic activity 
of a given compound was basically quantified as described by Soto et al. for the E-screen. 4 
Briefly, cells were plated into 24-well plates at an initial density of 25,000 cells/well in 500 µl 
assay medium (DMEM/F12 medium, without phenol red supplemented with 5% csFBS) 
and allowed to attach for 24h. After 24h, the assay medium was renewed with fresh medium 
containing test compounds dissolved in DMSO (maximum 0.2%). DMSO and E2 (300 pM) 
were included in each plate as, respectively, a negative and positive control. Each compound 
concentration was tested in threefold and cells were incubated for 6 days. After 6 days 
the cells were trypsinised and harvested. The amount of cells was counted using a Coulter 
Counter (Beckman Coulter Mijdrecht, The Netherlands) and proliferation of the cells in 
percentages was determined by dividing the amount of cells exposed to the compound by 
the amount of cells exposed to DMSO control and subsequently multiplied by 100%.
Proliferation of the ECC-1 cells was quantified as described by Gielen et al. 14 with some 
minor modifications. Cells were cultured in assay medium (DMEM/F12 medium, without 
phenol red supplemented with 5% csFBS) for 5 days before starting the experiment. Next, 
cells were plated into 24-well plates at an initial density of 5,000 cells/well and allowed to 
attach for 24h. After 24h, the assay medium was renewed with fresh medium containing test 
compounds dissolved in DMSO (maximum 0.2%). DMSO and E2 (300 pM) controls were 
included in each plate. Each compound concentration was tested in threefold and cells were 
incubated for 7 days. After 7 days the cells were trypsinised and counted as described above 
for the MCF-7/BOS cells. Proliferation of the T47D and BG-1 cells were measured using the 
method from MCF-7/BOS assay with two modifications: T47D and BG-1 cells were plated 
into 24-well plates at an initial concentration of 50,000 and 5,000 cells/well, respectively and 
both cell lines were exposed for 5 days.
ldh cytotoxicity test
At the end of the proliferation assay, lactate dehydrogenase (LDH) released by damaged 
cells into the cell culture medium was determined using a LDH cytotoxicity detection kit 
(Roche Diagnostics, Germany), according to the manufacturer’s instructions. Cells exposed 
to the highest concentration used in the proliferation assays were tested for LDH release. 
The cell culture medium was removed and centrifuged for 5 min at 800 × g. Aliquots of 
100 µl of the centrifuged medium was transferred to a 96-well plate and LDH substrate 
(100 µl) was added to each well and incubated for 30 min at room temperature, protected 
from light. The absorbance of the samples was measured at 490 nm and corrected for 
background absorption at 630 nm. 
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rnA isolation and reverse transcription
Total RNA was isolated from cultured cells using the QIAshredder and RNeasy Mini kits 
(Qiagen, Venlo, The Netherlands) with RNase-free DNase treatment according to the 
manufacturer’s protocols. In short: cells were seeded in 6-well plate in culture medium. 
When cells reached 80% confluence, the medium was removed and the cells were lysed 
in 600 μl RLT buffer with 1% β-mercaptoethanol. After extraction with QIAshredder and 
RNeasy Mini kits, the RNA concentration and purity were determined by absorbance at 
260/280 nm using a NanoDrop spectrophotometer (Nanodrop Technologies, Montchanin, 
DE, USA). For cDNA synthesis, 0.5 µg of oligo(dT) primer (Invitrogen) and pd(N)6 random 
hexamer (GE Healthcare, Roosendaal, The Netherlands) were added to the sample prior to 
heating. The mix was placed directly on ice and 200 units of M-MVL reverse transcriptase, 
RNase H Minus, Point Mutant (Promega, Leiden, The Netherlands), 10 nmol of each dNTP 
and RT buffer were added to a final volume of 20 µl. The mix was incubated for 10 min 
at 25 °C, 50 min at 40 °C and finally 10 min at 65 °C to inactivate the enzyme. All cDNA 
samples were stored at -20 °C until assayed.
Quantitative Pcr 
Quantitative real-time PCR was performed with specific primers (listed in table 1) and was 
carried out in 25 µl reaction mixture containing 5 µl 20 times diluted cDNA, 12.5 µl of power 
SYBR green mix (Applied Biosystems, Maarssen, The Netherlands), 1 µl of each 10 µM primer 
and 5.5 µl of milliQ. QPCR measurements were performed with the ABI7900HT Sequence 
Detection System (Applied Biosystems) with the following conditions: 10 min denaturation 
at 95 °C followed by 40 cycles consisting of 65 °C for 1 min for annealing, 95 °C for 15 s 
for denaturation and extension at 65 °C for 1 min. PCR products were checked by melting 
curve analysis applying an increment of 0.5 °C per 5 s from 60 °C to 95 °C. Gene expression 
was assayed in triplicate for each sample and normalised to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) or heterochromatin protein 1 (HP-1) mRNA levels. 
Western blotting 
Cells were seeded in 6-well plate in culture medium. When cells reached 80% confluence, 
the medium was removed and the cells were lysed with M-PER mammalian extraction 
buffer supplemented with phosphatase and protease inhibitors (Thermo Fisher Scientific, 
Table 1. Sequences of the primers used in Q-PCR.
Gene Forward primer Reverse primer
ERα 5’-CCTAACTTGCTCTTGGACAGGA-3’ 5’-GCCAGCAGCATGTCGAAGAT-3’
ERβ 5’-CGACAAGGAGTTGGTACACATGA-3’ 5’-CCAAGAGCCGCACTTGGT-3’
CYP19A1 5’-AGGTGCTATTTGTCATCTGCTC-3’ 5’-TGGTGGAATCGGGTCTTTATGG-3’
HP-1 5’-CCCACGTCCCAAGATGGAT-3’ 5’-CTGATGCACCACTCTTCTGGAA-3’
GAPDH 5’-AGGTCGGAGTCAACGGATTTGG-3’ 5’-GCTCCTGGAAGATGGTGATGGG-3’
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Etten-Leur, The Netherlands), according to the manufacturer’s instructions. The protein 
concentration was determined according to Lowry, 16 using the BioRad DC protein assay 
(BioRad, Veenendaal, The Netherlands) and BSA as a standard. Next, 10 µg of the protein 
sample was mixed with an equal volume of Laemmli sample buffer (BioRad) supplemented 
with 5% β-mercaptoethanol. After denaturation at 95 °C for 3 min, 20 µl sample was loaded 
on 10% Mini-PROTEAN® TGX™ precast gel (BioRad). Electrophoresis was carried out at 
50V for 30 min followed by 100V for 30 min using anode buffer (0.2M Tris-HCl, pH 8.9) 
and cathode buffer (0.1 M Tris, 0.1 M Tricine, 0.1% SDS, pH 8.2). Protein was transferred to 
PVDF membrane (Immobilon-FL, 0.45 µm pore size, Millipore B.V., Amsterdam Zuidoost, 
The Netherlands) at 100V for 1 h in Tris-glycine buffer (BioRad) containing 20% (v/v) 
methanol. Subsequently, membranes were blocked with Odyssey blocking buffer (LI-COR, 
Bad Homburg, Germany) for 1 h after which the membranes were probed overnight for 
proteins of interest with ERα, ERβ or β-actin primary antibodies (Cell Signaling, Bioké, 
Leiden, The Netherlands) diluted 1:1000 in Tris-buffered saline containing 1% Tween 20 
(TBS-T) and 5% BSA. The following day the membranes were washed with TBS-T and 
incubated with infrared dye-labeled IRDye 800CW donkey anti-mouse IgG and IRDye 
680 donkey anti-rabbit IgG (LI-COR). The final protein expression was detected using the 
Odyssey infrared imaging system (Westburg, Leusden, The Netherlands).
Aromatase enzyme assay
Aromatase activity in four different cell lines was measured by the tritiated water release assay, 
as previously described. 17 Briefly, cells were plated into 6-well plate at 1 × 106 cells/well in assay 
medium. Three days later, culture plate was washed with PBS. One ml of serum-free DMEM/
F12 medium containing 50 nM [1β-3H(N)]-androst-4-ene-3,17-dione (15–30 Ci/mmol, 
Perkin-Elmer Life Sciences) was then added to each well in triplicate. After 24h incubation 
at 37 °C, the reaction mixture was collected and extracted with two volumes of chloroform 
to extract unused substrate. After 2 min centrifugation at 11,000 × g, the aqueous phase was 
treated with an equal volume of dextran activated charcoal to eliminate residual steroids. 
After 15 min at 11,000 × g centrifugation, radioactivity was assessed by liquid scintillation 
counting. Aromatase activity was calculated as fmol estrogen formed/mg protein/h.
data analysis 
The relative proliferative potency (RPP), defined as the ratio of the concentration of E2 needed 
to achieve 50% of maximal cell yield and the dose of the test compounds required to achieve 
a similar effect and then multiplied by 100, was calculated from proliferation dose-response 
curves fitted using nonlinear regression analysis (sigmoidal dose-response curve, Graphpad 
Prism software version 5.04). The RPP value for E2 is thus set at 100. The relative proliferative 
effect (RPE) is defined as the maximal induction of cell proliferation by a compound relative 
to the maximal induction by E2 and is used to discriminate between full and partial estrogen 
receptor agonists. The log relative potency (logRP) values based on mouse or rat uterotrophic 
assay results were derived from the endocrine disruptor knowledge base (EDKB) designed 
and produced by the National Center for Toxicological Research (NCTR, USA). 18 
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reSulTS
characterisation of the cell lines
The estrogen receptor (ER) is present in the human body in two subtypes. The ERα subtype 
is mainly present in the sex organs, e.g. uterus, prostate (stroma), ovary (theca cells) and 
mammary gland, while the ERβ is mainly present in the colon, prostate (epithelium), testis, 
ovary (granulosa cells), bladder, lung and bone. 19-21 It is generally assumed that in cells 
expressing both receptor subtypes, the ERβ is a regulator/inhibitor of the ERα and thus affects 
the response of such cell types. 22-24 The relative levels of both receptor subtypes were therefore 
investigated at mRNA and protein level in the four human cell lines used in the present study, 
i.e. the MCF-7/BOS and T47D breast cells, the endometrial ECC-1 cells and the ovarian 
BG-1 cells. The aromatase enzyme catalyses the conversion of androgens to estrogens. It has 
been reported by Sonne-Hansen and Lykkesfeldt that the aromatase activity in the MCF-7 
cells was sufficient to aromatise testosterone to estrogen, resulting in significant cell growth 
stimulation. 25 Therefore, in addition to ER levels, aromatase activity was characterised as well 
in each of the four cell line at the mRNA level and by measuring activity.
ERα, ERβ and aromatase mRNA levels
Total RNA was isolated from each of the four cell line and the levels of ERα, ERβ and aromatase 
mRNA were determined by quantitative real-time PCR analysis using specific primers for 
each ER subtype and the aromatase gene. Figure 1 shows the ERα, ERβ and aromatase mRNA 
levels as determined in the four human cell lines. Figure 1A shows that, compared to the 
MCF-7/BOS cell line, the T47D, ECC-1 and BG-1 cell lines have about 1.5 to 2.0 times higher 
ERα mRNA amounts and that the T47D cell line expresses a relative high amount of the ERβ 
Figure 1. Relative estrogen receptor and aromatase mRNA expression measured in MCF-7/BOS, T47D, 
ECC-1 and BG-1 cells. (A) ERα (black column) and ERβ (white column) expression are normalised to HP-1 
mRNA. (B) aromatase expression is normalised to GAPDH mRNA. Average fold change and standard 
deviation were calculated from three biological replicate samples, each measured in triplicate.
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mRNA. Figure 1B shows that the MCF-7/BOS, ECC-1 and BG-1 cell lines have relatively high 
levels of the aromatase mRNA, while the T47D cell line hardly expresses this mRNA.
Western blotting and aromatase activity 
Levels in mRNA not necessarily reflect the actual protein levels. Additional western blots were 
therefore performed for ERα and ERβ and an enzyme assay was carried for detecting aromatase 
activity. Figure 2 shows the western blots and demonstrates that the four human cell lines clearly 
express the ERα protein and small but detectable amounts of ERβ protein. Figure 3 shows 
the aromatase activity as determined in the four cell lines. A similar pattern was observed as 
obtained for the aromatase mRNA levels, with only the aromatase activity in the ECC-1 cell line 
being about 2-fold higher than what would be expected based on the mRNA level.  
Figure 2. ERα and ERβ protein expression measured in MCF-7/BOS, T47D, ECC-1 and BG-1 cells. 
Upper part shows a Western blot of a total protein extract after treatment with ER antibodies, and the 
lower part the same blot after treatment with β-actin antibodies to show that equal amounts of protein 
had been loaded for each cell sample.
Figure 3. Aromatase enzyme activity 
measured in MCF-7/BOS, T47D, 
ECC-1 and BG-1 cells. Aromatase 
activity was measured as described 
in materials and methods. Results 
are presented as the mean aromatase 
enzyme activity ± SD (n=3) expressed 
as fmol estrogen formed/mg protein/h.
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cell proliferation assays
Figure 4 shows the dose–response curves of the natural estrogen 17β-estradiol (E2) as 
obtained in proliferation assays with the four different human cell lines derived from 
three different female estrogen-sensitive tissues. The maximal response (expressed as % 
of the DMSO control) was reached at 300 pM to 1 nM E2 for all four cell lines. The fold 
increase in cell proliferation ranged from 2.5 times for the endometrial ECC-1 cell line 
to 8 times for the T47D breast cell line. However, this fold increase is relative to a DMSO 
control and does not necessarily reflect the absolute increase in cell numbers. Although the 
relative fold increase of the T47D cell line seems high compared to the ECC-1 cell line, it 
should be emphasised that the T47D cell line is the only one of the tested cell types that 
essentially shows no proliferation in the absence of estradiol. At higher E2 concentrations 
a slight inhibition of the cell growth was observed with all four cell lines. This was not due 
to cytotoxicity, as no LDH leakage was observed at the highest concentrations of E2 tested 
(data not shown). The EC50, i.e. the E2 concentration giving a half-maximum proliferation 
response, was calculated as a mean ± SEM from at least five independent experiments and 
resulted in EC50 values of 25 ± 4.3 pM, 41 ± 5.2 pM, 15 ± 1.5 pM and 9 ± 2.8 pM for the 
MCF-7/BOS, T47D, ECC-1 and BG-1 cell line, respectively.
A set of 12 reference compounds, including E2, was chosen and their selection was 
based on their different modes of action leading to positive and negative outcomes in the 
in vivo uterotrophic assay (Allen and Doisy test). The RPP and RPE values of these 12 
compounds as calculated from the fitted proliferative responses on the four human cell 
lines are listed in Table 2. No LDH leakage was observed at the highest concentrations of 
the compounds tested (data not shown). To allow comparison with the observed in vivo 
effects, the relative potency (RP) of these compounds as determined previously in the in 
vivo mouse or rat uterotrophic assay are included and shown in the second column of 
Table 2. Figure 5 shows the comparison between the logRP values as determined in the in 
vivo mouse or rat uterotrophic assay and the logRPP values as determined in the in vitro 
proliferation assays using the four different human cell lines. From these data it becomes 
Figure 4. Proliferative response of 
17β-estradiol obtained in the four 
estrogen-sensitive human cell lines. 
Results are representative of at 
least five independent experiments 
and are presented as the mean 
proliferative response ±SD (n=3) 
expressed as a percentage of the 
solvent (DMSO) control.
34
2C
ell pRO
lIfeR
a
TIO
N
 a
ssa
y
s
clear that the estrogens E2, EE2, dienestrol, zearalenone, genistein and 4,4’-(octahydro-
4,7-methano-5h-inden-5-ylidene) bisphenol show similar relative potencies in the different 
proliferation assays. The negative controls, i.e. the androgen testosterone, the (pro)gestagen 
progesterone and the (glycol)corticoid corticosterone, are almost inactive in all five assay 
types. The only exception is testosterone, as a full dose response curve was obtained for 
testosterone in the MCF-7/BOS proliferation assay and also a clear response with T47D cell 
line, while EGF could not be compared as the in vivo data for this compound are yet 
unknown. However, EGF was clearly active in the proliferation assays, showing the highest 
potency in the BG-1 cell line (logRPP 1.4) and the most extensive proliferative effect in the 
ECC-1 cell line (RPE of 65). In addition, a MCF-7/BOS proliferation study with testosterone 
and the aromatase inhibitor letrozole was performed. Figure 6 shows that letrozole partially 
inhibited the proliferative response induced by testosterone.
The main differences between the in vivo and in vitro assays were observed for 
tamoxifen. This compound is clearly estrogenic in vivo (logRP of 0.9), but is almost inactive 
in the proliferation assays using the ECC-1 and BG-1 cell lines (logRPP of -5.0). Tamoxifen 
was clearly estrogenic in the proliferation assays using the MCF-7/BOS and, to a lesser 
Figure 5. Comparison of the in vivo uterotrophic assay with the proliferation assays using four 
different estrogen-responsive human cell lines. With tamoxifen excluded, the ECC-1 and BG-1 cell 
lines show a R2 = 0.92, y = 0.97x+0.06 and R2 = 0.91, y = 1.02x+0.34, respectively.
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Table 2. Comparison of the relative potencies obtained in the in vivo uterotrophic assay with those 
obtained in proliferation assays using four human cell lines derived from three female estrogen 
sensitive tissues.
Compounds
Uterotrophic 
assay MCF-7/BOS T47D ECC-1 BG-1
logRPa logRPPb RPEc logRPP RPE logRPP RPE logRPP RPE
Estradiol 2.0 2.0 100 2.0 100 2.0 100 2.0 100
Ethinyl estradiol 3.2 2.0e 92 e 2.2 93 2.8 103 2.5 103
Dienestrol 2.4 1.4 99 1.7 92 1.7 94 1.0 98
Zearalenone -0.7 0.7e 100 e 1.1 110 1.3 100 1.1 96
Genistein -2.7 -2.0 98 -2.4 84 -1.8 96 -1.8 108
4,4′-(octahydro-4,7-
methano-5H-inden-
5-ylidene)bisphenol
0.3d -0.4 47 -1.5 18 0.3 50 -0.6 38
Tamoxifen 0.9 -0.9 36 -2.3 19 -5.0 - -5.0 -
EGF uterotrophic 
effectf
-1.2 24 0.9 16 -0.4 65 1.4 36
Carbon 
tetrachloride
-5.0 -5.0 - -5.0 - -5.0 - -5.0 -
Corticosterone -5.0 -5.0 - -5.0 - -5.0 - -5.0 -
Progesterone -5.0 -5.0 - -5.0 - -5.0 - -5.0 -
Testosterone --5.0 -2.9 92 -2.2 35 -5.0 <5 -5.0 <15
a Relative potency values based on mouse or rat uterotrophic assay results, derived from EDKB (NCTR,USA). 
E2 is used as a reference chemical and is defined to have a relative potency of 100 (log10100=2) 18. A logRP 
cut-off value of -5.0 is listed for compounds showing no effect.
b Relative proliferative potency values are obtained from the ratio of the concentration of E2 needed to 
achieve 50% of maximal cell yield (proliferation) and the dose of the test compounds required to achieve a 
similar effect, and this ratio is subsequently multiplied by 100. The RPP value of E2 is thus 100, resulting in 
a logRPP of 2 (log10100=2). A cut-off value of -5.0 is listed for compounds showing no effect.
c Relative proliferative effect values are defined as the maximal cell proliferation induced by a compound 
relative to the maximal cell proliferation obtained with E2.
d logRP of 4,4′-(octahydro-4,7-methano-5H-inden-5-ylidene)bisphenol was calculated from a minimal 
active dose described by Yamasaki et al. 2003. 26
e Obtained from Fang et al. 2000. 27
f EGF is able to mimic the uterotrophic effects of estrogen in the rodent. 28
extent, the T47D breast cancer cell lines (logRPP of -0.9 and -2.3, respectively). The best 
correlation with the in vivo uterotrophic assay was therefore obtained with the human 
MCF-7/BOS breast cancer cell line (R2 = 0.85). 
Tamoxifen is not a pure estrogen receptor agonist or antagonist, but is a selective 
estrogen receptor modulator (SERM) and mainly reported to act as an ER agonist in uterus 
and as an ER antagonist in breast. 29 However, tamoxifen is also able to inhibit the effect 
caused by EE2 in the uterotrophic assay and to induce proliferation in the E-screen. 26, 27 In 
order to select the cell line showing proliferative responses with the best correlation with 
the outcomes of the in vivo the uterotrophic assay, the antagonistic properties of several 
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compounds were studied as well. Figure 7 shows the proliferative responses of the four cell 
lines upon exposure to 300 pM E2 giving 80-100% proliferation rate, in combination with 
different concentrations of tamoxifen. These results clearly show that tamoxifen acts as an 
ER antagonist in all four cell lines too. The antagonistic or additive effects of tamoxifen, 
4-hydroxytamoxifen, 4,4′-(octahydro-4,7-methano-5H-inden-5-ylidene)bisphenol, CCl4 
and EGF with respect to E2 are summarised in Table 3. The results presented reveal that in 
combination with E2, tamoxifen, 4-hydroxytamoxifen and 4,4′-(octahydro-4,7-methano-
5H-inden-5-ylidene) bisphenol all acted as antagonists both in vivo and in vitro, while CCl4 
and EGF only in vivo resulted in effects that were additive to those of E2.
diScuSSion
A set of 12 reference compounds representing diverse modes of estrogenic action and 
chemical classes were tested in four cell proliferation assays in order to establish which cell 
line most accurately predicts the in vivo observed effects. These four cell lines were derived 
from three different female estrogen-sensitive tissues: i.e. breast (the MCF-7/BOS and T47D 
cell lines), endometrium (the ECC-1 cell line) and ovary (the BG-1 cell line). These cell 
lines were first characterised with respect to their relative amounts of ERα and ERβ both 
at the mRNA and protein level, as it is known that the relative ERα/ERβ level affects the 
proliferation response of cells that express both receptor types. 22-24 All four cell lines clearly 
expressed the ERα type and a very low but detectable amount of ERβ at both the mRNA 
and protein level. The results conform to the expectations, as the ERα is known to be the 
predominant ER type expressed in these estrogen-sensitive tissues, 19-21 and in agreement 
with the general findings that most ER-positive tumours appear to exhibit increased ratios 
of ERα/ERβ, due to lower expression of ERβ. 30, 31 Given that the rat and mouse uterus are 
known to predominantly express the ERα and almost no ERβ, 32, 33 these data on the relative 
expression levels of ERα and ERβ in the four cell lines investigated indicate that the T47D 
Figure 6. Effect of the aromatase 
inhibitor letrozole (LE) on testosterone 
induced cell proliferation in MCF-7/
BOS cells. Results are representative 
of at least three independent 
experiments and are presented as 
the mean proliferative response ±SD 
(n=3) expressed as a percentage of the 
solvent (DMSO) control.
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Table 3. Reference compounds tested for antagonistic or additive effect on proliferation of the four 
human cancer cell lines upon exposure in combination with the prototype ER agonist E2. 
Compounds
Behaviour of test compounds 
in uterotrophic  assay
MCF-7/BOS
IC50
T47D
IC50
ECC-1
IC50
BG-1
IC50
Tamoxifen+E2 Antagonist 670 nM 650 nM 220 nM 240 nM
4OH-TAM+E2 Antagonist 18 nM 5.2 nM 6.5 nM 2 nM
4,4′-(octahydro-4,7-methano-5H-
inden-5-ylidene)bisphenol+E2
Antagonist 400 nM 230 nM 390 nM 130 nM
CCl4+E2 Enhanced a NE b NE NE NE
EGF+E2 Enhanced NE NE NE NE
a Enhanced uterotrophic effect as compared to E2 alone.
b No antagonistic or additive effect is observed on cell proliferation as compared to E2 alone.
Figure 7. Antagonistic effect of 
tamoxifen measured in MCF-7/
BOS, T47D, ECC-1 and BG-1 
cells. Cells were treated with 300 
pM 17β-estradiol in combination 
with different concentrations of 
tamoxifen. Results are expressed as 
the mean proliferative response ±SD 
(n=3) presented as a percentage of 
the solvent (DMSO) control. 
breast cancer cell line, with its relatively high ERβ levels, may be less suitable as a member 
of a panel of bioassay to replace the in vivo uterotrophic assay. It is important to note that 
it has been reported that long term estrogen deprivation can affect estrogen receptor levels 
in breast cancer cells, i.e. after culturing cells in estrogen free medium for several months. 34 
In the present study the proliferation assays are performed by culturing cells in estrogen 
free medium for 24 h or 5 days before exposure to the test compounds, and it cannot be 
fully excluded that during the prolonged pre-treatment of the ECC-1 cells, receptor levels 
may have changed somewhat more than in the other cell lines. However, given that all 
compounds in all cell lines were compared on a relative scale with estradiol used as the 
standard, the influence on the ultimate outcome is expected to be limited if any.
The logRPP values of the tested compounds were calculated from the dose–response 
relation determined by curve-fitting and they showed a good correlation with logRP values as 
obtained in the in vivo uterotrophic assay. Surprisingly, the best correlation between the in vivo 
uterotrophic assay and a proliferation assay was obtained with the MCF-7/BOS breast cell line 
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and not with the ECC-1 endometrial cell line. The highest R2 value (0.85) was thus obtained 
with the MCF-7/BOS proliferation assay. Compounds on the line, figure 5, have about the 
same relative potency in the in vitro proliferation assay as obtained in the in vivo uterotrophic 
assay, compounds clearly above the line are relatively more potent in vivo than in vitro, while 
compounds below the line are relatively more potent in the in vitro proliferation assays than 
in the in vivo uterotrophic assay. Deviations from the line have different causes, as will be 
discussed for testosterone and tamoxifen. Although the T47D cell line expresses a similar ERα 
and a much lower level of ERβ but still relatively high compared to the other three cell lines, the 
relative proliferative potencies observed for T47D do not much differ from the other cell types 
that express almost no ERβ. However, the fact that the T47D cell line showed the highest EC50 
for E2 and was not able to grow in the absence of estrogens, while the other cell lines were able 
to grow in assay medium (the amount of ECC-1 cells in the DMSO control even increased more 
than 10 times) might be due to the inhibitory effect of the relatively high levels of ERβ on the 
ERα activity in the T47D cell line as compared to the other cell lines. Testosterone was inactive 
in the in vivo uterotrophic assay and slightly active in ECC-1 and BG-1 cell proliferation 
assays, but induced a clear proliferative response in the MCF-7/BOS and T47D cells. In theory 
this proliferative response to testosterone might be due to aromatase activity in the latter two 
cell types. To test this hypothesis the four cell lines were characterised by determination of 
their aromatase mRNA levels and by aromatase activity measurements. The mRNA levels 
correlated well with the determined aromatase activities and the observed aromatase activity 
in the MCF-7/BOS cells might explain its proliferative response to testosterone. However, the 
aromatase inhibitor letrozole only partially inhibited the proliferative response as obtained 
with testosterone in MCF-7/BOS cells. In addition, aromatase activity was not observed in 
T47D cells, but still testosterone induced a clear response. These results indicating that other 
or combined modes of action underlay the proliferative effect of testosterone in the MCF-7/
BOS and T47D cell proliferation assays. For instance, the proliferative effect of testosterone 
could be due to the formation of other estrogenic metabolites than estradiol and estrone, i.e. 
androstenediol, hydroxytestosterone or dehydroepiandrosterone, which might also activate 
ER and induce cell proliferation. On the other hand, the proliferative effect of testosterone in 
the T47D assay might be caused by crosstalk from the androgen receptor (AR) as it is known 
that the T47D expresses a high amount of AR. 13, 35, 36 The ECC-1 and BG-1 cells show clear 
aromatase activities, but did not give clear proliferative response when exposed to testosterone. 
The reason for this unexpected observation remains to be elucidated.  
The main reason for the best correlation with the MCF-7/BOS cell line is due to the 
outcomes with tamoxifen. Tamoxifen is a selective estrogen receptor modulator (SERM), 
depending on the cell tissue type and the intrinsic E2 levels, it can act both as an agonist or 
an antagonist. 29 In order to select the cell line showing proliferative responses with the best 
correlation with the outcomes of the in vivo uterotrophic assay, the antagonistic properties 
of tamoxifen in these assay types were studied and compared as well. The results obtained 
showed that tamoxifen acted as an ER antagonist in all four cell lines and also in vivo, whereas 
the ER agonistic properties of tamoxifen, also observed in the uterotrophic assay, are only 
revealed by the MCF-7/BOS and T47D cell lines. This means that the ECC-1 and BG-1 
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cell lines are only capable to detect the antagonistic properties of tamoxifen. It is at least 
surprising that in the uterotrophic assay tamoxifen is a strong ER agonist and is not active as 
an agonist in the ECC-1 cell line, which is actually derived from uterus tissue (endometrium). 
The differences observed with tamoxifen might be due to differences in cofactor (repressor) 
concentrations in the different cell types, however, even today and despite the fact that 
tamoxifen is already used as a drug for more than three decades, its mechanism of action is 
still not fully understood. 29, 37 Differences in metabolism might be another explanation for the 
differences observed with tamoxifen, as it is known that tamoxifen is converted in vivo into 
the more active 4-hydroxytamoxifen (4OH-TAM) and 4-hydroxy-N-desmethyl-tamoxifen 
(endoxifen). It has been reported that 4OH-TAM possesses a high affinity for ERs and 30- 
to 100-fold more antagonist potency than tamoxifen in suppressing estrogen-dependent 
cell proliferation. 38 Several studies have shown that endoxifen is equipotent to 4OH-TAM 
with respect to inhibition of estradiol induced cell proliferation in vitro. 39, 40 If tamoxifen 
was metabolised to a substantial amount to 4OH-TAM or endoxifen in the four cell lines, 
exposure of the cells to tamoxifen and 4OH-TAM would have resulted in similar IC50 values 
for the two compounds when testing the antagonistic activity. However, when tested alone 
4OH-TAM was only active as an agonist in the MCF-7/BOS and T47D cell line but not 
active in the ECC-1 and BG-1 cell line (data not shown). In addition, our results show that 
4OH-TAM was 30-150 times more potent as an antagonist than tamoxifen in the four cells 
lines. Thus, taken together these data indicate that conversion of tamoxifen to 4OH-TAM or 
endoxifen does not occur in the cell lines tested and cannot explain the deviating behaviour of 
tamoxifen in the various cell lines. The in vitro/in vivo discrepancy observed with tamoxifen 
and 4OH-TAM is most likely due to the differences in the expression and/or activity of co-
regulators in the different cell lines. It is worth noting that 4,4′-(octahydro-4,7-methano-5H-
inden-5-ylidene)bisphenol shows both agonistic and antagonistic effects in the uterotrophic 
assay and when tested in the proliferation assays it also behaves as an agonist and antagonist, 
demonstrating a nearly identical biological effect profile as tamoxifen. This might indicate 
that it is to be expected that broad window screening of unknown compounds might involve 
many more cases of partial agonists/antagonists and/or SERMs, which an ideal assay battery 
should be capable to correctly classify with respect to estrogenic properties. This supports the 
notion that in the end it might require more than one cell type to correctly classify estrogens 
in general, including the SERM class, because of the mechanistic factors in addition to just 
ER-interaction involved in the estrogenic action of SERMs.
In conclusion, the MCF-7/BOS proliferation assay showed the best correlation with the 
in vivo uterotrophic assay and based on the 12 compounds tested in this study, was shown to 
be suited to be part of a panel of in vitro bioassays to replace this in vivo test. However, there 
are still compounds that cannot correctly be predicted such as the additive effect of carbon 
tetrachloride and EGF. Other in vitro assay formats, such as transcription activation assays 
based on cells that express no endogenous hormone receptors in order to avoid crosstalk 
or the H295R steroidogenesis assay in order to detect estrogenic effects of compounds that 
are not caused by a direct interaction with the ERα, are needed in such a panel of assays to 
increase its predictivity for the outcomes as observed in the uterotrophic assay.
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ABSTrAcT
In order to define an in vitro integrated testing strategy (ITS) for estrogenicity, a set 
of 23 reference compounds representing diverse chemical classes, were tested in a 
series of in vitro assays including proliferation and reporter gene assays. Outcomes 
of these assays were combined with published results for estrogen receptor (ER) 
binding assays and the OECD validated BG1Luc ER transcriptional activation (TA) 
assay and compared with the outcomes of the in vivo uterotrophic assay to investigate 
which assays most accurately predict the in vivo uterotrophic effect and to identify 
discrepancies between the in vitro assays and the in vivo uterotrophic assay. All in 
vitro assays used revealed a reasonable to good correlation (R2 = 0.62 - 0.87) with 
the in vivo uterotrophic assay but the combination of the yeast estrogen bioassay 
with the U2OS ERα-CALUX assay seems most promising for an ITS for in vitro 
estrogenicity testing. The main outliers identified when correlating data from the 
different in vitro assays and the in vivo uterotrophic assay were 4-hydroxytamoxifen, 
testosterone and to a lesser extent apigenin, tamoxifen and kepone. Based on the 
modes of action possibly underlying these discrepancies it becomes evident that to 
further improve the ITS and ultimately replace animal testing for (anti-)estrogenic 
effects, the selected bioassays have to be combined with other types of in vitro assays, 
including for instance in vitro models for digestion, bioavailability and metabolism 
of the compounds under investigation. 
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inTroducTion
Testing chemicals for their endocrine-disrupting potential, including interference with 
estrogen receptor (ER) signaling, is an important aspect to assess the safety of currently used 
chemicals. With the vast number of chemicals potentially targeted for endocrine-disruption 
testing, millions of animals are needed under the U.S. Environmental Protection Agency 
(EPA) Endocrine Disruptor Screening Program (EDSP) 1 and the European Union (EU) 
legislation on Registration, Evaluation, Authorization and Restriction of chemical substances 
(REACH). 2 In order to fulfill the 3R principle of Refinement, Reduction and Replacement of 
animal testing and reduce the costs, there is a clear need to develop high-throughput in vitro 
methods to efficiently screen chemicals and prioritize limited testing resources. 
Presently, the standard test for disruption of normal estrogen function is the Allen and 
Doisy test, a uterotrophic assay in immature or ovariectomised rodents with uterus weight 
as a crucial read-out parameter. 3, 4 As alternatives, a variety of in vitro bioassays has been 
developed to determine the potential estrogenic activities of compounds based on different 
steps in the estrogen receptor-dependent signal transduction pathway, e.g., ER binding, 
ER-controlled reporter gene expression or more downstream events such as ER-mediated 
cell proliferation. These in vitro assays have been shown to produce relevant and reliable 
outcomes. Sonneveld et al. (2006), for example, reported that the results obtained with the 
human U2OS osteosarcoma cell based reporter gene assay correlate well with the results from 
the in vivo uterotrophic assay for a set of 31 steroids. 5 In addition, Kolle et al. (2010) compared 
experimental data from a yeast estrogen screen (YES) assay with the literature data from the 
uterotrophic assay and showed that the YES assay has a very high concordance (87%) for 
predicting estrogenic effects in vivo. 6 Moreover, in a previous study, it was demonstrated 
that of four different proliferation assays, data obtained in the MCF-7/BOS proliferation 
assay correlate better with the data from the in vivo uterotrophic assay than the proliferative 
responses of three other human cell lines, i.e., another cell line derived from breast (T47D), 
one derived from the endometrium (ECC-1) and one from the ovary (BG-1). 7 These results 
indicate that in vitro assays may have high predictive value for in vivo estrogenic effects. 
However, outliers do occur, and this is due, at least to some extent, to the fact that these 
assays are generally based on a single estrogen-responsive human cell type cultured in vitro, 
and do not reflect the biological complexity of a whole animal, missing e.g. influences of 
bioavailability, metabolism or effects on steroidogenesis. In addition, a variety of cell types 
are used as hosts for different in vitro assays, including mammalian and yeast cells. This 
complicates the interpretation of the test results as the same compound may act differently 
and even show contradictory results in different in vitro assays. The aim of the present study 
was to further investigate which in vitro assays most accurately predict the in vivo observed 
uterotrophic effect and to identify the discrepancies between in vitro data and results from the 
in vivo uterotrophic assay, in order to better define gaps that have to be bridged by additional 
in vitro tests when developing an in vitro integrated testing strategy (ITS) for estrogenicity.
To this end, a set of 23 reference compounds was chosen and tested in the MCF-7/BOS 
proliferation assay and a battery of reporter gene assays. The MCF-7/BOS proliferation assay 
was chosen as it has been shown to correlate the best of a series of 4 proliferation assays with 
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the in vivo uterotrophic outcomes based on data for a set of 12 compounds. In the current 
study, this assay was further evaluated using a larger set of 23 compounds. The ER-CALUX 
assay based on the human T47D breast carcinoma cell was chosen as a model, because this 
cell line endogenously expresses both estrogen receptor α and β, 8 and therefore is likely to be 
more representative for the uterus and other estrogen-responsive human tissues expressing 
both ER subtypes. For comparison purposes, the ERα-CALUX assay based on the human 
U2OS osteosarcoma cell line stably transfected with an ERα expression vector and a luciferase 
reporter construct 9, 10 was chosen and added to test panel. Compared to mammalian cell 
lines, yeast cells are easy to culture. In addition, the simplicity of yeast-based assays can be an 
advantage when studying the estrogenic effect of chemicals as yeast-based assays do not suffer 
from crosstalk from other nuclear receptors and are devoid of steroid metabolism. Therefore, 
the third assay included in the present study was an estrogen bioassay based on yeast cells 
expressing yeast Enhanced Green Fluorescent Protein (yEGFP) as a marker protein. 11 In 
these cells both the human estrogen receptor α (hERα) expression and yEGFP reporter 
construct were stably transfected into the genome. Finally, the published results of ER binding 
assays and the OECD-validated BG1Luc ER TA reporter gene assay were also included and 
compared with the outcomes as obtained in the selected in vitro assays and in the in vivo 
uterotrophic assay. Special attention was directed at possible outliers and their possible mode 
of action since this was expected to provide further insight into possible remaining gaps and 
thus future assays required for further improvement of an in vitro ITS for estrogenicity.
mATeriAlS And meThodS
chemicals
Apigenin, bisphenol A (BPA), corticosterone, coumestrol, dienestrol, diethylstilbestrol 
(DES), diphenylamine, 17ß-estradiol (E2), ethyl paraben, meso-hexestrol, zearalenone, 
tamoxifen, 4-hydroxytamoxifen, o,p’-DDT, p-n-nonylphenol, type I calf thymus DNA 
(sodium salt) and 1,2-diaminocyclohexanetetraacetic acid monohydrate were obtained from 
Sigma-Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). 17α-Ethinyl estradiol (EE2), 
progesterone (P4) and testosterone (T) were purchased from Steraloids (Newport, RI, USA), 
while genistein was obtained from Apin Chemicals (Abingdon, Oxon, UK). Acetaldehyde 
and 4,4’-(octahydro-4,7-methano-5h-inden-5-ylidene)bisphenol (OMIY-bisphenol) were 
from Acros Organics (Fisher Emergo B.V., Landsmeer, The Netherlands). Kepone and 
2,4,5-trichlorophenoxyacetic acid (2,4,5-T) were obtained from Dr. Ehrenstorfer GmbH 
(Augsburg, Germany). Butylbenzyl phthalate and di-n-butyl phthalate were purchased from 
TCI Europe N.V. (Zwijndrecht, Belgium). Dimethylsulfoxide (DMSO) and perchloric acid 
were purchased from Merck (Darmstadt, Germany), d-Luciferin from Duchefa (Haarlem, 
The Netherlands) and ATP from Roche (Mannheim, Germany). Dextran-coated charcoal-
filtered fetal bovine serum (DCC-FBS), fetal bovine serum (FBS), ultrapure Tris, Dulbecco’s 
modified Eagle’s medium nutrient mixture F-12 HAM (DMEM/F12) with l-glutamine and 
15 mM HEPES and DMEM/F-12 with L-glutamine and 15 mM HEPES (without phenol 
red) were obtained from Gibco/Invitrogen (Breda, The Netherlands), while Dulbecco’s 
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modified Eagle’s medium (DMEM) was purchased from Lonza (Breda, The Netherlands). 
Chemicals to prepare the growth media for yeast were described previously 11.
cell culture 
The MCF-7/BOS human breast cancer cell line was kindly provided by Dr. Ana M. Soto 
(Tufts University, Boston, Massachusetts, USA) and was cultured in DMEM supplemented 
with 10% FBS. The T47D.Luc cell line, as described by Legler et al., 8 is a reporter gene variant 
of the estrogen-responsive human T47D breast carcinoma cell line, stably transfected with 
a pEREtata-Luc construct. The T47D cells were maintained in DMEM/F-12 supplemented 
with 7.5% FBS and non-essential amino acids solution (Sigma-Aldrich). The ERα U2OS.
Luc cell line, provided by BioDetection Systems B.V. (Amsterdam, The Netherlands), is a 
human U2OS line stably co-transfected with an expression construct for the human ERα 
(pSG5-neo-hERα) and a pGL3 (Promega)-based reporter construct containing 3 EREs and 
a TATA box in front of a luc+ luciferase reporter gene(pGL3-3xEREtataLuc) as described 
by Sonneveld et al. 9 The U2OS cells were cultured in DMEM/F-12 supplemented with 
7.5% FBS, 200 µg/mL geneticin and 50 µg/mL hygromycin. All cell lines were routinely 
maintained in 75 cm2 canted-neck tissue culture flasks (Greiner, Gloucestershire, UK) in a 
humidified incubator at 37 °C and 5% CO2. Cells were sub-cultured at approximately 80% 
confluence and tested negative for mycoplasma.
mcf-7/BoS cell proliferation assay
Proliferation of the human MCF-7/BOS breast cancer cells for estrogenicity testing 
was performed and quantified as described previously, but with some modifications. 12 
Briefly, cells were cultured in assay medium (DMEM/F12 medium, without phenol red 
supplemented with 5% csFBS) for 3 days before starting the experiment. Next, cells were 
plated into 96-well plates at an initial density of 2,000 cells/well in 200 µL assay medium. 
After 24 h, the assay medium was renewed with fresh medium containing test compounds 
dissolved in DMSO (maximum 0.2% DMSO, final concentration). Each test compound at 
each concentration was tested in quadruplicate. After 6 days of exposure, the amount of 
DNA per well, a measure of the amount of cells, was assayed using a microplate modification 
of the Burton diphenylamine assay. 13, 14
er-cAluX reporter gene assays
Human cell-based CALUX reporter gene assays were carried out as described previously. 8 
In short, T47D.Luc and ERα U2OS.Luc cells were plated in 96-well plates with DMEM/F12 
medium without phenol red and supplemented with 5% DCC-FBS for 48 h with a refreshment 
of the medium after 24 h. At 48 h post plating, the medium was refreshed and cells were 
incubated with the test compounds added from a stock solution in DMSO (maximum 
0.2% DMSO, final concentration). Each test compound at each concentration was tested in 
quadruplicate. After 24 h of exposure, media was removed, cells were washed with 0.5 x PBS 
and were lysed with 30 µL of hypotonic low-salt buffer (10 mM Tris, 2 mM DDT, and 2 mM 
CDTA; pH 7.8). Plates were put on ice for 15 min to allow swelling of the cells and subsequently 
frozen at -80 °C for at least 30 min to lyse the cells. Plates were thawed on ice and shaken 
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for 2 min at room temperature. Luciferase activity in cellular lysates was measured with a 
Labsystems Luminoskan RS ® luminometer (Thermo Electron, Breda, The Netherlands) by 
adding 100µl flash mix (20 mM Tricine, 1.07 mM (MgCO3)4Mg(OH)2, 2.67 mM MgSO4, 
0.1 mM EDTA, 2.0 mM dithiothreitol, 470 µM luciferine, 5.0 mM ATP) per well.
Yeast estrogen bioassay
The yeast cytosensor expressing the human estrogen receptor α (hERα) and yeast enhanced 
green fluorescent protein (yEGFP) in response to estrogens was developed in-house and the 
assay was performed as described previously. 11, 15 In short, the day before running the assay, 
a single colony of the yeast ERα cytosensor was used to inoculate 10 mL of minimal medium 
supplemented with 60mg/L L-leucine (MM/L medium). This culture was grown overnight 
at 30 °C with vigorous orbital shaking at 225 rpm. At the late log phase, the yeast ERα 
cytosensor was diluted in the selective MM/L medium to an optical density (OD) value at 
630 nm between 0.04 and 0.06. Subsequently, aliquots of 200 μL of the diluted yeast culture 
were pipetted into each well of a 96-well plate and 2 µL of test compound from a stock 
solution in DMSO (maximum 0.2% DMSO, final concentration) was added in triplicate. 
Exposure was performed for 24 h at 30 °C and orbital shaking at 125 rpm. Fluorescence and 
OD were measured at 0 and 24 h directly in a SynergyTM HT Multi-Detection Micro-plate 
Reader (BioTek Instruments Inc., USA) using excitation at 485 nm and measuring emission 
at 530 nm. The ODs at 630 nm were determined in order to check whether a sample was 
toxic for the yeast cells. Normally, the density at 630 nm increases from 0.05 at 0 h to about 
0.9 at 24 h. If the OD at 24 h was below 0.7, the concentration of the compound tested was 
considered to cause cytotoxicity and rejected for analysis.
data analysis 
The proliferation of the MCF-7/BOS cells was determined by dividing the mean value of DNA 
content per well from exposed and non-exposed (DMSO control) wells, subsequently multiplied 
by 100%. The relative proliferative potency (RPP), defined as the ratio of the concentration of 
E2 needed to achieve 50% of maximal cell yield and the dose of the test compounds required to 
achieve a similar effect and then multiplied by 100, was calculated from fitted proliferation dose-
response curves using nonlinear regression analysis (four parameter sigmoidal dose-response 
curve, Graphpad Prism software, version 5.04). For the luciferase reporter gene assays, luciferase 
activity per well was measured as relative light units (RLU). Fold induction was calculated by 
dividing the mean value of light units from exposed and non-exposed (DMSO control) wells. 
For the yeast estrogen bioassay, the fluorescence signals were corrected for the signal obtained 
with the MM/L medium containing DMSO solvent only. Regarding the three reporter gene 
assays, the relative estrogenic potency (REP), defined as the ratio of the concentration of E2 
needed to achieve 50% of maximal response and the concentration of the test compounds 
required to achieve a similar effect, multiplied by 100, was calculated from fitted dose–response 
curves (four parameter sigmoidal dose-response curve, Graphpad Prism software version 5.04). 
The REP value for E2 is hereby set at 100 for all three reporter gene assays. The estrogenicity 
data used for comparisons with the current proliferation assay and reporter gene assay data 
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were the median ER binding affinities (from several ER binding assays with ER obtained from 
e.g. rat/mouse uterine cytosol or intact MCF-7 cells, or with semi-purified human ERα protein) 
published in the review by ICCVAM, 16 the BG1Luc ER TA reporter gene transactivation assay 
data that were published by ICCVAM 17 and are based on BG-1 immortalized adenocarcinoma 
cells that endogenously express both human ERα and ERβ, and the uterotrophic assay data 
that were derived from the Endocrine Disruptor Knowledge Base (EDKB), developed by the 
National Center for Toxicological Research (NCTR, USA). 18
reSulTS 
A set of 23 reference compounds were tested in the MCF-7/BOS proliferation assay and 
three reporter gene assays, i.e., the T47D ER-CALUX, the U2OS ERα-CALUX and the 
yeast estrogen bioassay. Twenty-one of the 23 compounds tested were selected from the 
ICCVAM list of compounds defined for validation of in vitro tests for estrogenicity testing 
and representing a diverse range of chemicals, i.e., natural steroids, synthetic steroids, 
flavonoids, phenols, organochlorines, and phthalates. 16 Dose-response data were generated 
and for each compound the EC50 value, i.e., the concentration giving a half maximum 
response, was calculated from the fitted dose-response curve. Estradiol (E2) was used 
as a reference compound in each assay. The relative proliferative potency (logRPP) and 
relative estrogenic potency (logREP) values of these 23 compounds, as calculated from the 
determined EC50 values, are listed in Table 1. To allow comparison with data from other 
in vitro and in vivo assays, the relative binding affinity (logRBA), the relative estrogenic 
potency (logREP) and the relative potency (logRP) of these compounds as determined in 
the ER binding assays, the OECD validated BG1Luc ER TA reporter gene assay and the 
in vivo mouse or rat uterotrophic assay, respectively, are also listed in Table 1. In total, 19 
compounds mentioned in the ICCVAM BG1Luc ER TA assay evaluation report overlapped 
with the 23 compounds used in the current study, while ER binding assays data for only 
one compound (OMIY-bisphenol) were not available in the ICCVAM review report. In 
addition, at 10 µM, the organochlorine pesticide kepone was toxic to the yeast cells and this 
compound was therefore excluded from correlation analysis of the yeast estrogen bioassay 
with other assays. The selective estrogen receptor modulator (SERM) 4-hydroxytamoxifen 
(4-OHTAM) was slightly active in the MCF-7/BOS proliferation assay, however, the relative 
proliferative effect, i.e., the ratio between the highest cell yield obtained with 4-OHTAM 
to that obtained with E2, multiplied by 100, was less than 10%. As a result, the logRPP 
of 4-OHTAM could not be reliably determined and this compound was excluded from 
correlation analysis of the MCF-7/BOS proliferation assay with other assays. Moreover, 
ethyl paraben and o,p’-DDT induced a higher maximal response than E2 (being 100%), i.e., 
around 150% and 220%, respectively, in the luciferase-based reporter gene assays.
Subsequently, all the relative potency values were used to construct a correlation matrix. 
Table 2 shows the coefficient of determination (R2) between the different data sets. In general, 
reasonable to good correlations were observed between the in vitro and in vivo assays but also 
among the in vitro assays. The yeast estrogen bioassay showed the best correlation with the in 
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Table 1. Comparison of the relative potency values obtained in various in vitro assays with the in vivo 
uterotrophic for the 23 compounds.
Compound CAS nr.
Uterotrophic 
assay logRP a
MCF-7/BOS proliferation BG1Luc ER TA 
logREP f
T47D ER-CALUX U2OS ERα-CALUX Yeast estrogen bioassay ER binding 
log RBAhEC50 log REP EC50 log REP EC50 log REP EC50 log REP
17ß-Estradiol 50-28-2 2.0 2.0E-11 2.0 2.0 5.0E-12 2.0 8.6E-12 2.0 6.0E-10 2.0 2.0
EE2 57-63-6 3.0 9.7E-12 2.3 1.7 2.7E-12 2.3 5.6E-12 2.2 5.0E-10 2.1 2.2
DES 56-53-1 2.7 3.8E-11 1.7 1.2 1.8E-11 1.4 8.1E-11 1.0 6.0E-10 2.0 2.1
Dienestrol 84-17-3 2.4 3.8E-11 1.7 - 5.9E-11 0.9 8.5E-11 1.0 1.8E-09 1.5 2.0 i
meso-Hexestrol 84-16-2 2.5 3.8E-10 0.7 1.3 6.9E-11 0.9 1.7E-10 0.7 2.8E-09 1.3 2.4
Corticosterone 50-22-6 -5.0 b - -5.0 -5.0 - -5.0 - -5.0 - -5.0 -5.0
Progesterone 57-83-0 -5.0 - -5.0 -3.6 - -5.0 - -5.0 - -5.0 -3.5
Testosterone 58-22-0 -5.0 2.1E-06 -3.0 -3.2 - -5.0 8.5E-07 -3.0 3.0E-05 -2.7 -1.6
Coumestrol  479-13-0 -0.8 1.3E-08 -0.8 -2.6 5.2E-09 -1.0 4.4E-08 -1.7 1.4E-07 -0.4 1.1
Genistein 446-72-0 -2.7 4.6E-08 -1.4 -2.9 1.3E-07 -2.4 6.8E-08 -1.9 2.0E-06 -1.5 0.2
Apigenin 520-36-5 -5.0 6.2E-07 -2.5 -3.6 4.1E-07 -2.9 5.8E-07 -2.8 2.4E-04 -3.6 0.1
Zearalenone 17924-92-4 -0.7 1.5E-10 1.1 - 2.3E-10 0.3 4.2E-10 0.3 1.3E-07 -0.3 1.2
OMIY-bisphenol 1943-97-1 -0.3 c 2.3E-09 -0.1 - 3.2E-10 0.2 1.2E-08 -1.1 1.0E-07 -0.2 -
p-n-Nonylphenol 104-40-5 -5.0 - -5.0 - - -5.0 - -5.0 - -5.0 -1.5
Bisphenol A 80-05-7 -1.6 3.6E-07 -2.3 -3.1 7.7E-07 -3.2 2.2E-07 -2.4 3.0E-06 -1.7 -1.5
Kepone 143-50-0 -1.0 4.9E-07 -2.4 -3.1 6.7E-07 -3.1 8.5E-07 -3.0 - Toxic g -1.5
o,p’-DDT 789-02-6 -3.5 3.8E-07 -2.3 -3.1 4.1E-07 -2.9 7.2E-07 -2.9 6.0E-06 -2.0 -1.7
2,4,5-T 93-76-5 - d - -5.0 -5.0 - -5.0 - -5.0 - -5.0 -5.0
Butylbenzyl phthalate 85-68-7 -5.0 2.0E-06 -3.0 -3.8 5.7E-06 -4.1 1.0E-05 -4.1 - -5.0 -2.7
Di-n-butyl phthalate 84-74-2 -5.0 3.0E-06 -3.2 -4.1 1.7E-05 -4.5 1.9E-05 -4.3 - -5.0 -2.6
Ethyl paraben 120-47-8 -5.0 1.4E-05 -3.8 -4.9 5.5E-06 -4.0 4.2E-05 -4.7 1.0E-03 -4.2 -3.2
Tamoxifen 10540-29-1 1.0 4.1E-09 -0.3 -2.3 1.5E-08 -1.5 2.1E-08 -1.4 3.0E-06 -1.7 0.6
4-OHTAM 68047-06-3 1.0 presumed positive e - -5.0 - -5.0 - -5.0 2.0E-06 -1.5 2.2
a Median relative potency values based on uterotrophic assay in mouse or rat, derived from the EDKB 
(NCTR,USA). 17ß-estradiol is used as a reference chemical and is defined to have a relative potency of 100 
(logRP=2.0). 18 
b A cut-off value of -5.0 is listed for compounds showing no effect.
c logRP of 4,4′-(octahydro-4,7-methano-5H-inden-5-ylidene)bisphenol (OMIY-bisphenol) was calculated based 
on the minimal active dose described by Yamasaki et al. 2003. 19
d Data not available.  
e The EC50 of 4-Hydroxytamoxifen could not be reliably determined. 
f Relative estrogenic potency is defined as the ration between the median EC50 of 17ß-estradiol and the 
median EC50 of the compound, and this ratio is subsequently multiplied by 100 calculated based on the 
BG1Luc ER TA data reported by ICCVAM. 17 The REP value of 17ß-estradiol is thus 100, resulting in a 
logREP of 2.0.
g Toxic to the yeast cells at concentrations higher than 10 µM. 
h Logarithm of the median ER relative binding affinity values listed in the review report of  ICCVAM. 16
i Median logRBA value derived from the EDKB (NCTR,USA). 18
vivo uterotrophic assay (R2 = 0.87), followed by MCF-7/BOS proliferation assay (R2 = 0.85). 
The three human cell-based reporter gene assays showed a significant but relatively lower 
correlation with ER binding assays and the in vivo uterotrophic assay (R2 ranging from 
0.54 to 0.70). These low correlations were mainly caused by 4-OHTAM (see Figure. 1C-E). 
As shown in Table 1, a relatively high potency values was observed for 4-OHTAM in the 
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Table 1. Comparison of the relative potency values obtained in various in vitro assays with the in vivo 
uterotrophic for the 23 compounds.
Compound CAS nr.
Uterotrophic 
assay logRP a
MCF-7/BOS proliferation BG1Luc ER TA 
logREP f
T47D ER-CALUX U2OS ERα-CALUX Yeast estrogen bioassay ER binding 
log RBAhEC50 log REP EC50 log REP EC50 log REP EC50 log REP
17ß-Estradiol 50-28-2 2.0 2.0E-11 2.0 2.0 5.0E-12 2.0 8.6E-12 2.0 6.0E-10 2.0 2.0
EE2 57-63-6 3.0 9.7E-12 2.3 1.7 2.7E-12 2.3 5.6E-12 2.2 5.0E-10 2.1 2.2
DES 56-53-1 2.7 3.8E-11 1.7 1.2 1.8E-11 1.4 8.1E-11 1.0 6.0E-10 2.0 2.1
Dienestrol 84-17-3 2.4 3.8E-11 1.7 - 5.9E-11 0.9 8.5E-11 1.0 1.8E-09 1.5 2.0 i
meso-Hexestrol 84-16-2 2.5 3.8E-10 0.7 1.3 6.9E-11 0.9 1.7E-10 0.7 2.8E-09 1.3 2.4
Corticosterone 50-22-6 -5.0 b - -5.0 -5.0 - -5.0 - -5.0 - -5.0 -5.0
Progesterone 57-83-0 -5.0 - -5.0 -3.6 - -5.0 - -5.0 - -5.0 -3.5
Testosterone 58-22-0 -5.0 2.1E-06 -3.0 -3.2 - -5.0 8.5E-07 -3.0 3.0E-05 -2.7 -1.6
Coumestrol  479-13-0 -0.8 1.3E-08 -0.8 -2.6 5.2E-09 -1.0 4.4E-08 -1.7 1.4E-07 -0.4 1.1
Genistein 446-72-0 -2.7 4.6E-08 -1.4 -2.9 1.3E-07 -2.4 6.8E-08 -1.9 2.0E-06 -1.5 0.2
Apigenin 520-36-5 -5.0 6.2E-07 -2.5 -3.6 4.1E-07 -2.9 5.8E-07 -2.8 2.4E-04 -3.6 0.1
Zearalenone 17924-92-4 -0.7 1.5E-10 1.1 - 2.3E-10 0.3 4.2E-10 0.3 1.3E-07 -0.3 1.2
OMIY-bisphenol 1943-97-1 -0.3 c 2.3E-09 -0.1 - 3.2E-10 0.2 1.2E-08 -1.1 1.0E-07 -0.2 -
p-n-Nonylphenol 104-40-5 -5.0 - -5.0 - - -5.0 - -5.0 - -5.0 -1.5
Bisphenol A 80-05-7 -1.6 3.6E-07 -2.3 -3.1 7.7E-07 -3.2 2.2E-07 -2.4 3.0E-06 -1.7 -1.5
Kepone 143-50-0 -1.0 4.9E-07 -2.4 -3.1 6.7E-07 -3.1 8.5E-07 -3.0 - Toxic g -1.5
o,p’-DDT 789-02-6 -3.5 3.8E-07 -2.3 -3.1 4.1E-07 -2.9 7.2E-07 -2.9 6.0E-06 -2.0 -1.7
2,4,5-T 93-76-5 - d - -5.0 -5.0 - -5.0 - -5.0 - -5.0 -5.0
Butylbenzyl phthalate 85-68-7 -5.0 2.0E-06 -3.0 -3.8 5.7E-06 -4.1 1.0E-05 -4.1 - -5.0 -2.7
Di-n-butyl phthalate 84-74-2 -5.0 3.0E-06 -3.2 -4.1 1.7E-05 -4.5 1.9E-05 -4.3 - -5.0 -2.6
Ethyl paraben 120-47-8 -5.0 1.4E-05 -3.8 -4.9 5.5E-06 -4.0 4.2E-05 -4.7 1.0E-03 -4.2 -3.2
Tamoxifen 10540-29-1 1.0 4.1E-09 -0.3 -2.3 1.5E-08 -1.5 2.1E-08 -1.4 3.0E-06 -1.7 0.6
4-OHTAM 68047-06-3 1.0 presumed positive e - -5.0 - -5.0 - -5.0 2.0E-06 -1.5 2.2
a Median relative potency values based on uterotrophic assay in mouse or rat, derived from the EDKB 
(NCTR,USA). 17ß-estradiol is used as a reference chemical and is defined to have a relative potency of 100 
(logRP=2.0). 18 
b A cut-off value of -5.0 is listed for compounds showing no effect.
c logRP of 4,4′-(octahydro-4,7-methano-5H-inden-5-ylidene)bisphenol (OMIY-bisphenol) was calculated based 
on the minimal active dose described by Yamasaki et al. 2003. 19
d Data not available.  
e The EC50 of 4-Hydroxytamoxifen could not be reliably determined. 
f Relative estrogenic potency is defined as the ration between the median EC50 of 17ß-estradiol and the 
median EC50 of the compound, and this ratio is subsequently multiplied by 100 calculated based on the 
BG1Luc ER TA data reported by ICCVAM. 17 The REP value of 17ß-estradiol is thus 100, resulting in a 
logREP of 2.0.
g Toxic to the yeast cells at concentrations higher than 10 µM. 
h Logarithm of the median ER relative binding affinity values listed in the review report of  ICCVAM. 16
i Median logRBA value derived from the EDKB (NCTR,USA). 18
uterotrophic assay (logRP = 1.0) and an even higher median value in the ER binding assays 
(logRBA = 2.2). However, 4-OHTAM is not active in the three human cell-based bioassays. 
Only the yeast estrogen bioassay and the MCF7/BOS cell proliferation assay were able to 
display the ER-agonistic properties of 4-OHTAM and produce qualitative outcomes that are 
comparable to that obtained in vivo. When 4-OHTAM was excluded from the comparison, 
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the correlation of the uterotrophic assay or ER binding assays with the three human cell-
based reporter gene assays increased to R2 between 0.76 and 0.87. In addition to 4-OHTAM, 
several other compounds also revealed discrepancies, e.g., testosterone was negative in the 
T47D ER-CALUX assay and the uterotrophic assay but positive in the other three reporter 
gene assays and the ER binding assays; butylbenzyl phthalate and di-n-butyl phthalate were 
positive in the ER binding assays, the three CALUX assays, and the proliferation assay, 
but negative in the yeast estrogen bioassay and the uterotrophic assay. These discrepancies 
also have influences on the overall correlation between different bioassays, but to a lesser 
extent than observed with 4-OHTAM. To visualize these discrepancies, Figure 1 shows the 
comparison of different in vitro assays with the in vivo uterotrophic assay. Compounds 
on the dotted diagonal line depicted in all graphs of Figure 1, representing exact potency 
equality, have about the same relative potency in the in vitro assay as obtained in the in vivo 
uterotrophic assay, compounds clearly above the line are relatively more potent in vivo than in 
vitro, while compounds below the line are relatively more potent in the in vitro assays than in 
the in vivo uterotrophic assay. From Figure 1 it becomes clear that the main outliers between 
different in vitro assays and the in vivo uterotrophic assay are 4-OHTAM, testosterone (T), 
and, to a lesser extent, apigenin, tamoxifen (TAM) and kepone. The yeast estrogen bioassay 
showed the best correlation with the in vivo uterotrophic assay (R2 = 0.87), and moreover, 
the majority of the compounds lie close to the diagonal line of potency equality (Figure 1E). 
Although the relative binding affinities of TAM and 4-OHTAM to the ER correlated well with 
the relative estrogenic potencies of these two compounds as observed in the uterotrophic 
assay, most of the other compounds shown in Figure 1F lie below the dotted diagonal line of 
equal potency, included in all graphs in Figure 1. This indicates that most compounds show 
a weaker estrogenic potency relative to E2 in the uterotrophic assay than would be expected 
on the basis of their relative ER binding tendency. Moreover, the wider dispersion of the data 
points around the regression line in Figure 1F reveals an overall relatively low correlation of 
the results from the ER binding assays with in vivo estrogenicity displayed in the uterotrophic 
assay (R2 = 0.75). Altogether, the results presented in Figure 1 and Table 2 reveal that the in 
vitro assays showing the most accurate prediction of in vivo estrogenicity as observed in the 
uterotrophic assay are the yeast estrogen bioassay and the MCF-7/BOS proliferation assay.
diScuSSion
The aim of the present study was to further investigate which of a series of in vitro assays for 
estrogen activity most accurately predicts the uterotrophic effects observed in vivo. The outcomes 
of ER binding assays, four reporter gene assays and the MCF-7/BOS cell proliferation assay were 
compared with the outcomes of the in vivo uterotrophic assay. All together, these assays cover 
a broad range of endpoints representing different phases of the estrogen signaling pathway, i.e., 
receptor binding, target gene transcriptional activation, cell proliferation and in vivo uterotrophic 
effects. Results from these comparisons provide useful information to select the most suitable 
in vitro assays for estrogenicity testing and lead to the following considerations to be taken into 
account when defining an ITS for in vitro estrogenicity testing.
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Table 2. Coefficient of determination (R2) between different bioassay used in the study. Values given in 
brackets were obtained after 4-hydroxytamoxifen was excluded from the comparisons.
Uterotrophic 
assay
n=22
MCF-7/BOS 
proliferation
n=22
BG1Luc 
ER TA
n=19
T47D 
ER-CALUX
n=23
U2OS 
ERα-CALUX
n=23
Yeast 
estrogen 
bioassay
n=22
ER 
binding 
assays
n=22
Uterotrophic assay - 0.85 0.62 (0.82) 0.70 (0.87) 0.68 (0.86) 0.87 0.75
MCF-7/BOS 
proliferation
0.85 - 0.88 0.95 0.97 0.92 0.86
BG1Luc ER TA 0.62 0.88 - 0.91 0.94 0.80 0.54
T47D ER-CALUX 0.70 0.95 0.91 - 0.95 0.85 0.63
U2OS ERα-CALUX 0.68 0.97 0.94 0.95 - 0.87 0.64
Yeast estrogen 
bioassay
0.87 0.92 0.80 0.85 0.87 - 0.78
ER binding 0.75 0.86 0.54 (0.76) 0.63 (0.83) 0.64 (0.85) 0.78 -
In vitro ER competitive binding assays have been well established and extensively used 
to investigate ER-ligand interactions. These assays measure the displacement of a receptor-
bound probe molecule, e.g., [3H]E2, by a test compound and subsequently determine the 
relative binding affinity of the test compound for ER. The ER binding assays are rapid 
and easy to perform, but only the strength of the binding of a compound to the receptor 
is determined and not the activation or inhibition of activation of the receptor. Thus, 
compounds with high binding affinities to the ER might show lower estrogenic activities in 
cell-based and in vivo assays. This was clearly demonstrated in the current study, by the fact 
that several compounds showed high binding affinities to ER, but were inactive in the in 
vivo uterotrophic assay. It was also illustrated by the fact that -as shown in Figure 1F- most 
of the data points for the correlation between the logRBA from the ER binding assays and 
the logRP from the uterotrophic assay lie below the dotted diagonal line representing equal 
potency. In addition, conventional ER binding assays are unable to distinguish receptor 
agonists from receptor antagonists. Moreover, the rat uterine cytosol ER binding assay, 
currently listed as part of the Environmental Protection Agency (EPA) Endocrine Disruptor 
Screening Program Tier 1 screening battery, still requires the use of animals as a source 
of ERs. This test is therefore considered to be less suited for an in vitro high-throughput 
approach for screening of compounds for estrogenic activity. 
Proliferation assay based on the human MCF-7/BOS breast cancer cell line is widely used as 
a screening tool to detect environmental and xenobiotic estrogens. 12, 20 Based on 12 compounds, 
the MCF-7/BOS proliferation assay has previously been shown to correlate better with the in 
vivo uterotrophic assay (R2 = 0.85) than the proliferative responses of three other human cell 
lines derived from breast, endometrium and ovary. 7 The correlation with the uterotrophic assay 
as obtained in the present study with the extended set of 23 compounds (R2 = 0.85), is identical 
to the correlation obtained in the previous study in which only 12 compounds were studied. 
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Figure 1. Comparison of the relative potency values obtained from different in vitro assays with the 
relative potency values obtained from the in vivo uterotrophic assay. (A) MCF-7/BOS proliferation 
assay versus uterotrophic assay (R2=0.85, p<0.0001, n=21, regression equation y=1.15x+0.01); (B) 
BGLuc ER TA versus uterotrophic assay (R2=0.62, p<0.0001, n=16 and the regression equation is 
y=1.20x+0.60); (C) T47D ER-CALUX versus uterotrophic assay (R2=0.70, p<0.0001, n=22, regression 
equation y=0.96x+0.28); (D) U2OS ERα-CALUX versus uterotrophic assay (R2=0.68, p<0.0001, n=22, 
regression equation y=1.03x+0.45); (E) yeast estrogen bioassay versus uterotrophic assay (R2=0.87, 
p<0.0001, n=21, regression equation y=1.14x+0.29); and (F) ER binding assay versus uterotrophic 
assay (R2=0.75, p<0.0001, n=21, regression equation y=1.21x-1.20). The dotted diagonal line included 
in all figures represents potency equality. Compounds that deviating the most from the dotted diagonal 
line are indicated by their names. 
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This demonstrates that the cell proliferation endpoints  has a high predictive value for the in 
vivo uterotrophic effect. However, the MCF-7/BOS cell proliferation assay is not very fast, i.e., 
the proliferative responses of the MCF-7/BOS cells can be reliably quantified only after 6 days. 
This might limit its practical application in the current format as a high-throughput screening 
tool within massive screening programs such as REACH. Moreover, crosstalk can occur due to 
the fact that MCF-7/BOS cells also express androgen, progesterone, glucocorticoid and retinoid 
receptors 21. Thus, this assay may not provide straightforward information on the mechanism of 
action of the compound under investigation. 
Reporter gene assays, based on stably transfected cells (either mammalian or yeast cells), 
provide a more specific endpoint measurement, i.e. are based on estrogen receptor-mediated 
activation of gene transcription. As a result, these assays can distinguish between receptor 
agonists and antagonists. The three mammalian cell-based reporter gene assays used in 
the current study, i.e., the T47D ER-CALUX, the U2OS ERα-CALUX, and the BG1Luc ER 
TA assay yield satisfactory correlations (R2 = 0.62 - 0.70) with the uterotrophic assay. The 
T47D ER-CALUX assay is based on a human breast carcinoma cell line that endogenously 
expresses both ERα and ERβ. It has been shown previously that ERα activation enhances cell 
proliferation in breast and uterus, 22-24 while ERβ activation counteracts the ERα-mediated 
stimulation of cell proliferation. 25-27 Surprisingly, the estrogenic responses obtained for 
the 23 compounds tested in the T47D ER-CALUX assay were essentially similar to the 
responses obtained in the U2OS ERα-CALUX stably expressing only ERα (R2 = 0.95). This 
is most likely due to the fact that T47D cells express very low levels of ERβ, 7, 8 resulting in 
a minimal or even no effect via ERβ activation. A similar situation may hold for the OECD 
validated BG1Luc ER TA assay, which is based on the human BG1 ovarian cancer cell line 
that also endogenously expresses both ERs, but also with relatively low levels of ERβ. 7, 28, 29 In 
addition, a superinduction effect was observed for ethyl paraben and o,p’-DDT in both T47D 
ER-CALUX and U2OS ERα-CALUX assays, but not in MCF-7/BOS cell proliferation assay. 
It has been shown that the superinduction effect in the two CALUX assays could be ascribed 
to stabilization of the firefly luciferase reporter enzyme, thus increasing the bioluminescent 
signal during the assay. 30 In line with this, ethyl paraben and o,p’-DDT did not result in 
superinduction but rather induced a similar response as E2 in the fluorescence-based yeast 
estrogen bioassay. Although only 23 compounds were tested, the T47D ER-CALUX and 
U2OS ERα-CALUX showed a better correlation with the in vivo uterotrophic assay than the 
OECD validated BG1Luc ER TA assay. Due to the fact that the U2OS ERα-CALUX has also 
been pre-validated, 10 it is concluded that the U2OS ERα-CALUX seems the most promising 
human cell-based reporter gene assay to be part of an in vitro ITS for estrogenicity.
Compared with the human cell line based reporter gene assays, the yeast estrogen 
bioassay is less sensitive, e.g., the EC50 of E2 in the yeast assay is about 100 times higher than 
its EC50 in the mammalian cell-based CALUX assays. However, the yeast estrogen bioassay 
showed the best correlation with the uterotrophic assay (R2 = 0.87). Although yeast cell 
based assays are thought to suffer from poor transport of chemicals across the yeast cell wall, 
previous studies demonstrated that the yeast cell wall is easily permeable for compounds 
with a molecular weight up to 620 or even larger molecules due to the flexibility of the 
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wall of living yeast cells. 31, 32 Thus, the yeast cell wall does not provide a major obstacle for 
low molecular weight compounds to reach the inside of the cells and activate the ER. This 
consideration was confirmed by the good correlation observed between the yeast estrogen 
bioassay and the in vivo uterotrophic assay. In addition, Kolle et al. (2010) also showed that 
another yeast based assay, the YES assay, has a very high concordance (87%) for predicting 
estrogenic effects in vivo 6 and proposed to use the YES assay among other assays in the EPA’s 
Endocrine Disruptor Screening Program. 33 Moreover, the yeast estrogen bioassay is the only 
reporter gene assay used in the current study that was able to correctly predict the agonist 
effect of 4-OHTAM. All three mammalian cell-based reporter gene assays failed to detect the 
ER agonist effect of 4-OHTAM. TAM and its metabolite 4-OHTAM are not pure estrogen 
receptor agonists or antagonists, but act as selective estrogen receptor modulators (SERMs). 
They are mainly reported to act as ER-agonists on the endometrium and bone and as ER-
antagonists in breast. 34-36 Several studies have shown that TAM and 4-OHTAM are also able 
to inhibit the effect caused by potent estrogens, e.g. EE2 or E2, in the T47D ER-CALUX, 
U2OS ERα-CALUX, MCF-7/BOS proliferation assay, and in the in vivo uterotrophic assay, 7-9, 
19 but not in the yeast estrogen bioassay. 15, 37 Thus compared to its mammalian counterparts, 
the yeast estrogen bioassay failed to show the antagonistic activities of TAM and 4-OHTAM. 
A possible explanation for the differences observed in the different assays with the two 
SERMs is the absence or presence of cell-specific factors (coactivators and corepressors). It 
has been shown that TAM and 4-OHTAM can bind to the ligand-binding domain of ERα 
and cause a conformational shift of helix 12 into an adjacent coactivator binding site, which 
in turn prevents ERα from binding a coactivator. 38-42 The absence of the specific coactivator 
in different mammalian cell lines and yeast cells as compared to intact uterus tissue may 
therefore provide a possible explanation of the observed discrepancy. This indicates that 
an in vitro assay enabling to study ligand-modulated interaction of coregulators with ERα 
would have the potential to add relevant information to an ITS for estrogenicity testing. Such 
an ligand-induced coregulator binding assay has recently shown to provide results that also 
correlate well with the results from uterotrophic assay for a series of selected compounds. 43, 44 
The androgen testosterone (T) was used as a negative control, as it is inactive in the 
in vivo uterotrophic assay. However, T was slightly active in the BG1Luc ER TA assay and 
the yeast estrogen bioassay, and even resulted in full dose response curves in the U2OS 
ERα-CALUX assay and MCF-7/BOS proliferation assay. The effect of T in these assays could 
be due to activation of the ER, as it is known that T is able to bind ER (logRBA = -1.6). 
However, this can only partly explain the obtained results, as T did not elicit a full dose 
response in the yeast estrogen bioassay that stably expresses hERα. The full dose-response 
curves obtained for T in the U2OS ERα-CALUX and MCF-7/BOS proliferation assay may 
rather be due to the formation of estrogenic metabolites, as the aromatase enzyme or other 
P450 enzymes in the steroidogenesis pathway might be present in these mammalian cells, 
while being absent in the yeast cells. However, the T47D and BG-1 cells are also known to 
have aromatase activity, 7, 45 but did not give clear response when exposed to T. The reason 
for these unexpected observations remain to be elucidated, however, this could be due to the 
fact that T or the formed E2 are metabolised further in these cell lines into non-estrogenic 
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metabolites. On the one hand, the current study shows that presence of P450 enzymes in 
mammalian cell lines may lead to a false positive result as demonstrated for T in MCF-7/
BOS and U2OS cell based bioassays. On the other hand, these cell lines have only a very 
limited metabolic capacity. Compounds that are converted into more potent metabolites 
in vivo mostly show much lower estrogenic potencies in these in vitro assays. For example, 
in the U2OS ERα-CALUX assay the organochlorine insecticide methoxychlor is about 100 
times less potent than its in vivo metabolite 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane 
(HPTE). 5 This might also be the reason for the discrepancy observed for the organochloride 
kepone used in the present study, showing a lower logREP in all three reporter gene assay 
than the logRP in the uterotrophic assay. Taken together, in order to prevent misclassification 
of compounds it is necessary to characterize the metabolic capacities of the cell line used for 
estrogenicity testing. Furthermore, combination of the in vitro assays with a bioactivation 
step, e.g., S9 treatment, might further improve their  predictivity for estrogenic potency in 
vivo. In addition, the estrogenic effect of a chemical can also be due to alteration of normal 
hormone levels. This indicates that there is a need to include in an ITS for example the H295R 
steroidogenesis assay that measures the potential interference of exogenous compounds with 
endogenous steroid hormone synthesis. In addition, as the human H295R adrenocarcinoma 
cell line expresses all key P450 enzymes, including aromatase, it might also be a useful model 
to study effects of metabolites of (steroidal) parent compounds. 
Finally, the flavonone apigenin showed clear response in all the four reporter gene 
assays and the MCF-7/BOS proliferation assay. However, apigenin was negative in the 
uterotrophic assay. This is most probably due to the poor bioavailability of apigenin 
in rodents, as reported by Breinholt et al. (2000), showing that the urinary recovery of 
apigenin is only about 1% of the total administered dose in mice. 46 These results indicate 
that in order to better predict estrogenic property of a compound in vivo, the bioavailability 
of the compound should be taken into account as well. 
In conclusion, the present work demonstrates that each in vitro assay has its own 
advantages and disadvantages. The yeast estrogen bioassay is less sensitive, but the 
determined effects and relative potencies are very accurate and the assay showed the best 
correlation with the in vivo uterotrophic assay. Compared to its mammalian counterparts, 
the yeast estrogen bioassay does not need expensive growth media (csFBS) nor sophisticated 
cell culture facilities. However, due to the limited sensitivity and because the yeast estrogen 
bioassay is not able to show the antagonistic properties of the two SERMs tested as shown 
in the previous studies, it is recommended to combine the yeast estrogen bioassay with 
the U2OS ERα-CALUX assay into an ITS for the detection of estrogenic activity. The main 
outliers identified when correlating data from the different in vitro assays and the in vivo 
uterotrophic assay are 4-OHTAM, T and to a lesser extent apigenin, tamoxifen and kepone. 
Based on the modes of action possibly underlying these discrepancies it becomes evident 
that to further improve the ITS and ultimately replace animal testing for (anti-)estrogenic 
effects, the selected bioassays have to be combined with other types of in vitro assays, 
including for example the H295R steroidogenesis assay and in vitro models for digestion, 
bioavailability and metabolism of the compounds under investigation. 
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In the present study, a set of 12 reference compounds was tested in a low-density 
DNA microchip, which contains probes for 11 different estrogen-responsive marker 
genes. Our results show that the seven most informative marker genes on the chip 
resulted in fingerprints that correctly predicted the (anti-)estrogenic activity of the 
model compounds, except that of the negative control testosterone. Two marker 
genes (i.e., myeloid leukemia factor-1 interacting protein and ubiquitin-conjugating 
enzyme E2C) were even capable of correctly predicting the estrogenic potency of 
all five estrogen receptor (ER) agonists tested and correlated well with the potencies 
as determined in the MCF-7/BOS proliferation assay and the in vivo uterotrophic 
assay. In addition, it was demonstrated that the estrogenic responses of testosterone, 
both in the array tube assay and in the proliferation assay, were partially due to the 
conversion of testosterone into 17ß-estradiol by aromatase, but also due to formation 
of other estrogenic metabolites, the presence and estrogenic potency of which were 
confirmed by GC-MS/MS analysis and a yeast-based reporter gene assay, respectively. 
It is concluded that low-density DNA microchip-based fingerprinting in MCF-7/
BOS cells for estrogenicity marker genes provides a faster in vitro alternative to the 
current MCF-7/BOS cell proliferation assay (E-screen).
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Estrogens are a member of the family of steroid hormones and are primarily biosynthesized 
in the female ovaries. Estrogens influence the growth, differentiation and function of 
many target organs, such as mammary gland, uterus, ovary, vagina, as well as testis and 
prostate. 1-3 They also play a role in bone maintenance, the central nervous system and 
the cardiovascular system. 4 Estrogens mainly exert their effect through activation of the 
estrogen receptors (ERα and ERβ) in target cells. Upon ligand binding, a conformational 
change is induced and the estrogen receptor dissociates from the heat-shock proteins and 
becomes activated. Then, the ligand-bound activated ER dimerizes and binds to estrogen-
responsive elements (ERE) on the DNA. Subsequently, coregulator proteins (i.e. coactivators 
and corepressors) are recruited to the promoter region of estrogen-responsive genes. 5, 6 The 
DNA-bound dimer activates or represses transcription of target genes, depending on the 
type of coregulator bound, leading to altered protein synthesis and cellular functioning. 7
The Allen and Doisy test is the standard test for the determination of the estrogenic 
potency of a compound. The Allen and Doisy test is a uterotrophic assay in immature or 
ovariectomized rodents using uterus weight as a crucial read-out parameter. 8, 9 This in vivo 
test determines the overall biological effect of a given compound, including the interaction 
between cells and between different components of the endocrine system, thereby being 
able to detect complex modes of action that may occur only in the intact animal. However, 
this uterotrophic assay is labour-intensive and expensive; further, the use of laboratory 
animals raises ethical concerns. As alternatives, many in vitro assays have been developed to 
determine the potential estrogenic activities of compounds corresponding to the different 
steps in the estrogen receptor-dependent pathway. These in vitro assays were recently 
reviewed by Bovee and Pikkemaat, showing that every assay type has its own specific 
advantages and disadvantages 10. From the cell-based assays, reporter gene assays (based 
on either mammalian or yeast cells) and proliferative assays (based on human cell lines) 
are among the most used. Several reporter gene assays have been developed and applied 
as screening tools to determine the estrogenic/anti-estrogenic activities of compounds. 11-13 
These reporter gene assays measure the induction of a reporter gene, the expression of 
which is easy to quantify and is dependent on the level of activation of the estrogen receptor. 
Although this is very useful, these assays are based on a single estrogen-responsive cell type 
cultured in vitro, and do not reflect the biological complexity of multi-factorial networks 
regulating the physiology of native cells in a whole animal 14 (e.g., issues of bioavailability, 
metabolism or effects on steroidogenesis). Proliferative assays suffer the same drawbacks, 
although the endpoint is closer to the biological effect as determined in the in vivo 
uterotrophic assay. The E-screen is a proliferative assay based on the human MCF-7/BOS 
breast cancer cell line and is widely used as a screening tool to detect environmental and 
xenobiotic estrogens. 15, 16 However, the MCF-7/BOS cell proliferation assay is not very fast; 
i.e., the proliferative responses of the MCF-7/BOS cells can be reliably quantified only after 
6 days. This test is therefore considered to be less suited for the high-throughput screening 
of compounds. Moreover, crosstalk can occur due to the fact that MCF-7/BOS cells also 
express androgen, progesterone, glucocorticoid and retinoid receptors. 10 Nevertheless, the 
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MCF-7/BOS proliferation assay has previously been shown to correlate best with the in vivo 
uterotrophic assay when compared to the proliferative responses of three other human cell 
lines derived from breast, endometrium and ovary. 17
Transcriptomic fingerprinting techniques based on toxicant-specific changes of gene 
expression may provide an alternative tool to detect both known and unknown estrogenic 
compounds. Traditional methods such as northern blotting and, more recently, methods like 
the quantitative real-time polymerase chain reaction (qRT-PCR) are suitable, but only for 
analysis of a small number of candidate genes. 18 Furthermore, multiplex analysis by real-time 
PCR typically suffers from reduced quantification power due to inaccuracy and a relatively 
narrow dynamic range; therefore, optimization steps are needed. 19, 20 The introduction of the 
DNA microarray technology has made it possible to examine the expression of thousands of 
genes at the same time. Major drawbacks are related to the high costs and the time required 
for analysis and interpretation of the data. In contrast, low-density microarrays, containing a 
limited set of genes, still offer the ability to rapidly study expression changes of a substantial 
number of genes, and also provide a more cost-effective option to study known molecular 
pathways affected by exposure to a test chemical. 21 Such a low-density microchip in Array 
Tube format was recently developed by Alere (Jena, Germany), consisting of a custom probe 
microarray (the biochip) integrated into a micro reaction vial. This system has already been 
applied to detect zearalenone and type A trichothecenes in food matrices 21, 22 and more 
recently for the detection of lipophilic marine toxins. 23
In the present study a set of 12 reference compounds was tested using a newly developed 
array tube, which contains probes for 11 different estrogen-responsive genes selected from a 
comprehensive gene expression study of estrogen-treated MCF-7/BOS cells. 24 The objective 
of the present study was to determine to what extent this low-density DNA microchip 
correctly predicts the estrogenic/anti-estrogenic activities and potencies of these 12 
compounds when compared to the outcomes obtained in the MCF-7/BOS cell proliferation 
assay and in the in vivo uterotrophic assay.
mATeriAlS And meThodS
chemicals
Dienestrol, 17β-estradiol (E2), zearalenone, corticosterone, tamoxifen, epidermal growth 
factor (EGF), dehydroepiandrosterone (DHEA), letrozole, flutamide, and β-mercaptoethanol 
were obtained from Sigma-Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). 17α-Ethinyl 
estradiol (EE2), progesterone, 17β-testosterone (T), 4-androstenediol, 5-androstenediol, 
and androstenedione were purchased from Steraloids (Newport, RI, USA). Genistein was 
obtained from Apin Chemicals (Abingdon, Oxon, UK); 4,4’-(octahydro-4,7-methano-
5h-inden-5-ylidene)bisphenol (OMIY-bisphenol) from Acros Organics (Fisher Emergo 
B.V., Landsmeer, The Netherlands) and carbon tetrachloride (CCl4) from Supelco 
Inc. (Bellefonte, PA, USA). The RU 58668 compound was a gift from MSD (Oss, The 
Netherlands). Dimethylsulfoxide (DMSO), sodium chloride, Tween 20, Tris(hydroxymethyl)
aminomethane (Tris), and glycine were purchased from Merck (Darmstadt, Germany). Fetal 
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bovine serum (FBS), charcoal-stripped fetal bovine serum (csFBS), Dulbecco’s modified 
Eagle’s medium nutrient mixture F-12 HAM (DMEM/F12 1:1 mixture, with L-glutamine and 
15 mM HEPES) without phenol red, 20x saline-sodium phosphate EDTA (SSPE), and 20x 
saline-sodium citrate (SSC) were obtained from Gibco/Invitrogen (Breda, The Netherlands). 
Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Lonza (Breda, The 
Netherlands). Acetonitrile, ethanol, methanol, acetone, isopropanol, and n-pentane were 
from Biosolve (Valkenswaard, The Netherlands). The derivatization reagent MSTFA++ 
consisted of a mixture of N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) from 
Alltech (Anaconda, MT, US), ammonium iodide from Fluka (Zwijndrecht, the Netherlands) 
and dithiothreitol from Sigma-Aldrich Chemie B.V. (1000:2:4, v/w/w). Chemicals to prepare 
the growth media for yeast were described previously. 25
cell culture and treatment
MCF-7/BOS human breast cancer cells were kindly provided by Dr. Ana M. Soto (Tufts 
University, Boston, Massachusetts, USA) and were routinely grown at 37 °C under 
5% CO2 atmosphere in 75 cm2 canted-neck tissue culture flasks (Greiner, Gloucestershire, 
UK) containing 10 mL DMEM supplemented with 10% FBS. Cells were sub-cultured at 
approximately 80% confluence and tested negative for mycoplasma. For exposure, MCF-7/
BOS cells were plated into 6-wells plates containing 2 mL culture medium per well. When 
cells reached a confluence of approximately 60%, the medium was changed to assay medium 
(DMEM/F12 medium, without phenol red supplemented with 5% csFBS). After 24 h, the 
assay medium was renewed with fresh medium containing test compounds dissolved in 
DMSO (0.2%, v/v). Each compound concentration was tested in threefold and cells were 
incubated for 24 h.
rnA extraction, cdnA synthesis, amplification and biotin-labelling
Total RNA was isolated from MCF-7/BOS cells using QIAshredder and RNeasy Mini kits 
(Qiagen, Venlo, The Netherlands) with RNase-free DNase treatment according to the 
manufacturer’s protocols. In short, the medium was removed and cells were washed with 
1 mL PBS, and lysed with 600 μL RLT buffer containing 1% β-mercaptoethanol. The cell 
lysates were applied to the QIAshredder and RNeasy columns. RNA concentration and 
quality was determined spectroscopically (Nanodrop Technologies, Montchanin, DE, USA) 
and by automated electrophoresis using the BioRad Experion system (BioRad, Veenendaal, 
The Netherlands). Only RNA with A260/280 and A260/230 ratios above 1.8 and a quality 
index number above 8.0 was considered to be of sufficient quality. The specific transcripts 
of interest were synthesized and amplified in parallel in a linear manner, as described 
previously. 26 In short, multiplex cDNA synthesis was performed with 5 μg purified RNA and 
1.5 μL of 0.1 μM primer set 1 (rtprimers; supplementary Table S1), which hybridizes to the 
3’ sequence of each chosen transcript, in an end-volume of 25 μL using the Omniscript RT 
reverse transcription kit (Qiagen) according to the manufacturer’s instructions. Tubes were 
placed into a thermocycler for 30 min at 50 °C and subsequently put on ice. Primer set 2 is 
a mix of biotin-labelled forward primers for all selected genes (lbprimers; supplementary 
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Table S1). Primer set 3 is a mix of primers containing a complementary primer for each 
primer in primer set 1 (supplementary Table S2). They are added in excess in order to obtain 
linear amplification, i.e., to prevent primer set 1 from annealing to a product strand of 
the linear PCR. Labelling and a linear amplification were carried out by adding 1.3 μL of 
3.9 μM Primer set 2 (with a 5’-biotin label) and 1.3 μL of 3.9 μM Primer set 3 to the reverse 
transcription reaction mixture, followed by a multiplex linear amplification reaction of 40 
cycles in a thermocycler, consisting of an initial melting cycle for 15 min at 95 °C, followed by 
40 cycles of 45 sec at 94 °C, annealing for 45 sec at 56 °C, and elongation for 45 sec at 76 °C. 
low-density microchip hybridisations
Biotin-labelled amplification products were heat-denatured at 95 °C for 5 min and 
hybridized onto the low-density DNA microchip in Array Tube format (microchips of 
9 mm2, printed with 156 oligonucleotide probes, manufactured by Alere Technologies 
GmbH, Jena, Germany). Each gene was represented by 2-4 oligonucleotide probes and 
each oligonucleotide probe was printed on the microchip in triplicate at different locations. 
The microchips were equilibrated at 30 °C by rinsing them twice for 5 min with 500 μL 
hybridization buffer (0.9 M NaCl, 60 mM sodium phosphate, 6 mM EDTA, 0.05% Triton 
X-100, pH 7.4). Hybridizations (60 °C for 1 h) were performed using 2 µL-16 µL biotinylated 
cDNA samples in 100 μL hybridization buffer to make sure the responses obtained are within 
the dynamic range of the assay. Next, the array tubes were washed with 500 μL of 2xSSC 
containing 0.1% (w/v) Triton X-100 (5 min, 30 °C), with 2xSSC (5 min, 20 °C) and finally 
with 0.2xSSC (5 min, 30 °C) (1xSSC = 0.15 M NaCl, 15 mM sodium citrate, pH 7.0).
Probe detection and data analysis
After blocking with 2% (w/v) milk powder (Bio-Rad, Hercules, CA, USA) in 500 μL 
hybridization buffer containing 0.05% (w/v) Triton X-100 (15 min, 30 °C), the array tubes 
were incubated for 15 min at 30 °C with 100 μL of a 1:2500 dilution of a horseradish 
peroxidase-streptavidin conjugate (1 mg mL-1; Thermoscientific, Rockford, Canada) in 
hybridization buffer containing 0.05% (w/v) Triton X-100. Thereafter, the array tubes were 
washed with 500 μL of 2xSSC containing 0.1% (w/v) Triton X-100 (5 min, 30 °C), with 
2xSSC (5 min, 20 °C) and 0.2xSSC (5 min, 20 °C). The reaction was initiated by adding 
100 μL of TrueBlue Peroxidase substrate (KPL, Gaithersburg, MD, USA) and the blue 
precipitates were quantified by light absorption in a dedicated array tube reader ATR03 
(Alere Technologies). Data analysis was conducted with the IconoClust and Partisan 
software version 3.5r (Alere Technologies) and all transcript levels were normalised to 
the reference control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The relative 
induction potency (RIP), defined as the ratio of the concentration of E2 needed to achieve 
50% of maximal gene expression and the concentration of the test compounds required to 
achieve a similar effect, multiplied by 100, was calculated from dose–response curves for 
responsive genes, fitted by nonlinear regression analysis (sigmoidal dose-response curve, 
Graphpad Prism software version 5.04). Hereby the RIP value for E2 is thus set at 100, 
resulting in a logRIP of 2.0. 
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mcf-7/BoS cell proliferation assay
Proliferation of the human MCF-7/BOS breast cancer cells for testing the estrogenic 
activity of a given compound was quantified as described by Soto et al. for the E-screen. 15 
Briefly, cells were plated into 24-well plates at an initial density of 25,000 cells/well in 500 µL 
assay medium (DMEM/F12 medium, without phenol red supplemented with 5% csFBS). 
After 24 h, the assay medium was renewed with fresh medium to which the compound to 
be tested had been added from a solution in DMSO (0.2%, final concentration). DMSO 
(0.2%, v/v) and E2 (300 pM) were included in each plate as solvent and positive control, 
respectively. Each compound concentration was tested in threefold and cells were incubated 
for 6 days. After 6 days, cells were trypsinized, and the number of cells was counted using 
a Coulter Counter (Beckman Coulter, Mijdrecht, The Netherlands). The proliferation of 
the cells was determined by dividing the number of cells in the sample after exposure 
to the compound by the number of cells in the sample after exposure to DMSO (solvent 
control), subsequently converting the result to a percent change by multiplying by 100. 
The relative proliferative potency (RPP), defined as the ratio of the concentration of E2 
needed to achieve 50% of maximal cell yield and the dose of the test compounds required to 
achieve a similar effect, multiplied by 100, was calculated from proliferation dose–response 
curves, which were fitted by nonlinear regression analysis (sigmoidal dose-response curve, 
Graphpad Prism software version 5.04). Hereby the RPP value for E2 is thus set at 100. The 
median log relative potency (logRP) values based on the mouse or rat uterotrophic assay 
results were derived from the Endocrine Disruptor Knowledge Base (EDKB) designed and 
produced by the National Center for Toxicological Research (NCTR, USA). 27
Gc-mS/mS analysis
The applied GC-MS/MS analysis method is based on an established and validated method 
to screen for natural hormones in bovine urine. 28 Aliquots of 1 mL medium were filled up 
to 3 mL with Milli-Q water and 1 ng of deuterium-labelled internal standard mixture was 
added. Next, the samples were subjected to solid-phase extraction (SPE) using a C18 cartridge 
(500 mg, 3 mL, Varian Bond Elute, Harbor City, CA, USA) previously conditioned with 3 mL 
of methanol and 3 mL Milli-Q water. The column was washed with 3 mL water followed by 
3 mL acetonitrile/water (35:65, v/v) and the free steroids were eluted with 3 mL of acetone. The 
eluate was collected and evaporated at 50 °C under a gentle stream of nitrogen gas until nearly 
dry, and reconstituted in 100 µL methanol and 2 mL Tris-buffer (0.1 M, pH 9.5). Next liquid-
liquid extraction was performed with 7 mL of n-pentane, the mixture was centrifuged (5 min 
at 3,000 xg) and the organic layer was collected in a glass tube. This extraction procedure 
was repeated and the combined organic fraction was evaporated at 40 °C to dryness, under 
a gentle stream of nitrogen gas. The dried residues were reconstituted in 0.5 mL of ethanol, 
transferred into a derivatization-vial and evaporated at 50 °C under nitrogen until dryness. 
The dry residue was derivatized by adding 25 µL of MSTFA++ followed by incubation at 
60 °C for 1 h. The derivatized mixture was evaporated at 50 °C under nitrogen until dryness 
and reconstituted in 25 µL iso-octane. GC-MS/MS analysis was performed on a Varian 1200L 
triple quadrupole mass spectrometer equipped with a CP8400 autosampler and a CP-3800 
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gas chromatograph (GC). The GC was equipped with a VF-17MS GC column (L = 30 m, 
id = 0.25 mm, df = 0.25 µm), obtained from Varian (Houten, The Netherlands). Two microliter 
of the derivatized samples or standard solutions were injected onto the GC column at a pulsed 
pressure of 30 psi. The temperature program started at 110 °C (constant for 1 min), increased 
20 °C·min-1 to 240 °C and was maintained for 1.5 min. Subsequently, the temperature 
was increased 1 °C·min-1 to 244 °C followed by an increase of 25 °C·min-1 to 340 °C. This 
temperature was maintained for 2 min. The helium flow was kept constant at 1.0 mL·min-1 
and the GC-MS/MS was operated in electron ionization (EI) mode using Multiple Reaction 
Monitoring (MRM) transitions as described by Blokland et al. 28
Yeast estrogen bioassay
The yeast cytosensor expressing the human estrogen receptor α (hERα) and yeast enhanced 
green fluorescent protein (yEGFP) in response to estrogens was developed in-house and was 
described previously 25, 29. In short, the day before running the assay, a single colony of the 
yeast ERα cytosensor was used to inoculate 10 mL of minimal medium supplemented with 
60mg/L L-leucine (MM/L medium). This culture was grown overnight at 30 °C with vigorous 
orbital shaking at 225 rpm. At the late log phase, the yeast ERα cytosensor was diluted in 
the selective MM/L medium to an optical density (OD) value at 630 nm between 0.04 and 
0.06. Subsequently, aliquots of 200 μL of the diluted yeast culture were pipetted into each 
well of a 96-well plate and 2 µL of test compound in DMSO was added in triplicate. Exposure 
was performed for 24 h at 30 °C and orbital shaking at 125 rpm. Fluorescence and OD were 
measured at 0 and 24 h directly in a SynergyTM HT Multi-Detection Micro-plate Reader (BioTek 
Instruments Inc., USA) using excitation at 485 nm and measuring emission at 530 nm. The 
fluorescence signal was corrected for the signal obtained with the MM/L medium containing 
DMSO solvent only. In order to check whether a sample was toxic for the yeast cells, densities 
of the yeast culture were also determined by measuring the OD at 630 nm.
reSulTS And diScuSSion
detection of estrogenic activity and relative potency of a test compound
MCF7/BOS cells were exposed to 300 pM E2, 100 pM EE2, 300 pM dienestrol and varying 
levels of zearalenone, genistein, tamoxifen, 4,4′-(octahydro-4,7-methano-5H-inden-5-
ylidene)bisphenol, EGF and testosterone (i.e., at concentrations two times higher than their 
respective EC50 observed in the MCF7/BOS proliferation assay as described before 17). For 
negative compounds (i.e., progesterone, corticosterone and CCl4), cells were exposed to 
a concentration of 1 µM. No cytotoxicity effects were observed at the concentrations used 
based on LDH leakage (data not shown). After 24 h of exposure, RNA was extracted from 
the cells. Purified RNAs were converted to biotin-labelled complementary DNAs (cDNA) 
using three sets of oligonucleotide primers specifically targeting the 11 selected messenger 
RNA transcripts, the two constitutively expressed reference transcripts (i.e., glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) and β-actin), and two poorly expressed background 
control transcripts (i.e., protein tyrosine phosphatase non-receptor type 21 (PTPN21) and 
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RAD51-associated protein 1 (RAD51AP1)). These labelled PCR products were then hybridized 
onto the low-density DNA microchip in the Array Tube format. The expression fingerprints 
were visualized by addition of a streptavidin-horseradish-peroxidase conjugate and the blue 
precipitate formed was quantified by light absorption using a dedicated array tube reader. 
Figure 1 shows an example of hybridization images of the array tubes obtained from MCF7/
BOS cells exposed to a DMSO control and standards of E2 (30 and 100 pM) and EE2 (100 pM).
Figure 1. Hybridisation images from the array tube (microchips of 3 x 3 mm, printed with 156 
oligonucleotide probes) for the detection of estrogens with MCF7/BOS breast cancer cells exposed to 
a DMSO solvent control, and standards of 30,100 pM 17ß-estradiol and 100 pM 17α-ethinyl estradiol.
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The signal intensities of the spots on the microchip as measured by the array tube reader 
were analyzed using dedicated IconoClust software. As expected, the GAPDH and β-actin 
control were highly expressed and were not affected by any treatment (Figure 2A), whereas the 
expression level of the background controls PTPN21 and RAD51AP1 were all below 0.05 as 
determined by their spot intensities. From the 11 probes for estrogen-responsive transcripts 
printed on the chip, five were used for data analysis as they had been previously selected 
by the manufacturer as marker genes (i.e., cyclin-dependent kinase inhibitor 3 (CDKN3), 
myeloid leukemia factor-1 interacting protein (MLF1IP), thymidylate synthetase (TYMS), 
PDZ-binding kinase (PBK) and ribonucleotide reductase M2 (RRM2)). The response of 
these marker genes upon exposure to the 12 compounds tested is shown in Figure 2B to F. 
All five marker genes were clearly up-regulated by the full estrogen receptor agonists tested 
(E2, EE2, zearalenone and genistein). It should be noted that we observed in a previous study 
that dienestrol is about 3 to 10 times less potent than E2 in the MCF-7/BOS cell proliferation 
assay; 17 therefore, it is expected that 300 pM dienestrol would result in lower marker gene 
expression levels than would 300 pM E2. In contrast, EGF, tamoxifen and 4,4′-(octahydro-
4,7-methano-5H-inden-5-ylidene)bisphenol resulted in only moderate induction of the five 
selected marker genes. These compounds were classified as partial agonists in the MCF-7/
BOS proliferation assay 17 because they did not result in maximum proliferation rates as high 
as that induced by E2. The moderate inductions of the five marker genes by these three partial 
agonists as measured by the array tube assay for estrogenic effects are thus in agreement with 
the outcomes as obtained previously in the MCF-7/BOS proliferation assay 17. 
Except for testosterone, all the negative controls (i.e., progesterone, corticosterone 
and CCl4) had little, if any, effect on the expression of any of the marker genes. The clear 
up-regulation of all five marker genes upon exposure to testosterone, however, correlates 
well with the proliferative response of testosterone as observed in the MCF-7/BOS cell 
proliferation assay. 17 It is often assumed that this proliferative response of testosterone is 
caused by its conversion to 17ß-estradiol by aromatase, 30, 31 but in our previous study it 
was shown that the proliferative response of the MCF-7/BOS cells to testosterone could 
only partially be explained by aromatase activity. 17 The proliferative response induced by 
testosterone was therefore studied in more detail here.
In addition to the five marker genes selected by the manufacturer, six other marker genes 
on the chip were evaluated as well. Two of those genes turned out to be at least as informative 
as the five previously selected marker genes. The results of these two newly selected marker 
genes, ubiquitin-conjugating enzyme E2C (UBE2C) and kinesin family member 14 (KIF14), 
are shown in Figure 2G and H. Their expression is also specifically induced by estrogens, and 
their levels are not only in good agreement with the overall response of the five previously 
selected marker genes, but Figure 2G and H also demonstrate that valuable information is 
overlooked when using only the standard data analysis procedure for the array tube. The 
UBE2C and KIF14 marker genes give additional information and, as such, have an added 
value to distinguish partial and full ER agonists, since UBE2C expression is highly induced 
by the five pure ER agonists, E2, EE2, dienestrol, zearalenone, and genistein, but also by the 
partial agonists tamoxifen, 4,4′-(octahydro-4,7-methano-5H-inden-5-ylidene)bisphenol, and 
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EGF indicating that this marker gene is more robust than the others. KIF14, on the other hand, 
seems to be sensitive to pure ER agonists only, and almost insensitive for the partial agonists 
as well as for the negative controls CCl4, corticosterone and progesterone. The remaining four 
marker genes on the chip (i.e., transforming growth factor β2 (TGFβ2), histone 1 variant H4H 
(HIST1H4H), G protein-coupled receptor family C group 5 member A (GPCR5A) and cyclin-
dependent kinase inhibitor 2B (CDKN2B)) were also detectably up regulated by the different 
estrogenic compounds; however, compared to the other seven marker genes, the fold-changes 
in the expression levels were relatively low and less informative. To a certain extent, this may 
also be the consequence of the choice in the current study for a multiplex linear amplification 
technique, which does not suffer from saturation effects as quickly as would be the case with 
an exponential amplification, and therefore has a broader dynamic range. The drawback 
however, is that linear amplification has a higher threshold, so that targets with relatively low 
expression levels will not be sufficiently amplified. Given the current set-up of the assay, these 
four remaining genes are therefore considered to be less suited as marker genes.
In order to investigate whether the array tube could also be used to determine the relative 
potencies of estrogenic compounds, MCF-7/BOS cells were exposed to a concentration range 
of E2, EE2, dienestrol, zearalenone, genistein, and testosterone. The observed marker gene 
expression, expressed as fold induction relative to the DMSO control, was used to construct 
dose-response curves of each marker gene for these six compounds. Figure 3 shows that all six 
compounds, including testosterone, caused a dose-related increase in the expression of all seven 
marker genes selected. The relative induction potency (log RIP) as calculated for each marker 
gene from its dose-response curve is listed in Table 1. Note that no cytotoxicity based on LDH 
leakage was observed at the highest concentrations of the compounds tested. For comparison, 
the relative proliferative potency (log RPP) observed in the MCF-7/BOS cell proliferation assay 
and the relative potency based on the mouse or rat uterotrophic assay of these compounds 
are also shown in Table 1. From these data, it becomes clear that all marker genes correlated 
well with the MCF-7/BOS proliferation assay. The MLF1IP and UBE2C genes display the 
best correlation with the relative estrogenic potencies of the compounds as determined in the 
MCF-7/BOS proliferation assay (for both R2 = 0.96, p < 0.0001) and the uterotrophic assay 
(for both R2 = 0.72, p < 0.0001). The MLF1IP gene encodes for the myeloid leukemia factor-1 
(MLF1)-interacting protein. This protein interacts with MLF1 and nucleophosmin-MLF1 
(NPM-MLF1), which are both reported to induce apoptosis in different cell types. 32 The 
MLF1IP protein functions as a transcriptional repressor, preventing apoptosis by MLF1 and 
NPM-MLF1, and thus facilitating cell growth and proliferation. The UBE2C gene encodes for 
the ubiquitin-conjugating enzyme E2C and was reported to be involved in proliferation, and 
increased expression of UBE2C was associated with high mortality risk tumour grading and 
cancer progression in breast. 33 Thus, it seems logic that the expression of these genes correlates 
well with the proliferative response of the human breast MCF-7/BOS cells. 
detection of anti-estrogenic activity
In order to establish whether the newly developed array tube is also able to determine the ER 
antagonistic properties of chemicals, tamoxifen, 4,4′-(octahydro-4,7-methano-5H-inden-
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5-ylidene)bisphenol and RU58668 were tested in combination with 300 pM E2. The selective 
estrogen receptor modulator (SERM) tamoxifen and 4,4′-(octahydro-4,7-methano-5H-inden-5-
ylidene)bisphenol are known to possess both estrogenic and anti-estrogenic activities (both in vivo 
and in vitro), while RU58668 is a pure ER-antagonist. All three compounds with antiestrogenic 
properties tested were found to reduce the expression induced by 17ß-estradiol of all seven genes 
in the informative marker set (Figure 4 shows two representative marker genes), demonstrating 
that the array tube is also useful to test the anti-estrogenic properties of compounds.
Testosterone-induced responses
As mentioned above, the atypical responses observed with testosterone, both in the 
array tube and the proliferation assay, can only partially be explained by the conversion 
of testosterone into E2 by aromatase. 17 The main cause for these estrogenic effects of 
testosterone remains unknown and could possibly also result from the formation of other 
estrogenic metabolites or from testosterone itself. To further investigate the causes of the 
testosterone-induced responses, MCF-7/BOS cells were treated with testosterone alone, 
or with testosterone in combination with the aromatase inhibitor letrozole, the pure 
anti-androgen flutamide, or the pure anti-estrogen RU58668, and both the proliferative 
and array tube responses were analyzed. The results in Figure 5 show that only the ER-
antagonist RU58668 was able to inhibit the proliferative response induced by testosterone, 
demonstrating that this proliferative response was ER-mediated. This was strengthened by 
the observation that the AR antagonist flutamide had no significant effect on the proliferative 
response caused by testosterone, indicating that the androgen receptor was not involved. 
The aromatase inhibitor letrozole only partially inhibited the cell proliferation induced by 
testosterone, which indeed indicates that formation of E2 can only be partly responsible 
Figure 4. Expression profiles induced by anti-estrogens in MCF-7/BOS cells determined using the 
array tube assay. The MCF-7/BOS cells were exposed to tamoxifen, 4,4′-(octahydro-4,7-methano-
5H-inden-5-ylidene)bisphenol (OMIY-bisphenol) and RU 58668 in combination with 300 pM 
17ß-estradiol. The expression of the two representative marker genes UBE2C and RRM2 are shown 
as fold induction relative to the DMSO solvent control. Each point represents the mean of three array 
tube replicates ± SEM. * indicates that the expression of the gene is significantly different (p < 0.05) 
from the value of 17ß-estradiol alone.
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for the proliferative response induced by testosterone. This means that other estrogenic 
metabolites might be formed during the exposure of MCF-7/BOS cells to testosterone, or 
that testosterone itself is responsible for the ER-mediated cell proliferation. 
As testosterone is negative in the in vivo uterotrophic assay, the second reason is 
highly unlikely. Therefore the medium was collected after exposure of the MCF-7/BOS 
cells to testosterone and analyzed by GC-MS/MS. Table 2 shows that several metabolites 
were formed and could be identified after 6 days of exposure. No significant amounts of 
the known estrogens E2 or estrone were detected in the medium (both below the detection 
limit of 0.05 ng mL-1); however, large amounts of 4-androstenedione, 4-androstenediol, 
5-androstenediol and dehydroepiandrosterone (DHEA) were detected. Subsequently, pure 
standards of these metabolites were tested for estrogenic activity in the yeast estrogen 
reporter gene assay. Androstenedione turned out to be inactive, but 4-androstenediol, 
5-androstenediol and DHEA gave full dose-response curves (supplementary Figure S1). 
Their relative estrogenic potencies (REP), defined as the ratio between the EC50 of E2 and 
the EC50 of the compound, were determined and are shown in Table 2. As there is no steroid 
metabolism in yeast cells, these REPs really reflect the potency of the parent compound 
tested. Using these REPs as listed in the Table 2, the 17ß-estradiol equivalents represented 
by the amount of the metabolites identified in the medium after exposure of MCF-7/BOS 
cells to 10 µM testosterone was estimated. Table 2 shows that the E2 concentration is below 
the detection limit of 183 pM (0.05 ng mL-1) in the medium, while the detected amount 
of androstenediol (4- and 5-androstenediol) is equivalent to 55-166 pM E2. Testosterone 
(10 µM) would give a full response in the MCF-7/BOS proliferation assay, which only occurs 
above - and is thus equivalent to - at least 300 pM E2 according to the dose-response curve of 
E2 (supplementary Figure S2). Therefore, the proliferative response induced by testosterone 
cannot be due only to the formation of E2, which would result <183 pM in the culture medium. 
Instead, it is apparently also caused by the conversion of testosterone into other estrogenic 
metabolites (i.e., 4-androstenediol, 5-androstenediol and DHEA), of which the total amount 
is equivalent to an additional 55-166 pM E2, and thus will contribute significantly to the 
total estrogenic response. In addition to the effects of letrozole, flutamide and RU58668 
Figure 5. Proliferative response of 
MCF-7/BOS cells upon exposure to 
17ß-estradiol and testosterone alone, 
and testosterone in combination 
with the aromatase inhibitor 
letrozole, anti-androgen flutamide, 
and anti-estrogen RU58668. Results 
represent at least three independent 
experiments and are expressed as 
the mean proliferative response 
± SD (n=3). * indicates that the 
proliferative response is significantly 
different (p < 0.05) from the value of 
testosterone alone.
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on cell proliferation, their effect on testosterone-induced estrogen-responsive marker gene 
expression was also studied using the array tube assay. Figure 6 shows the effect of RU58668 
on the expression of UBE2C and RRM2 marker genes, and clearly demonstrates that these 
two genes are up-regulated by testosterone, and that this up-regulation can be inhibited 
completely only by the addition of RU58668. This confirms that the effect of testosterone is 
caused by activation of the ER, and that metabolites formed from testosterone, including E2 
as well as the other metabolites observed in the cell culture medium, may also be involved in 
the effect of testosterone as observed on the gene expression level. The present study shows 
that cell models cannot be used as a black box and that it is necessary to characterize the 
cell line on the metabolic level in order to prevent misclassification of compounds. In this 
case, testosterone would have been classified as an estrogen in both the proliferation assay 
and the array tube, even though the estrogenic response was mainly due to the conversion 
of testosterone into the estrogenic metabolites E2, 4-androstenediol, 5-androstenediol and 
DHEA. Taken together, this indicates that correct identification and classification of estrogens 
requires more than one in vitro assay or one cell type (e.g, combinations of mammalian cell 
lines like MCF-7/BOS and yeast-based reporter gene assays).
concluSionS
A dedicated array tube for the detection of estrogenic compounds was recently developed 
based on a previous global analysis of estrogen-dependent gene expression. 24 Eleven target 
Table 2. Levels of testosterone and its metabolites in the medium of MCF-7/BOS cells as determined 
by GC-MS/MS, and their relative estrogenic potencies in the yeast estrogen bioassay.
Identified 
compound
Concentration in nanograms per mililiter medium 
(±STDEV)
REP b
E2 
equivalent c
1 µM T a 
without 
cells
10 µM T  
without cells
MCF-7/BOS 
cells exposed 
to 1 µM T
MC-7/BOS 
cells exposed 
to 10 µM T
Estradiol < 0.05 < 0.05 < 0.05 < 0.05 1.0 < 183 pM
Estrone < 0.05 < 0.05 < 0.05 < 0.05 0.2 d < 37 pM
Testosterone 258(± 24.9) 2634(± 327) 57.9 (± 5.09) 657 (± 21.1) < 6.0E-6 < 14 pM
Androstenedione 1.26 (± 0.33) 13.04(± 0.81) 221 (± 50.9) 3393 (± 322) no response -
Androstenediol e < 1 < 1 1.82 (± 0.12) 40.2 (± 15.6) 0.4E-3 - 1.2E-3 55-166 pM f
DHEA < 0.05 < 0.05 0.55 (± 0.14) 6.19 (± 2.11) 1.0E-04 2.1 pM
a Testosterone
b The relative estrogenic potency (REP) is defined as the ratio between the EC50 of estradiol and the EC50 of 
the compound in the yeast estrogen bioassay.
c E2 equivalent was calculated based on the relative estrogenic potency using concentration of the 
metabolites identified in the assay medium after 6 days exposure of MCF-7/BOS cells to 10 µM testosterone.
d Obtained from Bovee et al. 2004. 25
e Quantification of 4-androstenediol interfered with 5-androstenediol quantification in the GC-MS/MS 
analysis. Therefore, the total androstenediol amount was calculated.
f Based on REP of 5-androstenediol or 4-androstenediol.
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genes that were clearly up-regulated by estrogens in MCF-7/BOS cells were selected, and the 
DNA probes for these transcripts were printed on a low-density DNA microchip. Although 
linear amplification as used with the dedicated array tube is not suffering from saturation 
effects as quickly as an exponential amplification, it has a broad dynamic range and a higher 
threshold. As a consequence, genes with relatively low expression levels cannot be detected 
by this technique. The seven most informative marker genes on the array tube resulted in 
fingerprints correctly predicting the (anti-)estrogenic activities of the compounds tested. 
Two of these marker genes, MLF1IP and UBE2C, were even found capable of correctly 
predicting the estrogenic potencies of the five compounds tested. The androgen testosterone 
induced cell proliferation and marker gene expression in MCF-7/BOS cells, but is negative 
in the in vivo uterotrophic assay. It has been demonstrated that the MCF-7/BOS cells are 
able to convert testosterone into E2, 4-androstenediol, 5-androstenediol and DHEA, which 
together are considered responsible for the observed estrogenic activity of testosterone, 
rather than testosterone itself. As it is faster and still in vitro, the low-density DNA 
microchip-based analysis of marker gene fingerprints provides an attractive alternative to 
the current MCF-7/BOS cell proliferation assay (E-screen). Although the low-density DNA 
microchip-based analysis of marker gene fingerprints (3 days) is faster than the MCF-7/
BOS cell proliferation assay (6 days), it is nevertheless quite laborious and requires highly 
skilled technicians; therefore, it is not ideal in its current format for the large-scale testing 
of chemicals as required by initiatives like REACH (EC 1907/2006).
SuPPlemenTArY dATA
Supplementary data associated with this article can be found, in the online version, at 
http://dx.doi.org/10.1016/j.ab.2012.12.016.
Figure 6. Marker gene expression profiles induced in MCF-7/BOS cells by 17ß-estradiol and testosterone 
alone, and testosterone in combination with the aromatase inhibitor letrozole, anti-androgen flutamide, 
and anti-estrogen RU58668, determined using the array tube assay. The expression of two representative 
marker genes UBE2C and RRM2 are shown as the fold induction relative to the DMSO solvent control. 
Each point represents the mean of three array tubes replicates ± SEM. * indicates that the expression of 
the gene is significantly different (p < 0.05) from the value of testosterone alone.
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ABSTrAcT 
To further develop an integrated in vitro testing strategy for replacement of in vivo 
tests for (anti-)estrogenicity testing, the ligand-modulated interaction of coregulators 
with estrogen receptor α was assessed using a PamChip® plate. The relative estrogenic 
potencies determined based on ERα binding to coregulator peptides in the presence 
of ligands on the PamChip® plate were compared to the relative estrogenic potencies 
as determined in the in vivo uterotrophic assay. The results show that the estrogenic 
potencies predicted for 18 compounds by the 57 coactivators on the peptide microarray 
that display a clear E2 dose-dependent response (goodness of fit of a logistic dose-
response model of 0.90 or higher) correlated very well with their in vivo potencies in 
the uterotrophic assay, i.e., coefficient of determination values for 30 coactivators higher 
than or equal to 0.85. Moreover, this coregulator binding assay is able to distinguish 
ER agonists from ER antagonists: profiles of selective estrogen receptor modulators, 
such as tamoxifen, were distinct from those of pure ER agonists, such as dienestrol. 
Combination of this coregulator binding assay with other types of in vitro assays, e.g., 
reporter gene assays and H295R steroidogenesis assay, will frame an in vitro test panel 
for screening and prioritization of chemicals, thereby contributing to the reduction 
and ultimately the replacement of animal testing for (anti-)estrogenic effects.
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inTroducTion
Estrogens exert their physiological effects mainly through activation of the estrogen receptor 
(ER) in target cells. 1, 2 Although two main forms of ER exist, ERα and ERβ, in (reproduction) 
toxicology the primary attention goes to the ERα, as it is the dominating type in breast and uterus 
tissue. 3, 4 Moreover, with respect to regulatory purposes, the focus is on ERα because binding and 
induction of ERα is implicated as a key molecular initiating event (MIE) in estrogenicity-related 
adverse endpoints. ERα and ERβ, like all the members of the nuclear receptor (NR) super-family, 
are ligand-dependent transcription factors that work in concert with transcriptional coregulators 
to control target gene transcription. Upon ligand binding, the ligand-binding domain (LBD) 
undergoes a conformational change that leads to receptor dimerization, translocation of the ER 
from cytosol to nucleus, and binding to estrogen-responsive elements. Moreover, as a result of 
the intramolecular conformational changes induced by ligand binding, the affinity of the ER for 
coregulator proteins is changed, resulting in recruitment or release of transcriptional coactivator 
or corepressor proteins, respectively, that enhance or repress interaction of RNA polymerase II 
with estrogen-responsive gene promoters and all of the subsequent reactions needed to actually 
induce or repress transcription of target genes. 5, 6
In general, the transcriptional coregulator family consists of coactivators, which 
augment the activity of receptors, and corepressors that mediate the repressive effects of 
receptors. 7, 8 The most studied group of ERα coactivators includes the p160 protein family, 
consisting of NCOA1 (SRC-1), NCOA2 (SRC-2), and NCOA3 (SRC-3), which interact 
with the activation function-2 (AF-2) domain of agonists-bound ERs through multiple 
LXXLL motifs present in these coactivator proteins (where L is leucine and X is any amino 
acid). 5, 9 Structural analysis of nuclear receptor (NR) LBDs has established that agonist 
binding stabilizes the AF-2 helix in an active conformation to form a charge clamp pocket, 
which is permissive for interactions with LXXLL motifs. In contrast, ER antagonists affect 
the positioning of the AF-2’s mobile C-terminal helix (helix 12) to form a large binding 
pocket that interacts with the LXXXIXXXL motifs of corepressor proteins such as nuclear 
receptor corepressor 1 (NCOR1) and nuclear receptor corepressor 2 (NCOR2), thereby 
disrupting the LXXLL-binding site and preventing coactivator recruitment. 10-12
The standard test for disruption of normal estrogen function is the in vivo uterotrophic 
assay, i.e., a test with immature or ovariectomized rodents using uterus weight as the 
crucial read-out parameter. 13, 14 With a view to the regulation on Registration, Evaluation, 
Authorization, and Restriction of Chemicals (EC, 2006) and the need to reduce, refine, and 
replace the use of experimental animals for safety testing (3Rs), modulation of ER activity is 
usually quantitatively analyzed by assaying ER binding, ER-controlled reporter gene or other 
downstream events such as estrogen receptor-mediated cell proliferation 15. ER binding 
assays are rapid and easy to perform; one of the main drawbacks, however, is that these 
assays are unable to distinguish receptor agonists from receptor antagonists. Moreover, the 
rat uterine cytosol ER binding assay, currently listed as part of the Environmental Protection 
Agency (EPA) Endocrine Disruptor Screening Program Tier 1 screening battery, still requires 
the use of animals as a source of ERs. Unlike receptor binding assays, reporter gene assays 
can distinguish between agonist and antagonist activity. Several reporter-gene assays have 
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been developed and applied as screening tools to determine the estrogenic/anti-estrogenic 
activities of compounds, as they are cheap, fast, robust, and have been shown to produce 
relevant and reliable outcomes 16-18. Proliferation assays and low-density DNA microchip-
based analysis of marker gene expression have also been shown to provide valuable tools 
for estrogenicity testing and outcomes correlate well with the in vivo uterotrophic assay, 19, 20 
but these two assays are laborious and request 3-6 days. They are therefore not ideal for the 
large-scale testing of chemicals with respect to initiatives such as REACH. 
Thus far, studying nuclear receptor interactions with coregulators has been performed 
mainly for theoretical reasons and drug development. 21-23 However, a high-throughput in 
vitro assay enabling quantification of coactivator or corepressor recruitment by receptors upon 
ligand binding would have the potential to add relevant information to an integrated in vitro 
strategy for (anti-)estrogenicity testing, aiming at prioritization of chemicals and reduction 
of in vivo animal experiments needed for initiatives such as REACH. In the present study, the 
ligand-modulated interaction of coregulators with ERα was assessed using a PamChip® plate 
consisting of 96 identical arrays, each array containing 155 immobilized nuclear receptor (NR) 
coregulator peptides harbouring either LXXLL (coactivators) or LXXXIXXXL (corepressors) 
motifs. A set of 23 reference compounds was tested in the coregulator binding assay based on 
the PamChip® plate. Twenty-one of these compounds were selected from the 78 compounds 
listed by the Interagency Coordinating Committee on the Validation of Alternative Methods 
(ICCVAM) for validation of in vitro ER binding and transcriptional activation assays assays. 24 
The objective was to determine to what extent this coregulator binding assay correctly predicts 
the estrogenic/anti-estrogenic activities and potencies of the test compounds when compared 
to the outcomes obtained in the in vivo uterotrophic assay.
mATeriAlS And meThodS
chemicals
17ß-Estradiol (E2), diethylstilbestrol, meso-hexestrol, coumestrol, dienestrol, zearalenone, 
corticosterone, tamoxifen, 4-hydroxytamoxifen, bisphenol A, ethyl paraben, o,p’-DDT, p-n-
nonylphenol and apigenin were obtained from Sigma-Aldrich Chemie B.V. (Zwijndrecht, 
The Netherlands). 17α-Ethinyl estradiol (EE2), progesterone and testosterone (T) were 
purchased from Steraloids (Newport, RI, USA), while genistein was obtained from Apin 
Chemicals (Abingdon, Oxon, UK). 4,4’-(octahydro-4,7-methano-5h-inden-5-ylidene)
bisphenol (OMIY-bisphenol) from Acros Organics (Fisher Emergo BV, Landsmeer, 
The Netherlands). Dimethylsulfoxide (DMSO) was purchased from Merck (Darmstadt, 
Germany). Kepone and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) were obtained from Dr. 
Ehrenstorfer GmbH (Augsburg, Germany). Butylbenzyl phthalate and di-n-butyl phthalate 
were purchased from TCI Europe N.V. (Zwijndrecht, Belgium).
nuclear receptor-coregulator interaction profiling
Ligand-modulated interaction of coregulators with ERα-LBD was assessed using a 
PamChip® plate described previously. 25 The PamChip® plate consists of 96 identical arrays, 
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each array containing 155 NR coregulator peptides harbouring either LXXLL (coactivators) 
or LXXXIXXXL (corepressors) motifs (PamGene International B.V., ’s-Hertogenbosch, 
The Netherlands). The coregulator peptides are immobilized on a porous metal oxide 
carrier by Piezo technology as previously used in kinase assays. 26, 27 The PamChip® plate 
was used in combination with the glutathione S-transferase (GST)-labelled ERα-LBD to 
screen dilution series of a set of 23 compounds. The peptide microarray was incubated 
with the test solution containing ERα-LBD-GST in the absence or presence of ligand by 
pumping the sample up and down the three dimensional metal oxide carrier (Figure 1A). 
In short, assay mixtures were prepared on ice in a master 96-well plate with 5 nM GST-
tagged human ERα-LBD (PamGene International B.V.), 25 nM Alexa 488-conjugated GST 
antibody (Invitrogen, Breda, The Netherlands) and ligand at the indicated concentration 
in reaction buffer (20mM Tris, pH 7.5, 500mM NaCl, 0.2% BSA, 0.05% Tween-20). All 
assays were performed in a fully automated PamStation-96 (PamGene International B.V.) at 
20 °C applying two cycles per min. The initial blocking was carried out by incubating each 
array for 20 cycles with 25 µL blocking buffer (TBS with 1% BSA, 0.01%, Tween-20, and 
0.3% skimmed milk). Subsequently, the blocking buffer was removed and 25 µL assay mix 
was transferred to each array and incubated for 80 cycles (~40 min). Eight concentrations 
with tenfold serial dilution in dimethyl sulfoxide (DMSO; final concentration 2%) of each 
compound were tested in singular. After removal of the unbound receptor by washing the 
plate with 25 µL TBS, tiff images were obtained by a CCD camera based optical system 
integrated in the PamStation®-96 instrument. The total set of compounds was tested over 
two PamChip® plates and by using E2 as a reference compound on each plate.
data analysis
Image analysis was performed using BioNavigator software (PamGene International B.V.), 
which performs automated array grid finding and subsequent quantification of signal 
and local background for each individual peptide. In short, the boundaries of a spot are 
determined and the median fluorescent signal was quantified within the spot (signal) as 
well as that in a defined area surrounding it (background). The signal-minus-background 
value was subsequently used as the quantitative parameter of binding. Ligand dose-response 
relations were analyzed using the DRC package in R (version 2.12.0, www.r-project.org). 
A sigmoidal 4-parameter logistic model was fitted to the dose-response data and the 
goodness-of-fit parameter and EC50 values as calculated by the DRC package were recorded. 
Relative binding potency (RBP) values were obtained from the ratio of the concentration 
of E2 needed to achieve 50% of maximal ERα-LBD binding to the coregulator and the 
concentration of the test compounds required to achieve a similar effect. This ratio 
subsequently is multiplied by 100. The RBP value of E2 is thus 100, resulting in a logRBP 
of 2.0. A cut-off value of -5.0 is listed for compounds showing no effect. The estrogenicity 
data used for comparisons with the current ERα-coregulator binding data were ER binding 
data in the review published by ICCVAM 24, and the BG1Luc ER TA data reported by the 
National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative 
Toxicological Methods (NICEATM) and ICCVAM. 28 For comparison of the presented in 
91
5C
O
Reg
U
la
TO
R bIN
D
IN
g
 a
ssa
y
vitro ERα-coregulator binding data with estrogenicity in vivo, uterotrophic assay data were 
used that were derived from the Endocrine Disruptor Knowledge Base (EDKB), designed 
and produced by the National Center for Toxicological Research (NCTR, USA).  29
reSulTS
Twenty-one of the 23 compounds tested were selected from the 78 compounds listed by 
the ICCVAM for validation of in vitro ER binding and transcriptional activation assays, 
representing the main groups of compounds with estrogenic activity, i.e., natural steroids, 
synthetic steroids, flavonoids, phenols, organochlorines, and phthalates. 24 Figure 1B 
shows the dose-response curves of ERα-LBD binding to the 155 coregulator peptides as 
induced by 17ß-estradiol (E2). Most of the coregulator spots showed an increased binding 
signal with increasing E2 concentrations, e.g., NCOA1_677_700, NCOA2_628_651 and 
NCOA3_673_695, which all have the LXXLL motif signature sequence and are known 
to function as coactivators. As an example, the E2 induced dose-response curve of 
ERα-LBD binding to coactivator peptide NCOA1_677_700 is shown in Figure 1C. The 
lowest concentration of the potent E2 that resulted in a detectable binding of ERα-LBD 
to NCOA1_677_700 was 0.19 nM, reaching a half maximal binding level (EC50) at 
approximately 0.7 nM and binding was saturated above 20 nM. However, not all the 
coactivator peptides immobilized on the peptide microarray showed an E2 concentration-
dependent binding response of ERα-LBD, e.g., chromodomain-helicase-DNA-binding 
protein 9 (CHD9_855_877) and centromere protein R (CENPR_1_18), did not show any 
E2 induced binding. As expected, the corepressor peptides with the LXXXIXXXL motif, 
e.g., NCOR1_1925_1946 and NCOR2_2330_2352, did not show an ERα-LBD binding 
response upon co-incubation with E2. E2 was used as a reference compound on each of 
the two PamChip® plates. To assess the reproducibility of the assay, all duplicate E2 data 
together were plotted against each other, which resulted in a correlation with coefficient 
of determination (R2) of 0.944. Moreover, the coefficient of variation (CV) was calculated 
at a binding-saturating E2 concentration (20 nM) over each pair of duplicate E2 data. This 
resulted a median intraplate CV of 8.0%.
All known estrogenic compounds tested on the peptide microarray (e.g., EE2, dienestrol, 
diethylstilbestrol, and meso-hexestrol) resulted in coregulator binding profiles similar to that 
of E2. Except for testosterone, the negative controls (i.e., corticosterone and progesterone) 
showed no statistically significant binding changes compared with the solvent control 
DMSO (data not shown), while the selective estrogen receptor modulators (SERMs), i.e., 
tamoxifen, 4-hydroxytamoxifen, and 4,4’-(octahydro-4,7-methano-5h-inden-5-ylidene)
bisphenol (OMIY-bisphenol), showed a completely different coregulator binding profile. 
As shown in Figure 2, compared with the solvent control DMSO and the known estrogen 
agonists, tamoxifen strongly inhibited binding of ERα-LBD to almost all coactivator 
peptides, and similar repression of binding was observed with 4-hydroxytamoxifen and 
OMIY-bisphenol (supplementary Figure S1 and Figure S2). Surprisingly, no binding was 
observed for these SERMs to the corepressors present on the peptide microarray. 
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Figure 3 shows the dose-response curves of 23 compounds based on three coregulators 
NCOA1_677_700, NRIP1_173_195, and PNRC2_118_139, resulting in curve fittings with 
a goodness of fit of 0.94, 0.78 and 0.63, respectively for E2. The relative coregulator binding 
potency (RBP) values of these 23 compounds were calculated for these three coactivator 
peptides and listed in Table 1. To allow comparison with the observed in vivo effects, the 
median log relative potency (logRP) of these compounds as determined previously in the in 
Figure 1. Analysis of ERα-LBD binding to coregulators induced by 17ß-estradiol. A. Schematic 
overview of peptide microarray technology. B. Dose-response curves for ERα-LBD binding to the 155 
coregulator-derived receptor binding motifs induced by 17ß-estradiol. C. Enlargement of the dose-
response curve for 17ß-estradiol-induced binding of ERα-LBD to coactivator NCOA1_677_700.
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vivo uterotrophic assay with mice or rats are included and shown in Table 1. Figure 4 shows 
the comparison between the logRP values as determined in the in vivo uterotrophic assay 
and the logRBP values as determined in the coregulator binding assay based on coactivators 
of NCOA1_677_700, NRIP1_173_195, and PNRC2_118_139. Although tamoxifen had 
a clear effect on the binding of these three coactivators, its effect is mostly opposite to 
that of E2. As tamoxifen is a SERM that mainly shows its antagonistic properties when 
tested on the current coregulator binding assay (Figure 2), it is not possible to compare 
its observed antagonistic binding effects with the agonistic binding effects obtained 
Figure 2. Analysis of ERα-LBD binding to coregulators induced by tamoxifen. 
Figure 3. Dose-response curves of ERα-LBD binding to the NCOA1_677_700, NRIP1_173_195 and 
PNRC2_118_139 coactivator peptides for the 23 compounds.
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with E2. The same is valid for the SERMs 4-hydroxytamoxifen and OMIY-bisphenol, 
which also show antagonistic coregulator binding effects. Therefore, for the comparison 
of the in vitro coregulator binding assay with the in vivo uterotrophic assay, tamoxifen, 
4-hydroxytamoxifen, and OMIY-bisphenol were left out (Figure 4 and Table 2). Instead, to 
provide an overall measure of the antagonistic binding potency for the SERMs, the median 
of the IC50 values were calculated over all those coregulators showing a very good fit of the 
standard dose-response model used (goodness-of-fit of a sigmoidal 4-parameter logistic 
model of 0.85 or higher). The number of coregulators meeting this requirement are 29 for 
OMIY-bisphenol, 41 for tamoxifen and 50 for 4-hydroxytamoxifen, resulting in median 
IC50 of 1.39×10-7 M, 2.55×10-7 M and 1.82×10-9 M, respectively. In addition to the SERMs, 
apigenin and 2,4,5-T also were left out for the comparison of coregulator binding assay 
with the in vivo uterotrophic assay. For 2,4,5-T there are no uterotrophic data available 
in the literature, and although apigenin has been shown to display estrogenic activities in 
in vitro reporter gene assays, 30, 31 it was negative for estrogenic effects on the uterus in 
the uterotrophic assay. However, this is most probably due to the poor bioavailability of 
apigenin in rodents.32 In the coregulator binding assay apigenin clearly induced binding of 
ERα-LBD to similar coactivators as E2. 
Figure 4 illustrates that using all dose-response curves and corresponding coregulator 
binding potencies (logRBP), the NCOA1_677_700 coactivator peptide-based logRBP values 
correlated very well with the in vivo relative potencies (logRP) values determined in the 
uterotrophic assay (R2 = 0.89, p < 0.0001, n=18). Binding of coactivator NRIP1_173_195, 
with an intermediate E2 dose-response curve goodness of fit of 0.78, still resulted 
in a relatively good correlation (R2 = 0.79, p < 0.0001, n=18), whereas the binding of 
PNRC2_118_139, which has a relatively low E2 dose-response curve goodness of fit of 0.63, 
showed no correlation with the in vivo determined logRP values of the uterotrophic assay 
(R2 = 0.01, p = 0.698, n=18). 
Next, the dose-response curve goodness-of-fit value for each coregulator of each 
compound was calculated. Out of the 155 coactivator peptides, 57 gave E2 curve fittings 
Figure 4. Comparison of the log relative potencies (logRP) measured in the in vivo uterotrophic 
assay with the log relative coregulator binding potency (logRBP) as determined in the coregulator 
binding assay for the NCOA1_677_700, NRIP1_173_195 and PNRC2_118_139 coactivators for the 18 
compounds. Tamoxifen, 4-Hydroxytamoxifen, OMIY-bisphenol, apigenin and 2,4,5-T were excluded 
from the comparison.
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Table 1. Comparison of the relative potencies obtained in the ER binding assay, BG1Luc ER 
transcriptional activation assay and  in vivo uterotrophic assay with those obtained in the coregulator 
binding assay for the 23 compounds.
Compounds CAS nr.
ER binding assay 
logRBA a
BG1Luc ER 
TA logREP e 
Uterotrophic assay 
logRP f
Coregulator binding assay logRBP h 
NCOA1_677_700 NRIP1_173_195 PNRC2_118_139
Steroids and  
synthetic estrogens
E2 50-28-2 2.0 2.0 2.0 2.0 2.0 2.0
EE2 57-63-6 2.2 1.7 3.0 2.0 2.2 -5.0
Diethylstilbestrol 56-53-1 2.1 1.2 2.7 1.6 2.4 -5.0
Dienestrol 84-17-3 2.0 b NA 2.4 1.6 1.9 -5.0
meso-Hexestrol 84-16-2 2.4 1.3 2.5 2.0 2.0 -5.0
Corticosterone 50-22-6 -5.0 c -5.0 -5.0 -5.0 -5.0 -5.0
Progesterone 57-83-0 -3.5 -5.0 -5.0 -5.0 -5.0 -5.0
Testosterone 58-22-0 -1.6 -3.2 -5.0 -3.0 -2.5 0.7
Phytoestrogens  
(natural products)
Coumestrol  479-13-0 1.1 -2.6 -0.8 -0.7 -2.1 -5.0
Genistein 446-72-0 0.2 -2.9 -2.7 -0.1 -0.1 -5.0
Apigenin 520-36-5 0.1 -3.6 -5.0 -1.3 -3.8 -5.0
Zearalenone 17924-92-4 1.2 NA -0.7 0.5 -5.0 -5.0
Phenol OMIY-bisphenol 1943-97-1 NA d NA -0.3 g - i - -
p-n-Nonylphenol 104-40-5 -1.5 NA -5.0 -5.0 -5.0 -5.0
Bisphenol A 80-05-7 -1.5 -3.1 -1.6 -2.6 -3.2 -5.0
Organochlorines Kepone 143-50-0 -1.5 -3.2 -1.0 -1.7 -0.7 -5.0
o,p’-DDT 789-02-6 -1.7 -3.1 -3.5 -5.0 -5.0 -5.0
2,4,5-T 93-76-5 -5.0 NA NA -5.0 -5.0 -5.0
Phthalates Butylbenzyl phthalate 85-68-7 -2.7 -3.8 -5.0 -5.0 -5.0 -5.0
Di-n-butyl phthalate 84-74-2 -2.6 -2.6 -5.0 -5.0 -5.0 -5.0
Paraben Ethyl paraben 120-47-8 -3.2 -4.9 -5.0 -5.0 -5.0 1.9
SERMs Tamoxifen 10540-29-1 0.6 NA 1.0 - - -
4-hydroxytamoxifen 68047-06-3 2.2 NA 1.0 - - -
a Logarithm of the median ER relative binding affinity values listed in the review of  ICCVAM. 24
b Median logRBA value derived from the EDKB (NCTR,USA). 29
c A cut-off value of -5.0 is listed for compounds showing no effect.
d Data not available.  
e Relative estrogenic potency is defined as the ration between the EC50 of 17ß-estradiol and the EC50 of the 
compound, and this ratio is subsequently multiplied by 100 calculated based on the BG1Luc ER TA data 
reported by ICCVAM. 28 The REP value of 17ß-estradiol is thus 100, resulting in a logREP of 2.0.
f Median relative potency values based on uterotrophic assay in mouse or rat, derived from the EDKB (NCTR,USA). 
17ß-estradiol is used as a reference chemical and is defined to have a relative potency of 100 (logRP=2.0). 29 
g logRP of 4,4′-(octahydro-4,7-methano-5H-inden-5-ylidene)bisphenol was calculated based on the 
minimal active dose described by Yamasaki et al. 2003. 33
h Relative binding potency values are obtained from the ratio of the concentration of 17ß-estradiol needed 
to achieve 50% of maximal binding of ERα-LBD to coregulator and the concentration of the test compounds 
required to achieve a similar effect, and this ratio is subsequently multiplied by 100. The RBP value of 
17ß-estradiol is thus 100, resulting in a logRBP of 2.0. 
i Compound only showing antagonist binding effect; therefore, the logRBP value cannot be determined.
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Table 1. Comparison of the relative potencies obtained in the ER binding assay, BG1Luc ER 
transcriptional activation assay and  in vivo uterotrophic assay with those obtained in the coregulator 
binding assay for the 23 compounds.
Compounds CAS nr.
ER binding assay 
logRBA a
BG1Luc ER 
TA logREP e 
Uterotrophic assay 
logRP f
Coregulator binding assay logRBP h 
NCOA1_677_700 NRIP1_173_195 PNRC2_118_139
Steroids and  
synthetic estrogens
E2 50-28-2 2.0 2.0 2.0 2.0 2.0 2.0
EE2 57-63-6 2.2 1.7 3.0 2.0 2.2 -5.0
Diethylstilbestrol 56-53-1 2.1 1.2 2.7 1.6 2.4 -5.0
Dienestrol 84-17-3 2.0 b NA 2.4 1.6 1.9 -5.0
meso-Hexestrol 84-16-2 2.4 1.3 2.5 2.0 2.0 -5.0
Corticosterone 50-22-6 -5.0 c -5.0 -5.0 -5.0 -5.0 -5.0
Progesterone 57-83-0 -3.5 -5.0 -5.0 -5.0 -5.0 -5.0
Testosterone 58-22-0 -1.6 -3.2 -5.0 -3.0 -2.5 0.7
Phytoestrogens  
(natural products)
Coumestrol  479-13-0 1.1 -2.6 -0.8 -0.7 -2.1 -5.0
Genistein 446-72-0 0.2 -2.9 -2.7 -0.1 -0.1 -5.0
Apigenin 520-36-5 0.1 -3.6 -5.0 -1.3 -3.8 -5.0
Zearalenone 17924-92-4 1.2 NA -0.7 0.5 -5.0 -5.0
Phenol OMIY-bisphenol 1943-97-1 NA d NA -0.3 g - i - -
p-n-Nonylphenol 104-40-5 -1.5 NA -5.0 -5.0 -5.0 -5.0
Bisphenol A 80-05-7 -1.5 -3.1 -1.6 -2.6 -3.2 -5.0
Organochlorines Kepone 143-50-0 -1.5 -3.2 -1.0 -1.7 -0.7 -5.0
o,p’-DDT 789-02-6 -1.7 -3.1 -3.5 -5.0 -5.0 -5.0
2,4,5-T 93-76-5 -5.0 NA NA -5.0 -5.0 -5.0
Phthalates Butylbenzyl phthalate 85-68-7 -2.7 -3.8 -5.0 -5.0 -5.0 -5.0
Di-n-butyl phthalate 84-74-2 -2.6 -2.6 -5.0 -5.0 -5.0 -5.0
Paraben Ethyl paraben 120-47-8 -3.2 -4.9 -5.0 -5.0 -5.0 1.9
SERMs Tamoxifen 10540-29-1 0.6 NA 1.0 - - -
4-hydroxytamoxifen 68047-06-3 2.2 NA 1.0 - - -
a Logarithm of the median ER relative binding affinity values listed in the review of  ICCVAM. 24
b Median logRBA value derived from the EDKB (NCTR,USA). 29
c A cut-off value of -5.0 is listed for compounds showing no effect.
d Data not available.  
e Relative estrogenic potency is defined as the ration between the EC50 of 17ß-estradiol and the EC50 of the 
compound, and this ratio is subsequently multiplied by 100 calculated based on the BG1Luc ER TA data 
reported by ICCVAM. 28 The REP value of 17ß-estradiol is thus 100, resulting in a logREP of 2.0.
f Median relative potency values based on uterotrophic assay in mouse or rat, derived from the EDKB (NCTR,USA). 
17ß-estradiol is used as a reference chemical and is defined to have a relative potency of 100 (logRP=2.0). 29 
g logRP of 4,4′-(octahydro-4,7-methano-5H-inden-5-ylidene)bisphenol was calculated based on the 
minimal active dose described by Yamasaki et al. 2003. 33
h Relative binding potency values are obtained from the ratio of the concentration of 17ß-estradiol needed 
to achieve 50% of maximal binding of ERα-LBD to coregulator and the concentration of the test compounds 
required to achieve a similar effect, and this ratio is subsequently multiplied by 100. The RBP value of 
17ß-estradiol is thus 100, resulting in a logRBP of 2.0. 
i Compound only showing antagonist binding effect; therefore, the logRBP value cannot be determined.
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higher than or equal to 0.9. The determined EC50 values for E2 derived from these 57 curves 
were all in the low nanomolar range and showed a median EC50 of 0.9 nM. Subsequently, 
similar to what is shown in Table 1 and Figure 4, the logRBP values based on these 57 
coactivators were calculated for each compound and correlated with different relative 
potency values from literature, i.e., logRBA values obtained in the ER binding assay (n=19), 
logREP values obtained in the BG1Luc ER transcriptional activation assay (n=16), and 
logRP values obtained in the uterotrophic assay (n=18). The resulting R2 values are shown 
in Table 2. In general, the estrogenic potencies predicted by the coregulator binding assay 
correlated well with the ER binding assay, as well as with the BG1Luc ER transcriptional 
activation assay, which was recently approved by OECD as a test method for identifying 
estrogen receptor agonists and antagonists. As shown in Table 2, 33 coactivators showed an 
R2 value higher than or equal to 0.80 with the ER binding assay and 32 coactivators showed 
an R2 value higher than or equal to 0.80 with the BG1Luc ER transcriptional activation 
assay. For the correlation with the in vivo uterotrophic assay, in total 48 coactivators 
showed an R2 value higher than or equal to 0.8, and among these, 30 coactivators showed 
an R2 value higher than or equal to 0.85 (e.g., NCOA1_677_700, NCOA3_673_695, and 
NR0B2_106_128). A low correlation coefficient was observed for BL1S1_1_11 (R2 = 0.49).
diScuSSion
The aim of the present study was to investigate the potential of the PamChip® plate based 
coregulator binding assay as part of an integrated in vitro testing strategy for detection of 
(anti-)estrogenic activity. To this end a set of 23 reference compounds was investigated using 
the peptide microarray in combination with the GST labelled ligand-binding domain of 
ERα. As a concentration series consisting of eight concentrations with tenfold serial dilution 
was tested for each compound, the dose-response relation could be determined with great 
statistical accuracy as demonstrated by the goodness of fit data. With a median EC50 of 
0.9 nM, an intraplate coefficient of variation of 8.0% at a saturating binding concentration 
of 20 nM E2, and an excellent correlation (R2 = 0.944) between duplicate E2 measurements, 
the sensitivity and reproducibility of the coregulator binding assay was well within the range 
observed for other commonly used in vitro ER functional assays. Moreover, the coregulator 
binding assay uses fluorescence as an endpoint measurement, which offers several advantages 
in comparison to radioligand receptor binding assays, such as low costs and avoiding 
problems related to health hazards of radiation exposure and radioactive waste disposal. 
Dose-response analysis of the binding of ERα-LBD to coregulators in the presence of the 
ligand showed that the known estrogens (e.g., EE2, dienestrol, diethylstilbestrol, and meso-
hexestrol) resulted in coregulator binding profiles similar to the reference compound E2, but 
each compound showed its own specific potency resulting in different EC50 values. Except 
for testosterone, the negative controls (i.e., corticosterone and progesterone) showed no 
significant binding changes compared with the solvent control DMSO. The SERMs tested on 
the peptide microarray (i.e., tamoxifen, 4-hydroxytamoxifen, and OMIY-bisphenol) showed 
no binding on the corepressors present on the peptide microarray and showed decreased 
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coactivator binding signals compared to the known ER agonists and the solvent control 
DMSO. The binding profiles of these SERMs are thus unique, as they are almost opposite to 
the profiles obtained with the known ER agonists and different from the profiles obtained with 
the negative controls and DMSO solvent control, indicating that the antagonistic properties 
of these SERMs mainly result from blocking the interaction of ERα with coactivator peptides 
rather than recruitment of corepressors. These findings are in agreement with other studies, 
showing that tamoxifen and 4-hydroxytamoxifen bind to the ligand-binding domain of ERα 
and cause a conformational shift of helix 12 into an adjacent coactivator site, which in turn 
prevents ERα from binding a coactivator. 10, 12, 34-36 Moreover, the calculated IC50 values, based 
on all the coregulators showing a very good fit of the standard dose-response model, were 
2.55×10-7 M and 1.82×10-9 M for tamoxifen and 4-hydroxytamoxifen, respectively. These 
IC50 values are also in line with data reported by ICCVAM, i.e., 7.12×10-7 M and 4.94×10-9 
M for tamoxifen and 4-hydroxytamoxifen, respectively, in the BG1Luc ER transcriptional 
activation assay, demonstrating that the coregulator binding assay is also useful to test anti-
estrogenic properties of compounds. Although tamoxifen and 4-hydroxytamoxifen are 
mainly reported to act as ER antagonists in breast and as ER agonists in uterus tissue, 37 
they are also able to inhibit the effect caused by EE2 in the uterotrophic assay and to induce 
breast cell proliferation in the E-screen. 19, 33, 38 The OMIY-bisphenol shows both agonistic 
and antagonistic effects in the uterotrophic assay, and when tested in proliferation assays it 
also behaves as an agonist and antagonist, demonstrating a biological effect profile nearly 
identical to tamoxifen. 19 Thus, transcriptional activation assays, cell proliferation assays 
and the in vivo uterotrophic assay are capable of displaying both the ER agonistic and ER 
antagonistic properties of tamoxifen, 4-hydroxytamoxifen and OMIY-bisphenol. However, 
when tested on the peptide microarray, these three compounds showed only antagonistic 
effects. It is highly unlikely that the profiles will reveal the agonistic properties of these 
SERMs when co-exposed with E2 or EE2. 
The androgen testosterone (T) was used as a negative control, as it is inactive in the in 
vivo uterotrophic assay. In the coregulator binding assay, T clearly induced the binding of 
ERα-LBD to several coactivators (e.g., binding of NCOA1_677_700 resulted a logRBP value 
of -3.0). However, in several studies it was shown that T can induce cell proliferation in 
the MCF-7/BOS cells (E-screen), and it has been demonstrated that this atypical response 
was mediated by activation of the ER. More specifically, the proliferative response induced 
by testosterone in the E-screen is partially due to its conversion into 17ß-estradiol by 
aromatase, 19 partially due to formation of other estrogenic metabolites 20 and also partially 
due to T, i.e., activation of ERα. These findings are in line with the observations in the present 
study, i.e., T is capable of activating ERα-LBD and induces subsequent binding of several 
coactivators. Moreover, when tested in a yeast estrogen bioassay, lacking steroid metabolism 
and steroidogenesis enzymes, T was also shown to elicit weak responses at the very high 
concentrations, 39 once again confirming that T is able to activate the ERα in vitro.
The environmental pollutant p-n-nonylphenol (CAS nr.104-40-5) was included by 
ICCVAM as a positive control in a set of reference compounds for validation of in vitro 
ER binding and transcriptional activation assays 24. In our coregulator binding assay, this 
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Table 2. Correlation ofthe relative potencies obtained in the ER binding assay, BG1Luc ER 
transcriptional activation assay and  in vivo uterotrophic assay with those obtained in the coregulator 
binding assay based on 57 coactivators showing a clear sigmoidal dose-response relation for 
17ß-estradiol-induced binding of ERα-LBD as reflected by a goodness-of-fit value of 0.9 or higher.
Coregulator binding assay
Peptide ID a Motif 
Uniprot 
Accession 
Coefficient of determination (R2)
ER binding 
assay(n=19)
BG1Luc 
ER TA 
(n=16)  
In vivo uterotrophic 
assay (n=18)
BL1S1_1_11 LxxLL2 P78537 0.51 0.54 0.49
BRD8_254_276 LxxLL267 Q9H0E9 0.74 0.80 0.87
CBP_57_80 LxxLL70 Q92793 0.65 0.84 0.71
EP300_69_91 LxxLL81 Q09472 0.73 0.82 0.84
GNAQ_21_43 LxxLL34 P50148 0.80 0.81 0.86
HAIR_745_767_C755S/C759S LxxLL758 O43593 0.46 0.53 0.46
IKBB_277_299 LxxLL289 Q15653 0.80 0.78 0.82
JHD2C_2054_2076 LxxLL2066 Q15652 0.85 0.79 0.88
LCOR_40_62 LxxLL53 Q96JN0 0.64 0.84 0.81
MED1_591_614 LxxLL604 Q15648 0.69 0.80 0.81
MLL2_4175_4197 LxxLL4188 O14686 0.65 0.81 0.79
NCOA1_620_643 LxxLL633 Q15788 0.82 0.80 0.87
NCOA1_677_700 LxxLL690 0.87 0.76 0.89
NCOA1_737_759 LxxLL749 0.78 0.81 0.83
NCOA1_1421_1441 LxxLL1435 0.84 0.74 0.89
NCOA2_628_651 LxxLL641 Q15596 0.86 0.75 0.88
NCOA2_677_700 LxxLL690 0.84 0.80 0.87
NCOA2_733_755 LxxLL745 0.82 0.81 0.87
NCOA3_609_631 LxxLL621 Q9Y6Q9 0.79 0.82 0.85
NCOA3_609_631_C627S LxxLL621 0.86 0.78 0.89
NCOA3_673_695 LxxLL685 0.85 0.78 0.89
NCOA3_725_747 LxxLL738 0.85 0.78 0.89
NR0B1_1_23 LxxML13 P51843 0.78 0.81 0.82
NR0B1_136_159 LxxLL146 0.83 0.75 0.83
NR0B2_9_31_C9S/C11S LxxLL21 Q15466 0.82 0.76 0.84
NR0B2_106_128 LxxIL118 0.83 0.71 0.89
NR0B2_201_223_C207S LxxVL214 0.78 0.80 0.82
NRBF2_128_150 LxxLL141 Q96F24 0.64 0.77 0.66
NRIP1_120_142 LxxLL133 P48552 0.78 0.80 0.85
NRIP1_121_143_P124R LxxLL133 0.64 0.81 0.78
NRIP1_253_275_C263S LxxLL266 0.81 0.80 0.88
NRIP1_368_390 LxxLL380 0.84 0.73 0.84
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NRIP1_488_510 LxxLL501 0.83 0.80 0.89
NRIP1_700_722 LxxLL713 0.81 0.80 0.87
NRIP1_701_723 LxxLL713 0.81 0.81 0.88
NRIP1_805_831 LxxLL819 0.81 0.80 0.88
NRIP1_924_946 LxxLL936 0.80 0.82 0.87
NRIP1_924_946_C945S LxxLL936 0.84 0.80 0.88
NRIP1_1055_1077 LxxML1068 0.84 0.79 0.89
NSD1_894_916 FxxLL907 Q96L73 0.62 0.81 0.74
PELP1_20_42 LxxLL33 Q8IZL8 0.76 0.79 0.84
PELP1_168_190 LxxLL181 0.80 0.75 0.83
PELP1_446_468 LxxLL459 0.77 0.81 0.82
PELP1_571_593_C575S/C581S LxxLL584 0.83 0.71 0.84
PPRC1_151_173 LxxLL164 Q5VV67 0.77 0.80 0.88
PRGC1_130_155 LxxLL144 Q9UBK2 0.73 0.61 0.82
PRGC1_134_154 LxxLL144 0.80 0.72 0.80
PRGC2_146_166 LxxLL156 Q86YN6 0.85 0.74 0.88
PRGC2_338_358 LxxLL343 0.83 0.80 0.88
PROX1_57_79 LxxLL70 Q92786 0.80 0.82 0.87
TIF1A_747_769 LxxLL760 O15164 0.83 0.74 0.82
TIP60_476_498 LxxLL489 Q92993 0.78 0.82 0.84
TREF1_168_190 LxxLL181 Q96PN7 0.76 0.80 0.87
TRRAP_3535_3557_C3535S/
C3555S
LxxLL3548 Q9Y4A5 0.60 0.71 0.74
TRXR1_132_154 LxxLL145 Q16881 0.81 0.83 0.89
WIPI1_119_141 LxxLL132 Q5MNZ9 0.60 0.76 0.78
ZNHI3_89_111 LxxLL101 Q15649 0.82 0.80 0.88
a ID as follows: [coregulator]_[aa start]_[aa end of peptide],  bold coactivators have been shown previously 
to bind to endogenous ERα in cell lysates and in breast tumors in the presence of E2. 25 
Table 2. Continued.
Coregulator binding assay
Peptide ID a Motif 
Uniprot 
Accession 
Coefficient of determination (R2)
ER binding 
assay(n=19)
BG1Luc 
ER TA 
(n=16)  
In vivo uterotrophic 
assay (n=18)
compound did not show any response. However, although others reported p-n-nonylphenol 
to be active in transcriptional activation assays based on either yeast cells or mammalian 
cells, 40, 41 a thorough review of these studies showed that a technical mixture like the one 
available from Fluka (approximately 85–92.7% of branched isomers) or p-nonylphenol 
(CAS No. 84852-15-3) was used instead of the unbranched nonyl chain (CAS nr.104-40-5). 
101
5C
O
Reg
U
la
TO
R bIN
D
IN
g
 a
ssa
y
Thus, the ICCVAM report may need to be updated in this regard. Meanwhile, it has been 
shown that the p-n-nonylphenol (CAS nr.104-40-5) was inactive in a yeast estrogen 
bioassay while a technical mixture of nonylphenol from Fluka was active in the estrogen 
yeast bioassay. 39 From this, it could be concluded that p-n-nonylphenol is not estrogenic 
and that the estrogenicity of the technical mixture is due to one or more isomers with 
a branched side-chain. A similar conclusion was presented by Pedersen et al. (1999) 
studying the induction of plasma vitellogenin in rainbow trout by linear and technical 
nonyl- and octylphenol. 42 In a more recent study, p-n-nonylphenol was even used as a 
negative control for the validation of a recombinant yeast estrogen receptor agonist assay. 43 
Moreover, butylbenzyl phthalate, di-n-butyl phthalate, and ethyl paraben were reported 
to bind weakly to the ER and were also slightly active in the BG1Luc ER transcriptional 
activation assay. In the coregulator binding assay, although they may also bind weakly to the 
ERα-LBD, detectable coregulator recruitment was not induced by these compounds under 
the concentrations tested. In the in vivo uterotrophic assay, butylbenzyl phthalate, di-n-
butyl phthalate and ethyl paraben also are not able to induce uterotrophic effect. 44-46 This 
demonstrated that the human cancer cell line based reporter gene assays are more sensitive 
than both the in vivo uterotrophic assay and the current coregulator binding assay, which 
is an advantage for screening estrogenicity in food or environmental samples. However, for 
prioritization and testing pure chemicals all these in vitro assays are sensitive enough to 
measure potent to weak estrogens. Compounds that are negative in the coregulator binding 
assay, although slightly active in the BG1Luc ER assay, may not have the highest priority to 
be further tested for estrogenicity in  the in vivo uterotrophic assay. In addition, o,p’-DDT is 
able to induce a uterotrophic effect in the rat, 47, 48 but did not show an effect in the current 
coregulator binding assay. This is probably due to the low concentration range tested 
(20 pM – 200 µM), resulting in poor fitting of the applied dose-response model to the data, 
and as a consequence, classification of the response of o,p’-DDT as negative. With excellent 
correlation with the estrogen receptor binding assay (33 coactivators with R2 ≥ 0.80, n=19), 
BG1Luc ER transcriptional activation assay (32 coactivators with R2 ≥ 0.80, n=16), and the 
in vivo uterotrophic assay (30 coactivators with R2 ≥ 0.85, n=18), the coregulator binding 
assay demonstrated its usefulness in screening substances for in vitro ER agonistic activity. 
Moreover, 25 coactivators have been shown to bind to endogenous ERα in cell lysates 
and in breast tumors when tested on PamChip® plate peptide microarray in the presence 
of E2. 25 Twenty-one of these 25 coactivators (highlighted in Table 2) also display a high 
correlation coefficient with the estrogenicity observed in the uterotrophic assay, indicating 
the biological relevance of the correlation found with these coactivators. 
In summary, the obtained results in this study with the SERMs indicate that the 
coregulator binding assay based on the PamChip® plate is able to distinguish receptor 
agonists from antagonists. Moreover, in transcriptional activation assays, cell proliferation 
assays and the in vivo uterotrophic assay the effects of ER antagonists are generally measured 
in combination with potent estrogens such as E2 or EE2, while in the coregulator binding 
assay, the antagonist properties can be measured directly, i.e., without the addition of a 
potent ER agonist. However, although the in vivo antagonist effects of the SERMs (e.g., 
102
5C
O
Reg
U
la
TO
R bIN
D
IN
g
 a
ssa
y
tamoxifen, 4-hydroxytamoxifen and OMIY-bisphenol) could be predicted correctly, the 
coregulator binding assay is not able to reveal the ER agonist properties of these SERMs. 
Therefore, other types of in vitro assays, e.g., reporter gene assays and H295R steroidogenesis 
assay, are needed to build a panel of in vitro assays to increase the predictive power and 
to reach a similar performance in qualifying compounds as that achieved by the in vivo 
uterotrophic assay. The present study thus shows that the coregulator binding assay is useful 
within such a panel of in vitro test systems for estrogenicity testing, allowing easy high-
throughput screening and prioritization of chemicals, thereby contributing to the reduction 
- and ultimately the replacement- of current animal testing for (anti)estrogenic effects.
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Figure S1. Analysis of ERα-LBD binding to coregulators induced by 4-Hydroxytamoxifen.
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Figure S2. Analysis of ERα-LBD binding to coregulators induced by OMIY-bisphenol.
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ABSTrAcT 
Testing chemicals for their endocrine-disrupting potential, including interference 
with estrogen receptor (ER) signaling, is an important aspect of chemical safety 
testing. Because of the practical drawbacks of animal testing, the development of in 
vitro alternatives for the uterotrophic assay and other in vivo (anti)estrogenicity tests 
has high priority. It was previously demonstrated that an in vitro assay that profiles 
ligand-induced binding of ERα to a microarray of coregulator-derived peptides 
might be a valuable candidate for a panel of in vitro assays aiming at an ultimate 
replacement of the uterotrophic assay. In the present study, the reproducibility 
and robustness of this coregulator binding assay was determined by measuring 
the binding profiles of 14 model compounds that are recommended by the Office 
of Prevention, Pesticides and Toxic Substances for testing laboratory proficiency 
in estrogen receptor transactivation assays. With a median coefficient of variation 
of 5.0% and excellent correlation (R2 = 0.993) between duplicate measurements, 
the reproducibility of the ERα-coregulator binding assay was better than the 
reproducibility of other commonly used in vitro ER functional assays. In addition, 
the coregulator binding assay is correctly predicting the estrogenicity for 13 out of 14 
compounds tested. When the potency of the ER-agonists to induce ERα-coregulator 
binding was compared to their ER binding affinity, their ranking was similar, and the 
correlation between the EC50 values was excellent (R2 = 0.96), as was the correlation 
with their potency in a transactivation assay (R2 = 0.94). Moreover, when the ERα-
coregulator binding profiles were hierarchically clustered using Euclidian cluster 
distance, the structurally related compounds were found to cluster together, whereas 
the steroid test compounds having an aromatic A-ring were separated from those 
with a cyclohexene A-ring. We concluded that this assay is capable of distinguishing 
ERα agonists and antagonists and that it even reflects the structural similarity of ERα 
agonists, indicating a potential to achieve identification and classification of ERα 
endocrine disruptors with high fidelity.
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inTroducTion
The estrogen receptor (ER) is a member of the nuclear receptor (NR) family, a class of gene 
transcription regulators which are activated upon binding of a low molecular weight ligand. 
The major endogenous agonist activating the ER is 17β-estradiol (E2), which regulates the 
expression of genes involved in the reproductive system and bone development, especially in 
females, but also in males.1, 2 Two types of ER can be found in mammalians, ERα and ERβ. 
The ERα type is mainly expressed in the sex organs, while ERβ is the dominating type in the 
bone and brain.3, 4 Transcription activation by the ER is dependent on binding of agonistic 
ligands to the binding site in the ligand-binding domain (LBD) of the ER polypeptide 
chain. The conformational change upon agonist binding results in uncovering of the DNA-
binding domain and of the cofactor-binding motif within the LBD.5 Two functional classes 
of cofactors or coregulators have been found to interact with the ER and other nuclear 
receptors, i.e., coactivators and corepressors, respectively, stimulating and inhibiting the 
basal transcription complex formed on promoter sequences.6, 7 Coactivators and corepressors 
interact with nuclear receptors through their specific (iso)leucine-rich amino acid sequence 
motifs, LXXLL and LXXXIXXX(I/L), for activators and repressors, respectively.5, 6
Investigating chemicals for their endocrine-disrupting potential, including interference 
with estrogen receptor (ER) signaling, is an important aspect of chemical safety testing. 
Because of the severe drawbacks of in vivo testing, e.g., ethical objections and its labor and 
resource intensiveness, the development of in vitro alternatives for in vivo (anti)estrogenicity 
tests, such as the in vivo uterotrophic assay, has high priority. Recently, an ERα-coregulator 
binding assay in PamChip plate format has been developed that enables one to measure the 
interaction of the ERα-LBD with these coregulator binding motifs. The PamChip plate consists 
of 96 identical arrays, each array holding 155 different NR-binding coregulator peptides 
immobilized on a porous metal oxide carrier.8, 9 First, purified LBD from ERα, labeled with 
glutathione-S-transferase (GST) or histidine (His), is preincubated with the test compound. 
Subsequently, the peptide microarray is incubated with this mixture and the binding of the 
labeled ERα-LBD to the coregulator binding motifs as induced by the test compound is 
quantified. In a previous study, it was demonstrated that the binding of tagged ERα-LBD 
to the peptide microarray correctly predicted the estrogenicity of the reference compounds 
tested and that the determined estrogenic potencies of the compounds also correlated well 
with their in vivo potency in the uterotrophic assay.10 Moreover, that study also indicated 
that the ERα-coregulator binding assay was capable of identifying ER antagonistic properties, 
and the obtained binding profiles for the selective estrogen receptor modulators (SERMs) 
tamoxifen, 4-hydroxytamoxifen, and 4,4’-(octahydro-4,7-methano-5h-inden-5-ylidene)
bisphenol suggested that their antagonistic properties are more likely to result from inhibition 
of the binding of ERα to coactivators than from increased binding to corepressors. Altogether, 
it was concluded that this ERα-coregulator binding assay is a valuable candidate to be part 
of a panel of in vitro assays for screening and prioritization of chemicals, and thus would 
contribute to reduce and ultimately replace animal testing for (anti)estrogenic effects.10
In this study, the reproducibility and robustness of the PamChip plate in combination 
with the ERα-LBD-His was investigated by determining the coregulator binding profiles of 
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14 model compounds (Table 1). This set of compounds included 10 proficiency compounds 
recommended by the Office of Prevention, Pesticides and Toxic Substances (OPPTS) for testing 
laboratory proficiency in carrying out ER-controlled reporter gene transactivation assays,11 i.e., 
seven compounds with varying (anti)estrogenic potential, hexestrol, 17α-ethinyl estradiol, 
diethylstilbestrol, estrone, genistein, 1,3,5-tris(4-hydroxyphenyl)benzene (1,3,5-TB), and butyl 
paraben; and three nonestrogenic compounds, atrazine, dibutyl phthalate, and corticosterone. 
The remaining 4 compounds were the reference compounds: 17β-estradiol (E2; strong 
estrogen), 17α-estradiol (weak estrogen), 17α-methyltestosterone (very weak ER agonist), 
and corticosterone (negative compound). The obtained binding profiles were also used to 
determine whether the ERα-coregulator binding assay correctly predicted the estrogenicity 
and potency of these compounds and furthermore to investigate the relationship between the 
coregulator binding profile and the structure of the compound under investigation.
mATeriAlS And meThodS
chemicals
17β-Estradiol (E2) was provided by MSD (Oss, The Netherlands) and another batch of 
17β-estradiol (referred to as from source 2), as well as diethylstilbestrol, hexestrol, estrone, 
17α-estradiol, butyl paraben, 1,3,5-tris(4-hydroxyphenyl)benzene (1,3,5-TB), atrazine, 
and corticosterone were purchased from Sigma-Aldrich Chemie B.V. (Zwijndrecht, The 
Netherlands). 17α-Ethinyl estradiol and 17α-methyltestosterone were purchased from 
Steraloids (Newport, RI, USA). Genistein was obtained from Apin Chemicals (Abingdon, 
Oxon, UK) and dibutyl phthalate from TCI Europe N.V. (Zwijndrecht, Belgium). Dimethyl 
sulfoxide (DMSO) was purchased from Merck (Darmstadt, Germany).
nuclear receptor-coregulator interaction profiling
Ligand-modulated interaction of ERα-LBD-His with coregulators was assessed using 
a PamChip plate (PamGene International B.V., ’s-Hertogenbosch, The Netherlands) 
containing 96 identical peptide microarrays (Figure 1a) as described previously.12, 13 The 
peptide microarray was used in combination with a polyhistidine-tagged human ERα-LBD 
(ERα-LBD-His; amino acids 302-552, partially purified from E.coli) to screen a dilution 
series of a set of 14 compounds. The peptide microarray was incubated with the test solution 
containing ERα-LBD-His in the absence or presence of ligand by pumping the sample up 
and down the three-dimensional metal oxide carrier (Figure 1b). In short, assay mixtures 
were prepared on ice in a master 96-well plate and contained ERα-LBD-His (optimal 
assay concentration of a crude lysate containing the conjugate was empirically determined 
and estimated to lie between 1 and 10 nM), 25 nM of an Alexa Fluor 488-conjugated 
polyhistidine antibody (penta-His Alexa Fluor 488 conjugate, Qiagen no. 35310), and ligand 
at the indicated concentration in reaction buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 
0.2% BSA, 0.05% Tween-20). All assays were performed in a fully automated microarray 
processing platform (PamStation96, PamGene International B.V.) at 20 °C applying two 
cycles per min. Initial blocking was performed by incubating the peptide microarray plate 
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Table 1. Chemical properties of the model compounds as recommended by the Office of Prevention, 
Pesticides and Toxic Substances (OPPTS) of the United States Environmental Protection Agency for 
testing estrogen receptor-mediated transcriptional activation (OPPTS guideline 890.1300).
Chemical name CAS No.
Chemical 
Classification
Functional 
Classification Structure
17β-Estradiol 50-28-2 Steroid; 
phenolic;estrene
Natural hormone
17α-Estradiol 57-91-0 Steroid; 
phenolic;estrene
Natural hormone 
stereoisomer
17α-Methyl-
testosterone
58-18-4 Steroid; 
nonphenolic; 
androstene
Pharmaceutical
Corticosterone a 50-22-6 Steroid; 
nonphenolic
Pharmaceutical
Hexestrol 84-16-2 Diphenylalkane; 
bisphenol; phenol
Pharmaceutical
17α-Ethinyl 
estradiol
57-63-6 Steroid, phenolic Pharmaceutical
Diethylstilbestrol 56-53-1 Stilbene; 
benzylidene; 
diphenylalkene
Pharmaceutical
Estrone 53-16-7 Steroid, phenolic; 
estrene
Pharmaceutical
Genistein 446-72-0 Flavanoid; 
isoflavone; phenol
Natural product
1,3,5-Tris 
(4-hydroxyphenyl)
benzene
15797-52-1 Triphenyl Chemical
Butyl paraben 94-26-8 Paraben; organic 
acid
Pharmaceutical
Atrazine 1912-24-9 Aromatic 
amine; Triazine; 
Arylamine
Pesticide
Dibutyl phthalate 84-74-2 Phthalate Plasticizer
a Corticosterone is both on the list of reference chemicals and on the list of proficiency compounds 
recommended by OPPTS. 113
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for 20 cycles with 25 µL of blocking buffer (TBS with 1% BSA, 0.01%, Tween-20, and 0.3% 
skimmed milk). Subsequently, the blocking buffer was removed, and 25 µL of the assay 
mix was transferred to each well/array on the plate and incubated for 80 cycles (~40 min). 
For each compound, 7–11 concentrations with 3-fold serial dilution in DMSO (final 
concentration 2%) were tested in two technical replicates (arrays). The tested compounds 
were distributed over four plate runs using 2% DMSO as the negative control and 50 μM 
E2 as the positive control on each plate (each measured in 4 technical replicates). After 
removal of the unbound receptor by washing each array with 25 µL of TBS, .tiff images were 
obtained by a CCD camera, which is part of the PamStation96 platform (Figure 1c).
data analysis
Image analysis was performed using BioNavigator software (PamGene International B.V.), 
which performs automated array grid finding and subsequent quantification of signal 
and local background for each individual peptide. In short, the boundaries of a spot are 
determined, and the median fluorescent signal was quantified within the spot (signal) 
as well as in a defined area surrounding it (background). The signal-minus-background 
value was subsequently used as the quantitative parameter of binding, and the average 
Coregulator binding profiles 
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concentration in reaction buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.2% BSA, 0.05% 
Tween-20). All assays were performed in a fully automated microarray processing platform 
(PamStation96, PamGene International B.V.) at 20 °C applying two cycles per minute. Initial 
blocking was performed by incubating the peptide microarray plate for 20 cycles with 25 µL 
of blocking buffer (TBS with 1% BSA, 0.01%, Tween-20, and 0.3% skimmed milk). 
Subsequently, the blocking buffer was removed, and 25 µL of the assay mix was transferred 
to each well/array on the plate and incubated for 80 cycles (~40 min). For each compound, 
7–11 concentrations with 3-fold serial dilution in DMSO (final concentration 2%) were 
tested in two technical replicates (arrays). The tested compounds were distributed over four 
plate runs using 2% DMSO as the negative control and 50 μM E2 as the positive control on 
each plate (each measured in 4 technical replicates). After removal of the unbound receptor 
by washing each array with 25 µL of TBS, .tiff images were obtained by a CCD camera, which 
is part of the PamStation96 platform (Figure 1c). 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic overview of the PamChip® peptide microarray for nuclear receptor-coregulator 
interaction profiling. a) PamChip®-96 design. The PamChip® plate consists of 96 identical arrays, 
each array containing 155 NR coregulator peptides (coactivators and  corepressors) immobilized on a 
porous metal oxide carrier; b) Ligand-modulated interaction of coregulators with ERα-LBD. 
Depending on the presence of ligand, the ERα-LBD will bind to coregulator-derived peptides, which 
Figure 1. Schematic overview of the PamChip peptide microarray for nuclear receptor-coregulator 
interaction profiling. a) PamChip-96 design. The PamChip plate consists of 96 identical arrays, 
each array containing 155 NR coregulator peptides (coactivators and  corepressors) immobilized 
on a po us metal oxide carrier; b) Ligand-modulated interaction of coregulators with ERα-LBD. 
Depending on the presence of ligand, the ERα-LBD will bind to coregulator-derived peptides, which 
can be detected by fluorescent antibodies against the ERα-LBD; c) Images obtained with an increasing 
series of concentrations of a ligand.
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over the duplicate measurements was calculated for each test compound concentration. 
Ligand dose–response curve fitting and hierarchical clustering (Euclidean distance, 
average linkage) were performed using the drc and stats packages in R (version 2.12.0, 
www.r-project.org). A sigmoidal, 4-parameter Hill (logistic) model (response = ((A – D)/
(1 + ((concentration/C)B))) + D, with parameters A = response minimum, B = Hill slope, 
C = EC50, and D = response maximum) was fitted to the dose–response data, and the 
goodness-of-fit parameter and EC50 values as calculated by the drc package were recorded.
The estrogenicity data used for comparisons with the presented ERα-coregulator 
binding data were ER binding data collected by the Interagency Coordinating Committee 
on the Validation of Alternative Methods (ICCVAM), 14 and ERα-controlled reporter 
gene transactivation data obtained by the Japanese Chemicals Evaluation and Research 
Institute (CERI) in the stably transfected hERα-HeLa-9903 human reporter cell line 15 
prescribed by the OPPTS guideline 890.1300 11 from which also our compound set was 
derived. The reporter gene assay using the hERα-HeLa-9903 human cell line is one of the 
ER transactivation assays that has been accepted for testing ER agonist activity and is part 
of the Test Guideline (TG) 455 from the Organisation for Economic Co-operation and 
Development (OECD).16 For comparison of the presented in vitro ERα-coregulator binding 
data with estrogenicity in vivo, uterotrophic assay data were used that were derived from 
the Endocrine Disruptor Knowledge Base (EDKB), designed and produced by the National 
Center for Toxicological Research (NCTR, USA).17
reSulTS
reproducibility and robustness of the erα-coregulator binding assay
In a preceding study, it was demonstrated that ERα-coregulator interaction profiling, using 
the PamChip technology, would make a valuable contribution to an in vitro battery for 
estrogenicity testing.10 With a view to practical application of such a coregulator binding 
assay, for example, in a regulatory toxicology setting, the present study assesses the 
technical characteristics of the assay, such as the reproducibility (by the same operator in 
the same laboratory) and robustness. The 14 compounds listed in Table 1 were tested in 
7–11 concentrations for their capacity to modulate coregulator binding by the ERα-LBD. 
Each concentration was tested on duplicate arrays on the same plate. The entire sample 
set was distributed over 4 PamChip plates holding 96 arrays each, with 50 μM E2 as the 
positive control and 2% DMSO as a negative control on each plate, comprising 363 ERα-
coregulator peptide array measurements in total. As an example, Figure 2a shows the 
induction of ERα-LBD-His binding to a peptide representing the NR-binding motif within 
amino acid 677–700 of the well-known nuclear receptor coactivator 1 (NCOA1_677_700) 
by E2, 17α-estradiol, 17α-methyltestosterone, and corticosterone, i.e., single measurements 
of all tested concentrations of these four compounds on 1 of the 155 coregulator peptides 
on the array. The lowest concentration of the potent E2 that resulted in a detectable binding 
of ERα-LBD-His to NCOA1_677_700 was 0.26 nM, a half maximal binding level (the 
EC50) was reached at approximately 1.0 nM, and binding was saturated above 6.4 nM. As 
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expected, the less potent agonists 17α-estradiol and 17α-methyltestosterone reached the 
half maximal binding level at higher concentrations, and the maximal binding levels were 
lower than obtained for E2. All experiments together, represented a thousand-fold signal 
dynamic range, from a minimum of 40 to a maximum of 40000 measured arbitrary units. 
The coefficient of variation (CV) was calculated over each pair of duplicate data, and the 
median of the CVs per plate is shown in Table 2, ranging from 4.7 to 6.4% at the highest 
on plate 1. All duplicate data together are plotted against each other in Figure 3, showing 
the excellent reproducibility of the measurements, which is generally increasing with signal 
strength, resulting in a CV between duplicates around 5.0% (median value over the four 
plates) and a correlation (R2) between the duplicates over all plates of 0.993 (p < 0.0001).
determination of the estrogenic potency of the test compounds
Binding of the ERα-LBD-His to two coregulator binding motifs, NCOA1_677_700 and 
nuclear receptor-interacting protein 1 (NRIP1_805_831, binding motif within amino acids 
805 – 831 of NRIP1), as a function of concentration is shown for the three positive reference 
compounds E2, 17α-estradiol, and 17α-methyltestosterone, the negative control corticosterone 
(Figure 2a and d), and for the 10 proficiency compounds recommended by the OPPTS. The 
proficiency compounds include 7 positive compounds (Figure 2b and e) and 3 negatives 
(Figure 2c and f). The selection of these coregulators was based on a previous study where the 
potency of tested compounds to induce the binding of ERα-LBD-GST to these coregulators 
was demonstrated to correlate well (R2 ≥ 0.88) with their in vivo estrogenic potency in the 
uterotrophic assay.10 The ERα-LBD-His binding curves obtained for these two coregulators in 
the present study demonstrate that binding is negative for all nonestrogens in the OPPTS test 
set and positive for all known estrogens, except for butyl paraben. The strong ER-agonists E2, 
17α-ethinyl estradiol, diethylstilbestrol, and hexestrol induced increased binding already at 
low concentrations (below 0.5 nM), and the moderate ER-agonists estrone and 17α-estradiol 
started to induce increased binding around 2 nM, while for the weak agonist genistein and 
very weak agonist 17α-methyltestosterone increased binding was observed to take off at a still 
higher concentration, around 200 nM and above 1 μM, respectively. In general, the maximal 
binding induced by a test compound decreased with decreasing ER agonist potency of the 
compound. Binding was reduced below baseline in the case of the very weak ER antagonist 
1,3,5-tris(4-hydroxyphenyl)benzene (1,3,5-TB; Figure 2b and e). Because of its antagonistic 
coregulator binding behavior, it was not appropriate to include 1,3,5-TB in the comparisons 
described below regarding the ER-agonistic potency of the test compounds.
Table 2. Median CV over all points in the signal range (40 - 40.000) and correlation (R2) between the 
duplicates listed per plate.
Plate number 1 2 3 4
Median CV(%) 6.4% 4.7% 4.7% 4.9%
R2 0.9651 0.9936 0.9926 0.9961
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Figure 2. Binding of ERα-LBD-His to the coregulator binding motif peptides NCOA1_677_700 (a-c) 
and NRIP1_805_831 (d-f) as function of the concentration of the indicated compounds measured in 
the ERα-coregulator binding assay. Curve-fitting was performed using the 4-parameter Hill (logistic) 
equation allowing to calculate the concentration resulting in 50% of the maximum coregulator binding 
(EC50 values) based on the best fit. Subsequently an overall EC50 over all coregulators was obtained by 
calculating the median of the EC50 values from the individual curves, as shown in this figure, over 
all those coregulators showing a goodness-of-fit above 0.9. a and d) Reference compounds; b and e) 
proficiency compounds classified as positive, or (c and f) negative for ERα-mediated transcription 
activation by the OPPTS 890.1300 guideline.
For each test compound, dose–response data were obtained for all 155 coregulator-derived 
NR-binding motifs on the peptide microarray. The resulting dose–response curves allowed us 
to determine for each compound and each coregulator peptide an EC50 for inducing ERα 
binding to that peptide. To obtain an overall measure for the potency as an inducer of ERα-
coregulator binding, the median of the EC50 values was determined, over all those coregulator 
peptides showing a comparatively good fit of the applied dose–response model (goodness-
of-fit of the Hill equation above 0.9). Relative binding potencies (RBPs) compared to E2 
were calculated on the basis of these median EC50 values (Table 3). For the positively tested 
estrogenic compounds, the number of coregulator peptides meeting this requirement varied 
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from 28 (for 17α-methyltestosterone) to 57 (for hexestrol). The relative potencies in the ERα-
coregulator binding assay were then correlated with the relative affinities for ER binding as 
listed in the review of ICCVAM,14 and the relative potency for ERα-controlled transcription 
activation insofar as available from CERI,15 and were also compared to the estrogenicity in 
vivo as observed in the uterotrophic assay 17 (Table 3). Only one compound was misclassified 
in the ERα-coregulator binding assay, i.e., butyl paraben was a false negative as compared 
to the in vivo uterotrophic assay. The ER binding data from ICCVAM, however, included 
three misclassifications, i.e., two false positives (dibutyl phthalate and atrazine) and one 
false negative (17α-methyltestosterone). When leaving out the compounds misclassified by 
ICCVAM (this would introduce unjustified negative bias since for misclassified compounds 
a bad correlation with another estrogenicity assay is to be expected), the ERα-coregulator 
binding and ER binding assay resulted in the same potency ranking for 8 out of the 9 
agonists tested and the correlation between the relative potency values for coregulator and 
ER binding was excellent (R2 = 0.96, p < 0.0001, n=9), as is shown in Figure 4. Although 
ERα transactivation is one step further downstream along the signal transduction pathway 
than ERα-coregulator binding, the correlation between the ERα-coregulator binding and ERα 
transactivation assay was found to be excellent as well (Figure 5, R2 = 0.94, p < 0.0001, n=11; 
1,3,5-TB and butyl paraben were excluded from this comparison since no data were available 
for these two compounds in the transactivation assay). In contrast to the situation for ER 
binding, no discrepancies appear to exist between the transactivation data from CERI and 
estrogenicity in vivo. Altogether, these findings imply that, in terms of misclassification with 
respect to in vivo estrogenicity, ERα-coregulator binding performs better than ligand binding 
and was found to be comparable to hERα-HeLa-9903 transactivation assay.
erα-coregulator binding profiles reflect compound structure similarity
For each test compound and each of the 155 coregulator–nuclear receptor binding motifs 
represented by the peptide microarray, the modulation index (MI) was calculated as the 
Figure 3. Technical variability of the 
PamChip ERα -coregulator binding assay. 
For each concentration of each compound 
duplicate assays were run on the same 
coregulator binding motif array plate. The 
signals (in arbitrary units, AU) of the two 
duplicate runs are plotted against each other 
for all samples tested. The average coefficient 
of variation (CV) between duplicate 
measurements was 5.0%. To achieve a 
more even distribution of the data we used 
a logarithmic scaling of the plot axes. The 
coefficient of determination (R2 = 0.993, 
p < 0.0001) across all duplicates and plates 
was however calculated using the original 
binding values.
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Table 3. Estrogenic properties of the OPPTS test compounds in uterotrophic assay, ERα-coregulator 
binding assay, estrogen receptor binding assay and HeLa-9903 transactivation assay.
Chemical name
Uterotrophic 
assay a
ERα-
coregulator 
binding
Median EC50 
(M)
 ERα-
coregulator 
binding log 
(Median 
RBP) e
ER  
binding
log 
(Median 
RBA) g
ERα  
transactivation 
EC50 (M) j
ERα 
transactivation 
logREP k
17β-Estradiol POS b 1.5E-09 2.0 2.0 8.2E-12 2.0 
17α-Estradiol POS 9.7E-09 1.2 1.0 6.0E-10 0.1 
17α-MT POS 7.6E-06 -1.7 -5.0 4.1E-6 -3.7 
Corticosterone NEG b NEG -5.0  f -5.0 NEG -5.0 
Hexestrol POS 1.0E-09 2.2 2.4 NA 1.5 l 
EE2 POS 1.2E-09 2.1 2.2 5.7E-12 2.2 
DES POS 1.5E-09 2.0 2.1 2.4E-11 1.5 
Estrone POS 3.7E-09 1.6 1.6 4.9E-10 0.2 
Genistein POS 9.6E-08 0.2 0.2 2.5E-08 -1.5 
1,3,5-TB NA c - d - -0.4 h NA NA
Butyl paraben POS NEG -5.0 -3.1 i NA NA
Atrazine NEG NEG -5.0 -3.5 NEG -5.0 
Dibutyl 
phthalate
NEG NEG -5.0 -2.6 NEG -5.0 
Corticosterone NEG NEG -5.0 -5.0 NEG -5.0 
a Data reported by CERI 15 and National Center for Toxicological Research (NCTR, USA) 17.  b POS / NEG = 
classified as positive / negative for estrogenic effect. c Data not available.   d Compound only showing antagonist 
binding effect, therefore the EC50 and relative potency values cannot be determined. e Relative binding potency 
values are calculated as the ratio of the concentration of E2 needed to achieve 50% of maximal ERα-LBD to 
coregulator binding (median EC50) and the concentration of the test compound required to achieve a similar 
effect, and this ratio is subsequently multiplied by 100. The RBP value of E2 is thus 100, resulting in a log (RBP) 
of 2.0. f Compounds which were found inactive for a particular effect were assigned an arbitrary low cut-off value 
of -5.0 for the log (relative potency).  g Logarithm of the median relative affinity value for ER binding as reported 
by ICCVAM 14.  h Obtained from Mizutani et al. 2012 41 i Obtained from Blair et al. 2000 27 j Data reported by 
CERI 15, obtained using the human cell line hERα-HeLa-9903 as prescribed by the OPPTS guideline 890.1300. k 
Relative estrogenic potency is defined as the ration between the EC50 of E2 and the EC50 of the compound, and 
this ratio is subsequently multiplied by 100. The REP value of E2 is thus 100, resulting in a logREP of 2.0. l Based 
on the relative estrogenic potency reported by CERI 15. Abbreviations: 17α-MT, 17α-Methyltestosterone; EE2, 
17α-Ethinyl estradiol; DES, Diethylstilbestrol; 
log-transformed ratio of receptor binding at a saturating compound concentration over 
that in the absence of ligand. The MIs for the 155 binding motif peptides constitute an 
ERα-coregulator binding profile for each compound tested. Unsupervised hierarchical 
clustering of these MI values over the various compounds and over all coregulator 
peptides on the array (Figure 6a) revealed that compounds with structural similarity 
tend to cluster together (Figure 6b). For instance, the structurally related compounds 
17β-estradiol and 17α-estradiol, as well as hexestrol and diethylstilbestrol, and the two 
compounds with a butyl-4-benzoate moiety, i.e., butyl paraben and dibutyl phthalate, 
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Figure 4. Correlation between the 
relative affinity for binding to the ER 
according to ICCVAM 14 and the relative 
potency to induce coregulator binding 
observed in this study, calculated over 
all coregulators showing a goodness-
of-fit of the 4-parameter Hill equation 
above 0.9. The two data sets compared 
were both plotted as the logarithm of 
the relative value as compared to E2 
expressed as a percentage. A cut-off 
value of -5.0 was arbitrarily assigned 
to inactive compounds (see Table 3). 
Coefficient of determination: R2 = 
0.96 (p < 0.0001, n = 9); correlation 
equation, y = 0.87x + 0.25.
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were both plotted as the logarithm of the relative value as compared to E2 expressed as a percentage. 
A cut-off value of -5.0 was arbitrarily assigned to inactive compounds (see Table 3). Coefficient of 
determination: R2 = 0.96 (p < 0.0001, n = 9); correlation equation, y = 0.87x + 0.25. 
 
ERα-coregulator binding profiles reflect compound structure similarity 
For each test compound and each of the 155 coregulator–nuclear receptor binding motifs 
represented by the peptide microarray, the modulation index (MI) was calculated as the log-
transformed ratio of receptor binding at a saturating compound concentration over that in 
the absence of ligand. The MIs for the 155 binding motif peptides constitute an ERα-
coregulator binding profile for each compound tested. Unsupervised hierarchical clustering 
of these MI values over the various compounds and over all coregulator peptides on the 
array (Figure 6a) revealed that compounds with structural similarity tend to cluster together 
(Figure 6b). For instance, the structurally related compounds 17β-estradiol and 17α-
estradiol, as well as hexestrol and diethylstilbestrol, and the two compounds with a butyl-4-
benzoate moiety, i.e., butyl paraben and dibutyl phthalate, cluster next to each other, while 
Figure 5. Correlation between the 
relative potency compared to E2 
for ERα-mediated transcription 
activation, as reported by CERI 15, and 
for inducing ERα-coregulator binding, 
calculated over all coregulators 
showing a goodness-of-fit of the 
4-parameter Hill equation above 0.9. 
Both relative potencies were expressed 
as the log(percentage of E2). A cut-off 
value of -5.0 was arbitrarily assigned to 
inactive compounds (see Table 3). R2 = 
0.94 (p < 0.0001, n = 11); correlation 
equation, y = 0.93x - 0.70.
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the steroids with an aromatic A-ring (17β-estradiol, 17α-ethinyl estradiol, 17α-estradiol, and 
estrone) are separated from those with a cyclohexene A-ring (corticosterone and 17α-
methyltestosterone) (Figure 6b). As expected, the closest correlation is obtained between 
two sources of the same compound (17β-estradiol_1 and 17β-estradiol_2 in Figure 6b). 
 
Figure 5. Correlation between the relative potency compared to E2 for ERα-mediated transcription 
activation, as reported by CERI 15, and for inducing ERα-coregulator binding, calculated over all 
coregulators showing a goodness-of-fit of the 4-parameter Hill equation above 0.9. Both relative 
potencies were expressed as the log(percentage of E2). A cut-off value of -5.0 was arbitrarily assigned 
to inactive compounds (see Table 3). R2 = 0.94 (p < 0.0001, n = 11); correlation equation, y = 0.93x - 
0.70. 
lus er next t  ach other, while the steroids with an aromatic A-ring (17β-estradiol, 17α-
ethinyl estradiol, 17α-e tradiol, and estron ) are separated from those with a cyclohexene 
A-ring (cortico t rone and 17α-methyltestosteron ) (Figure 6 ). As exp cted, the closest 
correlati n is obtained between two sources of the same compound (17β-estradiol_1 and 
17β-estradiol_2 in Figure 6b).
diScuSSion
Endocrine disruption, including interference with ER signaling, is an important endpoint, 
also with a view to identifying a potential risk for reproductive toxicity, and is therefore 
an important aspect of chemical safety testing. The uterotrophic assay in premature or 
ovariectomized rodents measures increase in uterus weight. This is a strictly estrogen-
dependent in vivo response and is considered the gold standard to identify compounds 
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with estrogenic or antiestrogenic activity, the latter being tested in general by measuring the 
potential to inhibit the effect of an uterotrophic dose of the reference estrogen 17α-ethinyl 
estradiol.18, 19 However, being a rodent-based in vivo assay, application of the uterotrophic 
assay has severe drawbacks because of the labor- and resource-intensive nature of animal 
Figure 6. Heatmap of the unsupervised hierarchically clustered values for ERα-coregulator binding 
across compounds and coregulators shows structural similarity of compounds. a) Two-dimensional 
clustering heatmap; b) clustering pattern of compounds.
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testing, not to mention the associated ethical issues and the resulting political and public 
resistance. Altogether, these issues hamper its practical application within massive 
screening programs such as the REACH initiative recently launched by the European 
Union. Therefore, the development of in vitro alternatives for in vivo (anti)estrogenicity 
tests, such as the uterotrophic assay, has a high priority. In a previous study,10 it was 
reported that coregulator binding to ERα could be measured in vitro, using a microarray 
of peptides representing nuclear receptor binding motifs from various coregulators. ERα-
coregulator binding measured using this array-based method appeared to be a very good 
predictor of estrogenic potency in vivo as observed in the uterotrophic assay (R2 values for 
the in vitro–in vivo correlation were higher than 0.85 for 30 of the coregulator–nuclear 
receptor binding motifs tested). The present study was undertaken to establish whether 
the ERα-coregulator binding assay, using the PamChip plate in combination with ERα-
LBD-His, gives reproducible results. In addition, the measured potencies (RBP values) of 
the current test panel of compounds to induce ERα-coregulator binding were compared 
to the relative affinities for ER binding as reported by ICCVAM,14 and the relative potency 
for ERα-controlled transcription activation from CERI,15 and were also compared to the 
estrogenicity in vivo as observed in the uterotrophic assay 17 (Table 3). Moreover, binding 
profiles were used to perform an unsupervised hierarchical clustering of the MI values over 
the various compounds and over all coregulator peptides on the array in order to determine 
whether the compounds with structural similarity cluster together.
With a median coefficient of variation of 5.0% and an excellent correlation (R2 = 0.993) 
between duplicate measurements, the reproducibility of the ERα-coregulator binding assay 
was better than other commonly used in vitro ER functional assays. For example, for ER 
transactivation assays, such as the ER-CALUX, the coefficient of variation (CV) between 
replicate EC50 measurements of E2 was reported 20 to amount up to 32.7%, and in a more 
extensive reproducibility study with the ERα-CALUX the CV averaged over all compounds 
measured was 19.8% for EC50 determinations carried out in the same lab. 21 For the yeast 
estrogen screen (YES) assay,22 another ER-controlled reporter gene transactivation assay 
using a recombinant yeast strain, the variability observed when measuring a saturating E2 
concentration (6.96 × 109 M), expressed as the CV, amounted up to 7.4%. However, this 
relatively low CV was only achieved after sophisticated optimization of the protocol,23 
whereas studies with other types of yeast estrogen assays reported mean CVs of 18.0%24 
and 18.6%.25 A variability in the same range as for the transactivation assays was reported 
for classical ERα ligand binding assays, e.g., a CV of 11% in a study performed by Kase 
et al. in 2009.26 In addition to its high reproducibility, the present study also shows that 
the ERα-coregulator binding assay is correctly predicting the estrogenicity for 13 out of 14 
compounds tested, as only the ER-agonistic properties of butyl paraben were not represented 
in the obtained binding profiles on the PamChip plate. However, this is probably due to the 
tested concentration range (20 nM–400 µM), which was too low compared to the reported 
IC50 (105 µM) for ER binding,27 resulting in poor fitting of the applied dose–response model 
to the data, and as a consequence, classification of the response of butyl paraben as negative 
according to the data quality criterion applied. When the potency to induce ERα-coregulator 
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binding of the ER-agonists was calculated over the entire coregulator binding profile of a 
compound and compared to the potency as observed for in vitro ER binding, the potency 
ranking of 8 out of 9 ER-agonists tested was exactly the same for binding to ER (butyl paraben 
is missed in the PamChip plate assay). A similar comparison was performed with the potency 
to induce ERα transactivation, and again, the ranking of the compounds was found to be 
essentially similar for ERα-coregulator binding and ERα transactivation, with only minor 
nearest neighbor swaps among the strong estrogens tested. The correlation of coregulator 
binding with both ERα binding and ERα-mediated transcription activation was excellent (in 
both cases R2 ≥ 0.94). This correlation was obtained when the three misclassifications as to 
estrogenicity in vivo within the ER binding data from ICCVAM were left out,14 i.e., two false 
positives (dibutyl phthalate and atrazine) and one false negative (17α-methyltestosterone). In 
addition to the ERα transactivation data from the CERI report 15 used in Table 3 of this study, 
the ICCVAM report also contains ER transactivation data, including a median EC50 calculated 
over the entire range of reporter gene studies covered by the report. Even though these EC50 
values were based not only on the hERα-HeLa-9903 human cell line recommended by 
OPPTS,11 but also on other mammalian cell lines, there were no inconsistencies (not shown) 
with our ERα-coregulator data, except for 17α-estradiol. The latter compound was reported 
by ICCVAM  to be slightly more potent than E2, but this was not confirmed by CERI, and 
therefore, it is unclear whether 17α-estradiol presents a true exception. Taken together, this 
study provides additional evidence that the ERα-coregulator binding assay reliably reflects 
ERα agonist potency, which is the crucial factor for being uterotrophic and estrogenic in vivo. 
As shown before,10 the PamChip plate assay also reflected inhibition of coregulator binding 
by the weak ER antagonist 1,3,5-TB (Figure 2b and 2e). This is consistent with the inhibitory 
effect observed with ER antagonists in previous studies using other ER–coregulator peptide 
binding assays,28-30 and is an advantage over the classical ligand binding assay.
During recent years, our understanding of the dynamics of NR–mediated transactivation 
of gene transcription has increased substantially, leading to the perception that allosteric 
effects within the NR-coregulator complex are a major determinant of the complex formation 
process. Besides the ligand bound to the ligand-binding pocket of the NR,31, 32 a number of 
other effectors have been reported to induce conformational changes in protein components 
or interfere with molecular interactions within the complex. These include cofactor proteins 
recruited to the complex,33 as well as the response element nucleotide sequence interacting 
with the DNA-binding domain,34 and even other small molecules,35 which may also have 
affinity for other sites within a NR than the ligand-binding domain.36 These allosteric effects 
have consequences for binding affinity and dynamics of the various components within 
the NR–coregulator complex, which ultimately determines target gene expression. For 
example, differences in the coregulator complement expressed in a certain cell type will not 
only have a direct effect on the composition of the ER–coregulator complex assembled on 
the estrogen response element (ERE) but also may influence the binding affinity of other 
coregulators. This may have consequences for the binding affinity for certain response 
elements as compared to others, dependent on nucleotide sequence context, and thereby for 
the target gene set of which the expression level is altered. Altogether, this points to a much 
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more complex role for coregulators of ERα and other NRs than just a connector to the RNA 
polymerase complex but rather indicates that NR coregulators provide an extra level of gene 
expression regulation, enabling subtle allosteric mechanisms of fine-tuning. Therefore, the 
possible relationship between ERα agonist structure and the induced coregulator binding 
profile was investigated in the present study by clustering the coregulator binding profiles 
in both dimensions (test compounds and coregulator peptides), applying hierarchical 
clustering with Euclidian distance as the cluster distance metric. The structurally related 
compounds, such as hexestrol and diethylstilbestrol, were found to cluster together, whereas 
the steroid test compounds having an aromatic A-ring were separated from those with a 
cyclohexene A-ring. Our observation that the coregulator binding profile induced by an 
ERα ligand reflects information about the molecular structure of the inducer, confirms that 
the molecular structure of an ERα ligand affects coregulator-binding affinities. This may be 
explained by the allosteric mechanisms discussed, implying that the actual conformation 
of the NR-LBD, imposed upon ligand binding, is an important determinant of coregulator 
binding. Using other techniques, mostly based on fluorescent microsphere-bound peptides 
to monitor interaction with ER receptors, it has been shown before that the ER-coactivator 
binding profile is dependent on the type of ligand bound.29, 37-40 However, most studies 
involve only very few ER ligands and therefore can only reveal incidental associations 
between ligand molecular structure and the peptide binding profile induced. An exception 
is the study by Iannone et al. (2004),38 which investigated 405 ERα-binding compounds and 
reported peptide binding profile similarity within relatively large clusters of compounds. 
However, the structures of the cluster members remain mostly unspecified, except for the 
structurally related compounds raloxifene, lasofoxifene, and levormeloxifene. However, E2 
and diethylstilbestrol, which have a clearly different molecular structure, display a similar 
peptide binding profile in the study of Iannone et al. (2004), whereas these two compounds 
show a separate peptide binding profile in our study (Figure 6b), as was to be expected. Our 
study extends these preliminary observations to a larger group of ER ligands, including both 
closely and more distantly related molecular structures, and thereby decisively substantiates 
the relationship between the coactivator binding profile induced and ligand molecular 
structure. Moreover, our observations only involve known coregulator NR box-derived 
peptides, not random peptides,38, 40 of which the mechanistic relevance is less obvious. 
In conclusion, the results of the present study demonstrate that the high reproducibility 
of the coregulator binding assay in combination with a high multiplicity level (155 
coregulator peptides for 96 samples tested in one plate run) and short processing time 
(less than 2h), present important benefits, enhancing its practical applicability as a 
high-throughput estrogenicity assay within current chemical safety screening programs. 
Moreover, the results of the present study illustrate the biological relevance of the outcomes 
of the ERα-coregulator binding assay, which even reflects the structural similarity of ERα 
agonists. Thus, the ERα-coregulator binding assay is a promising assay that has the potential 
to achieve identification and classification of ERα endocrine disruptors with high fidelity 
for those disruptors affecting the ERα directly. Further validation with a larger set of test 
compounds will be the next step toward implementation in practice.
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ABSTrAcT 
In the present study the previously established integrated testing strategy (ITS) for 
in vitro estrogenicity testing was extended with additional in vitro assays in order to 
broaden its sensitivity to different modes of estrogenic action than estrogen receptor 
(ER) binding. To this end an additional series of 10 estrogenic compounds with modes 
of action in part different from ER binding were tested in the previously defined 
ITS, i.e., in a yeast estrogen reporter gene assay, a U2OS estrogen receptor (ER) α 
CALUX reporter gene assay and a cell-free coregulator binding assay. Results show 
that the two reporter gene assays in the ITS accurately predict the estrogenicity of 
the model compounds and revealed 100% concordance with the in vivo uterotrophic 
assay. Moreover, the coregulator binding profiles provided new mechanistic insights 
into estrogen receptor signaling of the model compounds tested. Moreover, by 
adding androgen reporter gene assays as well as the H295R steroidogenesis assay 
to the ITS, several model compounds also showed potent antiandrogenic properties 
and effects on steroidogenesis that might potentiate the estrogenic effects in vivo. By 
covering these additional mechanisms of estrogen-related endocrine disruption, this 
extended ITS will go beyond in vivo estrogenicity testing by the uterotrophic assay. 
The extended ITS presented in this study may allow easy high-throughput screening 
and prioritization of chemicals, thereby contributing to refinement, reduction and to 
some extent even a replacement of current animal testing for (anti)estrogenic effects.
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inTroducTion
With a view to the regulation on Registration, Evaluation and Authorisation of Chemicals 
(REACH) in the European Union and the need for reducing, refining and replacing 
(3Rs) the use of experimental animals for safety testing, there is a clear need to develop 
high-throughput in vitro methods to efficiently screen chemicals and prioritize them for 
further testing. Due to the increasing need for new methods to be developed and proposed 
for validation in the European Union, the European Union Reference Laboratory for 
alternatives to animal testing (EURL ECVAM) has been formally established in 2011. In 
the US, the Environmental Protection Agency (EPA) is in the process of establishing in 
vitro testing programs and strategies to predict potential toxicity and to develop a cost-
effective approach to prioritize toxicity testing of chemicals. For example, one of the leading 
programs is ToxCast, which is currently evaluating over 1,000 chemicals in more than 600 
in vitro assays resulting in hazard identification. 1
Testing chemicals for their endocrine-disrupting potential, including interference 
with estrogen receptor signaling, is an important factor to be taken into account when 
assessing the safety of currently used chemicals. Presently, the standard test for disruption 
of normal estrogen function is the Allen and Doisy test, a uterotrophic assay in immature 
or ovariectomised rodents with uterus weight as the crucial read-out parameter. 2, 3 Due to 
the high costs, ethical objections and labour intensiveness of the in vivo uterotrophic assay, 
the development of an in vitro battery for prediction of in vivo (anti)estrogenicity has high 
priority. We have previously demonstrated that combination of a yeast or U2OS estrogen 
receptor α (ERα) reporter gene assay with a cell-free coregulator binding assay that enables 
characterisation of ligand-modulated interaction of coregulators with ERα, would have the 
potential to form an adequate integrated testing strategy (ITS) for in vitro estrogenicity 
testing. These three assays were selected from a large battery of in vitro tests based on 
the fact that their outcomes correlated best with results from the in vivo uterotrophic 
assay 4, 5 for a set of reference compounds selected from the ICCVAM list of compounds 
defined for validation of in vitro tests for estrogenicity. 6 However, the uterotrophic assay 
has its limits for estrogenicity testing, for example because it does not include estrogenic 
effects on the hypothalamic-pituitary-gonadal (HPG) axis or male organs, since the assay 
uses either female ovariectomised or immature rodents, i.e. animals without endogenous 
estrogen production. Additional in vivo assays are needed to achieve more comprehensive 
estrogenicity screening, and provide data on multiple mechanisms and organs, e.g. the 
female and male pubertal assays (OPPTS 890.1450 and OPPTS 890.1500, respectively). 
Indeed, the shortcoming of the uterotrophic assay has been demonstrated by the fact that 
several compounds failed to show an (anti)estrogenic effect in the uterotrophic assay while 
eliciting (anti)estrogenic effects in other in vivo tests, e.g. atrazine and carbon tetrachloride 
(CCl4). Atrazine delayed puberty and sexual development in both male and female 
rodents 7, 8 and CCl4 is estrogenic as it decreases the metabolic inactivation of endogenous 
estradiol. 9, 10 In addition, antiandrogenic compounds elicit in vivo effects by the androgen 
receptor (AR) that can hardly or not be distinguished from an estrogenic effect by an 
estrogen via the ER and some compounds even have combined modes of action, e.g. several 
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estrogenic compounds like 17α-ethinyl estradiol (EE2) and diethylstilbestrol (DES) are 
also antiandrogenic, and in this way enhance the overall ‘estrogenic’ effect in vivo. 11, 12 
The previously established ITS correlates well with the in vivo uterothropic assay, but is 
expected to suffer from the same drawbacks as the in vivo uterotrophic assay, as the selected 
in vitro bioassays only measure effects directly mediated by ERα, and are not able to detect 
chemicals that elicit their estrogenic effects through indirect mechanisms, such as, alteration 
of hormone biosynthesis, hormone metabolism and transport, and mixed estrogenic/anti-
androgenic effects. This emphasises the need to extend the previously established in vitro 
ITS, by including androgen reporter gene assays and the H295R steroidogenesis assay. Such 
an extended ITS would have the clear advantage that it would outcompete the uterotrophic 
assay with respect to the multitude of mechanisms of estrogen signaling disruption that can 
be detected. Thereby, such an extended ITS would allow to further reduce or eliminate the 
need for testing certain endocrine disruption effects in animal models.
The aim of the present study was to demonstrate whether the extension of the previously 
established ITS for in vitro estrogenicity testing by two androgen reporter gene assays as well 
as the H295R steroidogenesis assay goes beyond replacement of the in vivo uterotrophic assay, 
i.e., is able to detect (anti)estrogenic and antiandrogenic effects in intact animals as observed in 
the female and male pubertal assays and the Hershberger assay (OECD 441). Ten compounds, 
with (expected) specific modes of action, were tested, i.e., equilin, mestranol, diethylstilbestrol 
monomethyl ether (DES-ME), bisphenol A (BPA), bisphenol B (BPB), bisphenol C1 (BPC1), 
bisphenol C2 (BPC2), butyl paraben, atrazine and vinclozolin. Equilin was included because 
it is structurally related to the well-known ERα agonist estrone. Mestranol and DES-ME were 
included because they are structural analogues of the previously tested EE2 and DES that 
have been shown to be able to activate the ER and inactivate the AR. Bisphenol A (BPA) was 
included since this compound is shown to be weakly estrogenic in several in vitro models, 13-15 
whereas controversy exists about the relevance of these effects for the in vivo situation. 16 Some 
studies suggest that BPA has a greater in vivo potency than would be predicted based on the 
results obtained in vitro, indicating that certain test animal species might be more sensitive to 
BPA than the in vitro models commonly used, 17 while other studies suggest the opposite. 18, 19 
Since it is also reported that some BPA analogues might even be more potent than BPA, 20 
bisphenol B (BPB), bisphenol C1 (BPC1) and bisphenol C2 (BPC2) were included in order 
to investigate this phenolic compound group in more detail. The herbicide atrazine and the 
pesticide vinclozolin do not show any direct ER (ant)agonistic effects but have been shown 
to exert estrogenic effects through mechanisms other than ER binding. 21-24 The endogenous 
estrogen 17β-estradiol (E2) was chosen as a reference compound and was used to derive 
relative estrogenic potencies of the ten newly selected test compounds.
mATeriAlS And meThodS
chemicals
Atrazine, bisphenol A (BPA), bisphenol B, bisphenol C1, bisphenol C2, butyl paraben, equilin, 
17ß-estradiol (E2), flutamide, mestranol, tamoxifen, vinclozolin, 4-dimethyl-aminopyridine, 
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2-methyl-6-nitrobenzoic anhydride, picolinic acid, triethylamine, tetrahydrofuran, 
Dulbecco’s modified Eagle medium/Ham’s F-12 nutrient mix (DMEM/F12), NaHCO3 and 
PBS were obtained from Sigma-Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). 
Diethylstilbestrol monomethyl ether (DES-ME) was purchased from LGC Standards GmbH 
(Wesel, Germany). Ammonia, acetic acid, formic acid and dimethyl sulfoxide (DMSO) were 
obtained from Merck (Darmstadt, Germany). Methanol, acetonitrile, acetone and ethanol 
were from Biosolve (Valkenswaard, The Netherlands). Pregnenolone, 17α-OH-pregnenolone, 
progesterone, 17α-OH-progesterone, dehydroepiandrosterone (DHEA), androstenedione, 
testosterone, estrone, estradiol, 11-deoxycorticosterone, corticosterone, 11-deoxycortisol, 
cortisol and dihydrotestosterone (DHT) were obtained from Steraloids (Newport, RI, USA) 
and the deuterium-labelled internal steroid standards were from CDN isotopes (Point-
Claire, Canada) and ITS+ premix and NuSerum from BD Biosciences (Bedford, MA, USA). 
Chemicals to prepare the growth media for yeast were described previously 25. Milli-Q water 
was obtained using a Purelab Ultra system from Elga (Bucks, UK).
cAluX bioassays
The ERα and AR agonist or antagonist potencies of a test compound were determined in 
the ERα- and AR-CALUX bioassays, respectively, as described previously. 26, 27 In short, 
CALUX cells were plated in 96-well plates with phenol red-free DMEM/F12 (1:1) mixture 
supplemented with dextran-coated charcoal-stripped FCS. One day later, the medium 
was refreshed and cells were incubated with the compounds to be tested (final DMSO 
concentration 2%). Each test compound at each concentration was tested in triplicate. 
After 24 h exposure, the medium was removed, cells were lysed in Triton lysis buffer and 
measured for luciferase activity. To test for antagonism, CALUX cells were incubated with 
test compound in combination with a non-saturating level of agonist (around the EC50 
value of the reference compound), i.e., 10−11 M E2 in the ERα-CALUX bioassay, and 2 × 
10−10 M DHT in the AR-CALUX bioassay.
Yeast estrogen and androgen bioassays
The estrogenic, anti-estrogenic, androgenic and anti-androgenic properties of the 
compounds were tested as described previously. 11, 28 In short, cultures of the yeast estrogen 
and androgen biosensor were grown overnight at 30 °C with vigorous orbital shaking. At 
the late log phase, the culture was diluted in selective MM/L medium till an OD value 
at 630 nm between 0.04 and 0.06 was reached. To expose the yeast cells, 200 μL aliquots 
of the diluted culture were pipetted into each well of a 96-well plate and 2 μL of a stock 
solution in DMSO was added when testing the agonistic properties of the compounds (final 
DMSO concentration 2%). To test for antagonism, yeast cells were incubated with test 
compound in combination with a non-saturating level of agonist (around the EC50 value of 
the reference compound), i.e., 10−9 M E2 in the yeast estrogen bioassay, and 7 × 10−9 M T 
in the yeast androgen bioassay. DMSO (negative control), and E2 or T (positive controls) 
were included in each experiment, and each sample concentration was assayed in triplicate. 
Exposure was performed for 24 h at 30 °C and orbital shaking at 125 rpm. Fluorescence and 
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OD were measured at 0 and 24 h directly in a SynergyTM HT Multi-Detection Microplate 
Reader (BioTek Instruments Inc., USA) using excitation at 485 nm and emission at 530 nm. 
Normally, the cell density at 630 nm increases from 0.05 at 0 h to about 0.9 at 24 h. If the 
OD at 24 h was below 0.7, concentrations of the test compound were considered to cause 
cytotoxicity and the corresponding data were rejected for analysis.
erα coregulator binding assay
Ligand-modulated interaction of ERα-LBD-His with coregulators was assessed using 
a PamChip® plate (PamGene International B.V., ’s-Hertogenbosch, The Netherlands) 
containing 96 identical peptide microarrays as described previously. 4, 29-31 The peptide 
microarray was incubated with the test solution containing ERα-LBD-His in the absence or 
presence of ligand by pumping the sample up and down the three-dimensional metal oxide 
carrier. In short, assay mixtures were prepared on ice in a master 96-well plate and contained 
ERα-LBD-His (optimal assay concentration of a crude lysate containing the conjugate was 
empirically determined, and estimated to lie between 1 and 10 nM), 25 nM of an Alexa 
Fluor 488-conjugated polyhistidine antibody (penta-His Alexa Fluor 488 conjugate, Qiagen 
no. 35310), and ligand at the indicated concentration in reaction buffer (20mM Tris-HCl, 
pH 7.5, 500 mM NaCl, 0.2% BSA, 0.05% Tween-20). All assays were performed in a fully 
automated microarray processing platform (PamStation®96, PamGene International B.V.) 
at 20 °C applying two incubation cycles per min. For each compound, 8 concentrations 
added from 50 fold concentrated stock solutions with fivefold serial dilutions in DMSO 
were tested in singular (final DMSO concentration 2%). After removal of the unbound 
receptor by washing each array with 25 µL Tris-buffered saline, tiff images were obtained by 
the CCD camera which is part of the PamStation®96 platform. The tested compounds were 
distributed over one plate run using 2% DMSO as the negative control and 50 μM E2 as the 
positive control (each control measured in 4 technical replicates).
enhanced h295r steroidogenesis assay
Human H295R adrenocarcinoma cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) and were cultured according to the protocol 
described in the OECD test guideline 456. Cells were routinely grown at 37 °C under 5% 
CO2 atmosphere in 75 cm2 culture flasks containing 12 mL DMEM/F12 culture medium 
supplemented with 1.2 g/L NaHCO3, 1% ITS+ premix and 2.5% NuSerum. For sub-
culturing, the H295R cells were washed three times with PBS, detached by trypsine/EDTA 
(0.25/0.05 v/v-% in HBSS) and seeded in a 1:3 ratio. For testing, 1 mL cell suspension 
containing 2 × 105 to 3 × 105 cells was seeded in each well of the 24-well plate. After 24 h, the 
medium was refreshed and compounds dissolved in DMSO (1µL) were added. Exposures 
were performed in triplicate and the final concentration of the solvent carrier DMSO 
was 0.1%. After 48 h of exposure, the medium was stored at -80 °C for steroid hormone 
analysis. Effects on viability and cytotoxicity were evaluated by the live/dead viability/
cytotoxicity kit (Molecular probes, Eugene, OR, USA) using the protocol described by the 
OECD (OECD TG 456). After washing the cells with PBS twice, a calcein and ethidium 
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bromide solution was added to the cells. After 1 h, fluorescence was measured (excitation/
emission at 530/645 nm and excitation/emission at 485/530 nm) using a SynergyTM HT 
multi-detection microplate reader (BioTek Instruments Inc., USA). Exposures showing a 
decrease in cell viability were excluded from hormone analysis.
For hormone analysis, 900 µL H295R medium aliquots were adjusted to 1 mL with 18 µL 
of deuterium labelled internal steroid standard mix and Milli-Q water. Similarly, a standard 
steroid curve was prepared by spiking 900 µL of supplemented DMEM-F12 medium with a 
mix of steroid standards, resulting in final concentrations of 10, 25, 50, 100, 250, 500, 1000, 
2500, 5000, 10000 and 25000 pg/mL. Next, both standards and samples were subjected to 
solid-phase extraction (SPE) using OASIS HLB cartridges (Waters, 60 mg) in 96-wells format, 
previously conditioned with 1 mL methanol and 1 mL Milli-Q water. Washing was carried out 
with subsequently 1 mL Milli-Q water, 1 mL of methanol/water/acetic acid (55:43:2, v/v/v-%), 
1 mL of methanol/water/25% ammonia (30:62:8, v/v/v-%), 1 mL MillQ water and 1 mL 
acetonitrile/water (35/65, v/v-%). The free steroids were eluted with 1 mL acetone and this 
eluate was evaporated to dryness at 45 °C under nitrogen. The derivatising reagent was prepared 
freshly before use by mixing 1 mg 4-dimethyl-aminopyridine, 5 mg 2-methyl-6-nitrobenzoic 
anhydride and 3 mg picolinic acid in 1 mL tetrahydrofuran, after which 10 µL of triethylamine 
was added. Picolinoyl derivatisation was achieved by incubating the dried sample extracts with 
35 µL of derivatisation reagent for 45 min at room temperature. The reaction was terminated 
by adding 50 µL of a 5% ammonia solution after which the samples were analysed directly 
by Ultra Performance Liquid Chromatography tandem Mass Spectrometry (UPLC-MS/
MS) according to the method described by Rijk et al. (manuscript in preparation). Steroid 
hormone concentrations in the samples were calculated using the steroid standard reference 
line, constructed by plotting the peak area ratios versus the spiked concentration.
data analysis
For the CALUX bioassays, luciferase activity per well was measured as relative light units 
(RLU). Fold induction was calculated by dividing the mean value of light units from exposed 
and non-exposed (DMSO control) wells. For the yeast bioassays, the fluorescence signals 
were corrected for the signal obtained with the MM/L medium containing DMSO solvent 
only. The relative estrogenic potency (REP), defined as the ratio of the concentration of 
E2 needed to achieve 50% of maximal response (EC50) and the concentration of the test 
compounds required to achieve a similar effect multiplied by 100, was calculated from fitted 
dose–response curves (four parameter sigmoidal dose-response curve, Graphpad Prism 
software version 5.04). The REP value for E2 is, hereby, set at 100 for both the CALUX 
and the yeast ERα reporter gene assays. The relative transactivation activity (RTA) of each 
compound tested was calculated as the ratio of maximal luciferase or yEGFP reporter gene 
induction values of each compound and the maximal induction value of reference compound 
E2. The antiandrogenic activity was characterized by the IC50, i.e. the concentration that 
inhibited the response of DHT or T by 50%.
For the coregulator binding assay, image analysis was performed using BioNavigator 
software (PamGene International B.V.) as described previously. 4, 29 In short, the boundaries 
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of a spot are determined and the median fluorescent signal was quantified within the 
spot (signal) as well as in a defined area surrounding it (background). The signal-minus-
background value was subsequently used as the quantitative parameter of binding, and 
the average over the duplicate measurements was calculated for each test compound 
concentration. Ligand dose-response curve fitting and hierarchical clustering (Euclidean 
distance, average linkage) were performed using the drc and stats packages in R (version 
2.12.0, www.r-project.org). A sigmoidal, 4-parameter Hill (logistic) model was fitted to the 
dose-response data and the goodness-of-fit parameter and EC50 values as calculated by the 
drc package were recorded.
Fold changes in steroids levels in the H295R steroidogenesis assay were calculated by 
comparing the mean steroid levels of the DMSO solvent control (SC) versus the mean 
steroid levels in medium of H295R cells exposed to the compound under investigation. A 
one-tailed Student’s t-test was used to test for significance. For comparison of the presented 
in vitro data with estrogenicity in vivo, uterotrophic assay data were used that were derived 
from the Endocrine Disruptor Knowledge Base (EDKB), designed and produced by the 
National Center for Toxicological Research (NCTR, USA). 32
reSulTS
estrogenic and antiestrogenic activities
Ten compounds, selected based on their different modes of disruption of normal estrogen 
action, were tested in the U2OS ERα-CALUX and the yeast estrogen bioassay for estrogenic 
and antiestrogenic activities. Figure 1 shows typical dose-response curves for several of the 
compounds as obtained in these two assays. The EC50 and relative transcriptional activity 
(RTA) value of each compound was calculated from the fitted dose-response curve and are 
shown in Table 1. The reference compound estradiol (E2) was the most potent ER agonist 
and showed an EC50 of 8.8 × 10-12 M and 8.7 × 10-10 M in the U2OS ERα-CALUX and the 
yeast estrogen bioassay, respectively. Equilin, mestranol and DES ME were about 2-30 times 
less potent compared to E2 and the obtained RTA values were between 80% and 105% 
(E2 being 100%). All four phenolic compounds showed full agonistic responses in the two 
reporter gene assays (Figure 1 and Table 1), with BPC1 being the most potent compound 
and BPA being the weakest compound in both assays. Butyl paraben was negative under 
the concentration range tested in a previous study using the ERα-coregulator binding 
assay 29. However, when tested at higher concentrations this compound was clearly positive 
in the yeast and U2OS cell based estrogen bioassays and induced a much higher maximal 
response (RTA =256%) than E2 in the U2OS ERα-CALUX. The fungicide vinclozolin was 
slightly active (RTA < 10%) in both cell based estrogen bioassays, showing only a response 
at the highest concentration tested, and therefore the EC50 value could not be calculated 
reliably. The herbicide atrazine was not active in these two reporter gene assays. In addition 
to the agonist activity, all the compounds were tested in combination with E2 for potential 
antagonist activities. However, no ER-antagonism was observed for any of the compounds 
tested (data not shown).
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coregulator binding
The 10 compounds were also tested in the coregulator binding assay to evaluate their capacity 
to modulate ERα-LBD binding to NR-coregulator motifs. As an example, Figure 2 shows the 
induction of ERα-LBD-His binding to a peptide representing the NR-binding motif within 
amino acid 677-700 of the well-known nuclear receptor coactivator 1 (NCOA1_677_700) 
by several compounds tested, i.e. single measurements of 8 concentrations per compound 
on 1 of the 155 coregulator peptides on the array. The lowest concentration of E2 resulting 
in a detectable binding of ERα-LBD-His to NCOA1_677_700 was 1.3 × 10-9 M, and a half 
maximal binding level (EC50) was reached at approximately 6.4 × 10-9 M. Equilin, mestranol 
and DES-ME also induced binding of ERα-LBD to NCOA1_677_700, while the bisphenol 
compounds displayed antagonist binding curves on NCOA1_677_700 when compared to 
the solvent control DMSO and the known ER-agonists (Figure 2).
Dose response curves were generated for all 155 coregulator-derived NR-binding motifs 
for each compound in order to obtain an overall measure for the potency as an inducer of ERα-
coregulator binding. These dose-response curves allowed to determine for each coregulator 
Figure 1. Dose-response curves of the indicated test compounds in the ERα-CALUX (A) and yeast 
estrogen bioassay (B). The response is displayed as the mean with SD of a triplicate measurement.
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peptide an EC50 for inducing ERα binding by a compound to that peptide. The median EC50 value 
of each compound was determined over 48 coregulator peptides that show a comparatively 
good fit of the applied dose-response model (goodness-of-fit of the four parameter Hill 
equation above 0.9) and are shown in Table 1. The selection of these coregulators was based 
on a previous study where the potency of compounds to induce binding of ERα-LBD-GST to 
these coregulators was demonstrated to correlate well (R2 ≥ 0.80) with their in vivo determined 
estrogenic potency in the uterotrophic assay. 4 Equilin, mestranol and DES-ME resulted in 
coregulator binding profiles similar to that of E2 and the calculated median EC50 values were 
in the nanomolar range. BPA showed a slightly bell-shaped dose-response binding profile, 
i.e. inducing low level binding to coactivators at low concentrations and inhibitory effects 
at high concentrations (not shown). In contrast, BPB, BPC1 and BPC2 strongly inhibited 
binding of ERα-LBD to almost all coactivator peptides on the peptide microarray, however, 
no increased binding was observed for any of the compounds on the corepressors present 
on the peptide microarray (see supplementary Figure 1 for BPC1 as an example). To provide 
an overall measure of the antagonistic binding potency for the bisphenols, the median IC50 
values were calculated and are shown in Table 1. Vinclozolin showed no statistically significant 
altered binding signals compared to the DMSO solvent control. Butyl paraben was negative 
under the concentration range (20 nM−400 μM) tested in a previous study. However, higher 
concentrations of butyl paraben tested in the current study lead to precipitation in the assay 
buffer and resulted in an overall negative binding profile. Atrazine was also tested in our 
previous study (negative) and the results for the coregulator binding assay were taken from 
that study. For each test compound and each of the 155 coregulator-nuclear receptor binding 
motifs represented by the peptide microarray, the modulation index (MI) was calculated as 
the log-transformed ratio of receptor binding at a saturating compound concentration over 
that in the absence of ligand. The MIs for the 155 binding motif peptides constitute an ERα-
coregulator binding profile for each compound tested. Unsupervised hierarchical clustering 
of these MI values over the various compounds over all coregulator peptides on the array 
revealed that compounds with structural similarity tend to cluster together (Figure 3).
Figure 2. Binding of ERα-LBD-His to the coregulator binding motif peptide NCOA1_677_700 as function 
of the concentration of the indicated compounds measured in the ERα-coregulator binding assay.
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Figure 3. Heatmap of the unsupervised hierarchically clustered values for ERα-coregulator binding 
across compounds and coregulators shows structural similarity of compounds. A) Two-dimensional 
clustering heatmap;  B) Clustering pattern of compounds.
comparison with the in vivo uterotrophic assay
To compare relative estrogenic potencies of positively tested compounds with their 
uterotrophic effects in vivo, the relative estrogenic potencies (REP) or relative binding 
potencies (RBPs) of these compounds were calculated on the basis of the obtained EC50 
values (Table 1). The estrogenic potencies obtained from the yeast estrogen bioassay and 
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the U2OS ERα-CALUX assay showed very good correlation with the outcomes of the in 
vivo uterotrophic assay, i.e., in both case R2 = 0.99 (p < 0.0001, n=6). Because no estrogenic 
potency data were available for butyl paraben, BPB, BPC1 and BPC2, these compounds 
were excluded from correlation analysis. Furthermore, both reporter gene assays showed 
100% (8/8) concordance with the in vivo uterotrophic assay, with no misclassification of 
compounds. In addition, the U2OS ERα-CALUX assay and the yeast estrogen bioassay 
resulted in similar potency ranking of the 10 compounds and the correlation between the 
relative potency values obtained from these two assays was excellent (R2 = 0.93, p < 0.0001). 
In the ERα coregulator binding assay butyl paraben was classified as negative. BPA, BPB, 
BPC1 and BPC2 showed only antagonistic binding profiles and can therefore not be compared 
with the agonistic effects as observed in the uterotrophic assay or in the reporter gene assays. 
This assay gave a lower correlation (R2 = 0.86) and lower concordance (83%; 5/6) with the in 
vivo uterotrophic assay. However, the potency ranking of equilin, mestranol and DES-ME in 
the ERα coregulator binding assay was the same as in the U2OS ERα-CALUX assay.
Antiandrogenic activities
No androgen agonism was observed for any of the compounds tested (data not shown). 
The potential antiandrogenic activity of the test compound was studied by co-exposure of 
each compound with DHT or testosterone in the AR-CALUX assay or the yeast androgen 
bioassay, respectively. Figure 4 shows the antagonistic effects of several of the compounds 
tested. The potent androgen antagonist flutamide was used as positive control in both assays. 
Surprisingly, BPC1 and vinclozolin showed even more potent antiandrogenic activities than 
flutamide in both reporter gene assays (Figure 4 and Table 2). Although less potent, also 
Table 2. Antiandrogenic activities of the test compounds in the U2OS AR-CALUX and yeast androgen 
bioassay.
Compound
U2OS AR-CALUX assay
IC50 (M)
Yeast androgen bioassay
IC50 (M)
Equilin + a +
Mestranol + +
DES-ME + +
Bisphenol A 1.5 × 10-06 8.1 × 10-05
Bisphenol B 9.3 × 10-07 - a
Bisphenol C1 4.3 × 10-08 2.4 × 10-06
Bisphenol C2 6.3 × 10-07 2.2 × 10-05
Butyl paraben 7.1 × 10-06 2.0 × 10-06
Atrazine 4.7× 10-05 +
Vinclozolin 4.8× 10-08 1.9 × 10-06
Flutamide b 5.1× 10-07 1.5× 10-05
a  + = positive; - = negative  b Flutamide was used as a positive control.
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BPA and BPC2 inhibited the response induced by the potent androgens (DHT or T) to the 
baseline level. Equilin, mestranol and DES-ME showed weak antiandrogenic activities at 
relative high concentrations. However, due to the poor fitting of the applied dose-response 
model to the data, IC50 values for these compounds could not be reliably calculated.
modulation of steroidogenesis
Effects on steroidogenesis were evaluated using the H295R steroidogenesis assay. The effects 
of 7 of the model compounds were assessed by measuring levels of 13 steroids in medium 
of H295R cells, and for each steroid hormone a dose response curve was constructed. 
Figure 5 shows for example the BPA dose-dependent changes in hormone levels in medium 
of H295R cells being exposed for 48 h. Exposing H295R cells to increasing concentrations 
of BPA resulted in increased levels of pregnenolone, progesterone and estradiol, while levels 
of 17α-OH-progesterone, 11-deoxycortisol, cortisol, androstenedione and testosterone 
were dose-dependently decreased by BPA. Levels of the other steroids were not significantly 
affected by BPA. Among the 8 steroids modulated by BPA, androstenedione and testosterone 
were the two most sensitive endpoints with a lowest observed effective concentration 
(LOEC) of 0.03 and 0.1 µM BPA, respectively.
Figure 4. Antagonistic effect of several compounds, including the reference antiandrogen flutamide, 
measured in the AR-CALUX (A) and the yeast androgen bioassay (B). Signals are displayed as the 
mean with SD of triplicate measurements. 
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A summary of the results of all compounds tested in the H295R steroidogenesis assay is 
presented in Table 3, showing the LOEC together with the maximal fold change of induction 
or inhibition. The hormone profile caused by BPB was similar to that caused by BPA, showing a 
dose dependent decrease in androgens (androstenedione and testosterone) and glucocorticoids 
(11-deoxycortisol and cortisol) and an increase in pregnenolone, progesterone, and less 
pronounced, in estrone. BPC1 resulted in a dose-dependent increase in levels of pregnenolone, 
progesterone, 17α-OH-progesterone and estradiol with an LOEC of 10, 0.3, 0.3 and 10 µM 
respectively. With the exception of testosterone and estrone, levels of all other steroids were 
decreased by BPC1. BPC2 resulted in a dose-dependent decrease in the levels of most steroid 
hormones, while progesterone and estradiol were up-regulated, but only at the highest nontoxic 
test-concentration of BPC2 (10 µM). The highest concentration of BPC2 (30 µM) was cytotoxic 
for the H295R cells (data not shown). Results of equilin, mestranol and DES-ME were not 
included, as these compounds did not significantly affect the hormone levels (data not shown). 
In general it is observed that all four bisphenolic compounds show a dose-dependent decrease 
in androgens, while levels of estrogens are increased after exposure. Exposure of H295R cells 
to the fungicide vinclozolin resulted in a maximum 1.99 fold increase in estradiol (LOEC of 
10 µM), while levels of progesterone, 17α-OH-progesterone, androstenedione, testosterone, 
11-deoxycorticosterone and 11-deoxycortisol were down-regulated by vinclozolin.
diScuSSion
Our previous studies have shown that the yeast estrogen bioassay, the U2OS ERα-CALUX 
reporter gene assay and the ERα coregulator binding assay all revealed a good correlation 
with the in vivo uterotrophic assay based on a set of 23 compounds (most of which were 
selected from the ICCVAM list of compounds defined for validation of in vitro tests for 
estrogenicity testing). 4 It was advised to include these assays in an ITS for estrogenicity testing 
and prioritization of chemicals, aiming at refinement, reduction and ultimately replacement 
of the current animal testing for (anti)estrogenic effects, as these three high-throughput in 
vitro assays were also shown to be reproducible, fast and robust. The present study with 10 
extra compounds with specific modes of action was set up in order to further validate the 
previously established ITS and to demonstrate the added value of including in vitro tests 
for AR-antagonism and interference with steroidogenesis. Among these compounds, five of 
the them (i.e., equilin, DES-ME, BPB, BPC1 and BPC2) have not been tested before in any 
of the three in vitro assays in the ITS and the other five compounds (i.e., BPA, mestranol, 
butyl paraben, vinclozolin and atrazine) have been tested only in some of the assays of our 
previously proposed ITS or by other groups using the same assays. The present results show 
that the U2OS ERα-CALUX and yeast estrogen bioassays both revealed 100% concordance 
with the in vivo uterotrophic assay, i.e., no misclassification of any compound for which 
uterotrophic potency data are available. In addition, these two reporter gene assays resulted 
in similar potency ranking of all the 10 compounds tested. In the ERα coregulator binding 
assay, only butyl paraben was misclassified as negative. Overall, these results demonstrated 
that the previously established ITS enables accurate prediction of the estrogenic properties 
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Figure 5. (A) Steroid biosynthesis pathway. 
in vivo as observed in the uterotrophic assay. However, quantitative discrepancies do exist 
between the results obtained in vitro and in vivo, as well as between the results obtained by 
the different in vitro assays. Mestranol and DES-ME were about 20 to 300 times less potent 
than E2 in the ITS, while these two compounds showed a similar estrogenic potency as E2 
in the in vivo uterotrophic assay. It has been shown that mestranol and DES-ME bind to the 
ER with high affinity 33 and act as ER agonists in the in vivo uterotrophic assay. 32 As expected 
both compounds elicited clear ER-agonistic properties in the ITS, but with lower potencies 
compared to in vivo. However, mestranol and DES-ME are structural analogues of EE2 and 
DES, respectively, both known ER-agonists that are also antiandrogenic (AR-antagonists) 
and in this way enhance the overall ‘estrogenic’ effect in vivo. 11, 12 For example, it is known 
that estrogens and antiandrogens inhibit prostate cancer cell proliferation in vitro 34, 35 and 
cause feminization in fish. 36, 37 Estrogens and antiandrogens are also used for the treatment of 
prostate cancer. 38 Thus, compounds that possess both estrogenic and antiandrogenic activity 
may induce stronger estrogenic effects in vivo than what would be expected based on their 
estrogenic activity alone. 39 In the present study, both mestranol and DES-ME were shown to 
act as AR-antagonist too, but this is likely not the only explanation for the observed in vitro/
in vivo discrepancy in potency. Differences in metabolism provide a better explanation, as it 
is known that mestranol is demethylated in vivo into the more potent ER-agonist EE2. 40, 41 
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Figure 5. (continued). (B) Changes in hormone levels in medium of H295R cells exposed to BPA. 
Changes in hormone levels are expressed relative to the DMSO solvent control (mean ± SD, n=3). 
Statistical significance:  * = p<0.05: ** = p<0.01 and *** p<0.001.
The observed in vitro/in vivo discrepancy for mestranol could thus be due to the lack of 
metabolism in the in vitro systems used in the current ITS. A similar explanation might be 
valid for DES-ME, as this compound can be metabolised in vivo into the more potent ER-
agonist DES. 42 Thus, despite the fact that the ERα-CALUX assay is based on a mammalian 
cell line, this assay did not perform better in predicting the estrogenic potency of mestranol 
or DES-ME when compared to the in vitro systems that are lacking mammalian steroid 
metabolism, i.e., the yeast based reporter gene assay or the cell-free coregulator binding 
assay. Taken together, this strengthened the idea that mammalian cell lines, at least the U2OS 
cell line on which the ERα-CALUX is based, are generally quite limited in their metabolic 
capacity, and therefore, the combination of the ITS with a bioactivation step might further 
improve its predictive capacity for estrogenic potency in vivo.
Numerous studies have shown that BPA exhibits (weak) estrogenic activity 13, 20, 43 and 
strong antiandrogenic activity in vitro. 44-46 In our study, all three BPA analogues showed 
stronger estrogenic activities than BPA, and BPC1 was even 10 to 100 times more potent than 
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BPA in both reporter gene assays. In addition to the estrogenic effects, unique antagonistic 
coregulator binding characteristics were observed in the ERα coregulator binding assay 
for the bisphenols. The coregulator binding profile obtained for BPC1 was essentially the 
same as that of the selective estrogen receptor modulator (SERM) tamoxifen reported in 
our previous study. 4 Interestingly, no estrogen antagonism was observed for the bisphenols 
when tested in combination with E2 in the two reporter gene assays. However, a recent 
study of Delfosse et al. shows that both tamoxifen and BPC1 prevent NOCA1 binding to 
ERα LBD. 47 As the coregulator binding assays use ERα-LBD that contains the activation 
function 2 (AF-2; localized within the C-terminal of LBD), our study reveals that BPB, BPC1 
and BPC2 act as general AF-2 antagonists, similar as tamoxifen. Additionally, the estrogen 
reporter gene assays used in the present study stably express full-length ERα. This further 
suggests that the ERα activation function 1 (AF-1; localized within the N-terminal A/B 
domain) is needed for the estrogenic activities of the bisphenols. Moreover, BPC1 and BPC2 
showed significant inhibitory effects on the transcriptional activity induced by DHT in or 
T in the AR-CALUX and the yeast androgen bioassay, respectively. The IC50 values of BPC1 
and BPC2 were 2 to 30 times lower than that of BPA and were comparable with the potent 
AR antagonist flutamide, demonstrating the strong antiandrogenic activities of BPC1 and 
BPC2. Furthermore, the bisphenols elicited strong disruptions on the hormone synthesis 
in the H295R cells, in general resulting in decreased levels of androgens and elevated levels 
of estrogens. Together these properties of the bisphenol compounds, i.e. ER-agonist, AR-
antagonist and decreasing androgen levels and elevating estrogen levels in the H295R assay, 
possibly direct these compounds to be stronger estrogens in vivo than predicted by the in 
vitro ER-agonist properties alone. BPA was shown to be weakly estrogenic in several in vitro 
models, 13-15 and some studies suggest that BPA has also a greater in vivo potency than would 
be predicted based on the results obtained in vitro. Thus the combined actions as determined 
in vitro in the present study might explain the in vivo potency of BPA more accurately. 
BPC1 is apparently the most potent bisphenol analogue that possesses estrogenic and 
antiandrogenic properties and at the same time affects steroidogenesis into the direction of 
decreased androgen levels and elevated estrogen levels. Furthermore, BPA and its analogues 
are widely used as raw material in the production of polycarbonate plastics and epoxy resins, 
and are found to contaminate a broad range of end products. 48-51 Given the complex biological 
activities of BPC1 and the on-going debate on endocrine disrupting chemicals and BPA in 
particular, further in vivo testing of BPC1 in animal models should have high priority, as our 
data suggest that the use of BPA analogues might lead to a higher risk than BPA itself. Similar 
concerns were published by Grignard et al. (2012), showing that bisphenol S (BPS), used as a 
BPA substitute in the production of plastic baby bottles, has a comparable estrogenic potency 
as BPA in in vitro transcriptional activation assays. 13
It has been shown that atrazine does not to bind to the ER or AR 33, 52 and, consistently, 
failed to induce ER- or AR-dependent transcription in several reporter gene assays. 50, 53-55 
Atrazine is also unable to stimulate estrogen-dependent MCF-7 cell proliferation in the 
E-screen. 56, 57 These findings are in agreement with the outcomes of the present study, i.e. 
demonstrating that atrazine has no affinity for the ER and only showed weak antiandrogenic 
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activities in the AR reporter gene assays. However, atrazine showed clear effects in the 
H295R steroidogenesis assay, resulting in elevated levels of estradiol. 58 Thus, the results 
from the current study indicate that further testing of atrazine in the in vivo uterotrophic 
assay or Hershberger assay is not needed, as atrazine did not show clear effects via the ER or 
AR and only affected the steroidogenesis. Therefore atrazine should rather be tested in an in 
vitro model or a panel of models replacing  the male and female pubertal assays. Indeed, this 
was demonstrated by the fact that atrazine failed to show estrogenic or androgenic activities 
in the uterotrophic assay or Hershberger assay, 59, 60 respectively, but delayed puberty and 
sexual development in both male and female rodents in pubertal assays. 7, 8 The fungicide 
vinclozolin does not bind to the ER and was also unable to induce uterotrophic effects 
in vivo, 33, 61 but has been reported to have antiandrogenic effects in vitro and vivo. 62, 63 
In the present study, vinclozolin did not show any estrogenic effects, but elicited strong 
antiandrogenic activity. It also resulted in increased estrogen levels and decreased androgens 
levels in the H295R cells, suggesting that vinclozolin may induce aromatase activity. 
Taken together, the extended ITS, including the H295R steroidogenesis assay and an 
androgen reporter gene assay, would allow to reduce or eliminate the need for testing certain 
endocrine disruption effects in animal models as illustrated for atrazine and vinclozolin. 
However, the examples of mestranol and DES-ME show that the current ITS has to be 
combined with additional types of in vitro assays, including in vitro models for digestion, 
bioavailability and metabolism of the compounds under investigation.
In conclusion, the ITS consisting the U2OS ERα-CALUX, yeast estrogen bioassay and 
ERα coregulator binding assay enables an accurate prediction of the estrogenic effects in vivo 
and provides mechanistic insights. By including the H295R steroidogenesis assay as well as 
an androgen reporter gene assay, the extended ITS was demonstrated to go beyond in vivo 
estrogenicity testing by the uterotrophic assay, as it can detect possible (anti)androgenic 
effects and effects on steroidogenesis that are not covered by the in vivo uterotrophic 
assay. The extended ITS presented in this study may therefore allow easy high-throughput 
screening and prioritization of chemicals, thereby contributing to refinement, reduction 
and to some extent even a replacement of current animal testing for (anti)estrogenic effects.
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Supplementary Figure 1. Analysis of ERα-LBD binding to the 155 coregulators on the peptide 
microarray as induced by BPC1.
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GenerAl diScuSSion 
In the present thesis, results obtained from a series of in vitro assays covering a broad range 
of endpoints and representing different steps of the estrogen-signaling pathway, i.e., receptor 
binding, receptor-coregulator binding, reporter-gene transcriptional activation, targeted gene 
expression, and cell proliferation were compared with outcomes from the in vivo uterotrophic 
assay, in order to define an integrated testing strategy (ITS) for in vitro estrogenicity 
testing. The selected in vitro assays mainly focus on measuring effects directly mediated by 
estrogen receptor (ER)α. This is because binding and activation of ERα is implicated as a 
key molecular initiating event (MIE) in estrogenicity-related adverse endpoints. 1 Moreover, 
activation of ERα is the driving force behind the uterus growth response in the uterotrophic 
assay, and accordingly, ERα knockout animals have an irresponsive uterus. 2 Most of the test 
compounds used, were selected from the ICCVAM defined list for validation of in vitro tests 
for estrogenicity testing and represent a diverse range of chemicals, i.e., natural steroids, 
synthetic steroids, flavonoids, phenols, organochlorines, and phthalates. 3 In addition, 
published results from ER binding assays and two OECD-validated reporter gene assays 
(i.e., ERα-HeLa-9903 and BG1Luc ER TA) were also compared to the results obtained in the 
current thesis and with the data from the in vivo uterotrophic assay. 
In general, results showed that all in vitro assays revealed a reasonable to good 
correlation with the in vivo uterotrophic assay (R2 = 0.62-0.89). However, in order to define 
a test panel which allows easy high-throughput screening and prioritization of chemicals, 
the selection of the in vitro assays cannot be based only on the in vitro-in vivo correlation, 
since other aspects such as fastness, simplicity, reproducibility and adaptability for high-
throughput applications should also be taken into account. Table 1 summarizes some of 
these properties of the in vitro assays used in the present thesis.
Based on 12 reference compounds, data obtained in the MCF-7/BOS proliferation 
assay correlate better (R2 = 0.85) with the data from the in vivo uterotrophic assay than the 
proliferative responses of three other human cell lines, i.e., another cell line derived from 
breast (T47D), one derived from the endometrium (ECC-1) and one from the ovary (BG-1) 
(Chapter 2). When tested with a larger set of 23 compounds, the obtained correlation of 
the MCF-7/BOS proliferation assay with the uterotrophic assay showed an identical 
correlation (R2 = 0.85) (Chapter 3). This demonstrates that the proliferation endpoints has 
a high predictive value for the in vivo uterotrophic effect. However, the MCF-7/BOS cell 
proliferation assay is not very fast, i.e., the proliferative responses of the MCF-7/BOS cells 
can be reliably quantified only after 6 days. This might limit its practical application in the 
current format as a high-throughput screening tool within massive screening programs 
such as REACH. Moreover, crosstalk can occur due to the fact that MCF-7/BOS cells also 
express androgen, progesterone, glucocorticoid and retinoid receptors. 4 Thus, this assay 
may not provide straightforward information on the mechanism of action of the compound 
under investigation. Therefore, a newly developed low-density microarray assay, based on 
marker gene expression in estrogen-treated MCF-7/BOS cells, was evaluated in chapter 4. 
These microarrays allowed to rapidly study expression changes of a substantial number of 
genes, and also provided a more cost-effective option to study known molecular pathways 
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Table 1. Summary of the characteristics of the in vitro estrogenicity assays studied in the present thesis. 
Thesis 
chapter Assay name
In vivo 
correlation 
(R2)
Time 
required 
ER-dependent  
endpoint 
measured Comments
Chapter 
2,3
MCF-7/BOS 
proliferation
0.85 6 days Cell 
proliferation
Simple, but crosstalk with other 
nuclear receptor may occur  
Chapter 
3, 7
Yeast 
estrogen 
bioassay
0.87 1 day Transcription 
activation
Simple and robust; validated for 
screening calf urine, animal feed 
and water samples, but less sensitive 
compared to mammalian cells
Chapter 
3
T47D 
ER-CALUX
0.70 3 days Transcription 
activation
Sensitive, expresses endogenous 
ERα and ERβ
Chapter 
3, 7
U2OS 
ERα-CALUX
0.68 3 days Transcription 
activation
Sensitive; prevalidated; 
constitutively expresses ERα
Chapter 
4
DNA 
microchip
0.72 3-4 days Marker gene 
expression
Labor-intensive, expensive 
Chapter 
5, 6, 7
Coregulator 
binding assay
0.89 < 2 hours Ligand-induced 
ERα binding to 
coregulators
Cell-free method; highest 
reproducibility, but requires to use 
PamStation platform and expensive 
PamChip arrays
Chapter 
3 a
ER binding 
assays
0.75 2 days Receptor 
binding
Validated by EPA; only measures the 
affinity of a ligand binding to ER; 
animals are needed as a source of ERs
Chapter 
3 a
BG1Luc  
ER TA
0.62 3 days Transcription 
activation
Validated by OECD (TG 457) 
for testing both ER agonist and 
antagonist activities 
Chapter 
6 a
ERα-HeLa-
9903
- 3 days Transcription 
activation
Validated by OECD (TG 455) for 
testing only ER agonist activity 
a Literature data were used, no experimental data were generated in the present thesis study.
affected by exposure to an estrogenic test chemical. Eleven target genes that were clearly 
up-regulated by estrogens were selected, and the DNA probes for these transcripts were 
printed on a low-density DNA microchip. The seven most informative marker genes on 
the DNA microchip resulted in fingerprints correctly predicting the estrogenic activities of 
the compounds tested. Two of these marker genes, MLF1IP and UBE2C, were even found 
capable of correctly predicting the in vivo estrogenic potencies of the five ER-agonists tested 
and resulted in a satisfactory correlation with the in vivo uterotrophic assay (R2 = 0.72). 
Although the low-density DNA microchip-based analysis of marker gene fingerprints takes 
only 3 days and is faster than the MCF-7/BOS cell proliferation assay, which takes 6 days, it 
is nevertheless quite laborious and requires skilled technicians; therefore, this assay is also 
not ideal in its current format for the large-scale testing of chemicals.
In vitro ER competitive binding assays have been well established and extensively used to 
investigate ER-ligand interactions. These assays measure the displacement of a receptor-bound 
probe molecule, e.g., 3H-labeled estradiol, by a test compound and subsequently determine 
the relative binding affinity of the test compound for the ER. The ER binding assays are rapid 
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and easy to perform, but only the strength of the binding of a compound to the receptor is 
determined and not the activation or inhibition of activation of the receptor. Thus, compounds 
with high binding affinities to the ER might show lower estrogenic activities in cell-based and 
in vivo assays. This was clearly demonstrated in chapter 3, by the fact that several compounds 
showed high binding affinities to the ER, but were inactive in the in vivo uterotrophic assay. 
In addition, conventional ER binding assays are unable to distinguish receptor agonists from 
receptor antagonists. Moreover, the rat uterine cytosol ER binding assay, currently listed as 
part of the Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program 
Tier 1 screening battery, still requires the use of animals as a source of ERs. These ER binding 
assays are therefore considered to be less suited for an in vitro high-throughput screening 
approach to test compounds for estrogenic activity. It was therefore decided to investigate the 
performance of three existing in vitro reporter gene assays for estrogenicity testing that are 
known to be fast and suited for high-throughput purposes.
The three reporter gene assays used in chapter 3 are based on stably transfected cells, 
either mammalian (T47D ER-CALUX assay and U2OS ERα-CALUX assay) or yeast 
cells (yeast estrogen bioassay). These assays measure the induction of a reporter gene, the 
expression of which is easy to quantify, and is put under transcriptional control of one or 
more EREs and therefore depends on the level of activation of the estrogen receptor. As 
shown in Table 1, compared to its mammalian counterparts, the yeast estrogen bioassay is 
faster, easier to perform and does not need expensive growth media (e.g., charcoal-stripped 
fetal bovine serum) nor sophisticated cell culture facilities or an expensive substrate (e.g., 
luciferine in the luciferase based CALUX assays). Moreover, the results of the yeast estrogen 
bioassay showed a good and better correlation (R2 = 0.87) with the outcomes of the in vivo 
uterotrophic assay than those obtained with the mammalian cell-based CALUX assays. 
Although yeast cell-based assays are thought to suffer from poor transport of chemicals across 
the yeast cell wall, previous studies demonstrated that the yeast cell wall is easily permeable 
for compounds with a molecular weight up to 620 daltons, or even larger molecules, due 
to the flexibility of the wall of living yeast cells. 5, 6 Thus, the yeast cell wall does not provide 
a major obstacle for low molecular weight compounds to reach the inside of the cells and 
activate the ER. This consideration was confirmed by the good correlation observed between 
the yeast estrogen bioassay and the in vivo uterotrophic assay. In addition, Kolle et al. (2010) 
compared experimental data from a yeast estrogen screen (YES) assay with the literature data 
from the uterotrophic assay and also showed that the YES assay has a high degree of qualitative 
concordance (the rate agreement of the results among assays; 87%) with estrogenic effects in 
vivo. 7 The human cell-based T47D ER-CALUX and the U2OS ERα-CALUX assay showed 
a relatively lower correlation with the uterotrophic assay (R2 of 0.70 and 0.68, respectively); 
however, this was mainly due to 4-hydroxytamoxifen being an outlier. When this compound 
was excluded from the comparison, the R2-value of the correlation between the uterotrophic 
assay and the two human cell-based reporter gene assays increased to around 0.85. Moreover, 
these human cancer cell line-based reporter gene assays are generally more sensitive than 
the yeast-based reporter gene assays, which is an advantage for screening samples with low 
concentrations of estrogenic compounds such as usually found in food or environmental 
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samples. For prioritization and testing of pure chemicals, all these in vitro assays are sensitive 
enough to measure potent to weak estrogenic compounds. 
From Table 1 it becomes clear that the coregulator binding assay (chapter 5, 6 & 7) is 
the fastest assay and showed the best correlation with the in vivo uterotrophic assay. The 
coregulator binding assay uses the PamChip® plate holding 96 identical peptide probe arrays, 
thus allowing the ligand-modulated interaction of 155 different NR-binding coregulator 
peptides with ERα to be measured for 96 samples in one plate run. It was shown in chapters 5 
and 6 that the coregulator binding assay is capable to distinguish ERα agonists from antagonists 
and is even reflecting structural similarity of ERα agonists, indicating its potential to achieve 
identification and classification of ERα endocrine disruptors with high fidelity. In addition, 
ERα LBD−coregulator binding profiles induced by a series of bisphenols provided new 
mechanistic insights into estrogen receptor signaling by these compounds. The antagonistic 
binding profiles demonstrated that bisphenol A, B, C1 and C2 might act as general ERα 
activation function 2 (AF-2) antagonists, similar to the selective estrogen receptor modulator 
tamoxifen (chapter 7). Moreover, the coregulator binding assay is a cell-free method; therefore 
no cell culturing facilities are needed. However, this assay requires the use of a dedicated 
PamStation platform and multiple PamChip arrays for generating dose-response curves of 
test compounds. The total costs of this assay are therefore rather high when compared to 
the consumables needed for the cell-based assays described in the present thesis. For further 
practical application of the coregulator binding assay, a more cost-effective screening protocol 
is needed. This may be achieved, for example, by testing multiple doses of a compound on a 
single array. However, the feasibility of such an approach should be further explored. 
Reproducibility and robustness are also important aspects to take into account when 
selecting in vitro assays for an ITS. With a median coefficient of variation of 5.0 % and excellent 
correlation (R2 = 0.993) between duplicate measurements, the reproducibility of the coregulator 
binding assay was better than the reproducibility of other commonly used in vitro ER functional 
assays. The yeast cell-based reporter gene assay also showed good results on reproducibility in an 
inter-laboratory study. 8 In addition, yeast-based reporter gene assays are extremely robust and 
can be used for screening of complex biological samples without extensive clean-ups. This was 
demonstrated by the validation studies of the yeast estrogen bioassay for screening of estrogenic 
activity in calf urine, 9 animal feed 10 and water samples. 11 The ERα-CALUX has been prevalidated 
as a test for ER agonist and antagonist activity of compounds. Although the ERα-CALUX had 
problems in the initial phase of the validation studies with transferability, these issues were 
solved by isolation of a novel cell clone of the ERα-CALUX line with greatly improved stability 
and luciferase levels. 12 Thus far, the coregulator binding assay, the yeast estrogen bioassay, and 
the ERα-CALUX bioassay showed a clear advantage over the T47D ER-CALUX bioassay, the 
MCF-7/BOS cell proliferation assay and the low-density DNA microchip, and no real validation 
studies have been carried out yet to demonstrate the reproducibility of the later three bioassays, 
as was done for the first three bioassays. 
When compared to the published results, as shown in Table 1, the coregulator 
binding assay and the yeast estrogen bioassay showed a better correlation with the in vivo 
uterotrophic assay than the OECD validated BG1Luc ER TA assay (based on the results 
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of the 23 compounds tested). The T47D ER-CALUX and the U2OS ERα-CALUX assay 
showed relatively lower correlation with the uterotrophic assay, however, their results were 
found to be slightly better than those from the BG1Luc ER TA assay. Further evaluation of 
the performance of the in vitro assays used in the present thesis with the OECD-validated 
BG1Luc ER TA assay, and formal validation might be the next steps towards the practical 
application of these in vitro bioassays. At the moment, validation of an in vitro alternative 
method is a lengthy process and may take about 5 years. 13 However, this process can be 
speeded up through the so called “catch-up” or “Me-too” validations, i.e., by comparison of 
the results to the validated method using defined ‘‘performance standards” or ‘‘performance 
criteria”. 14 To date, several in vitro reconstructed human epidermal models have been 
successfully validated in “catch-up” validation studies and are implemented into the 
OECD in vitro skin corrosion Test Guidelines (e.g., TG 430 and TG 431). 15, 16 Therefore, 
the coregulator binding assay, the U2OS ERα-CALUX bioassay and the yeast estrogen 
bioassay could be validated through the “catch-up” validation by testing the complete set 
of 78 reference compounds defined by ICCVAM for validation of in vitro ER binding and 
transcription activation test methods.
The results from the comparisons made in the present thesis provide useful 
information to select the most suitable in vitro assays for estrogenicity testing. However, 
the complementary nature of each assay should also be taken into account when defining 
an ITS. Therefore, a multiple linear regression analysis was performed to demonstrate 
whether linear combinations of certain in vitro assays can lead to a higher prediction value 
for the outcomes as observed in the in vivo uterotrophic assay. Results showed that upon 
combining all the in vitro data sets the correlation with the in vivo uterotrophic assay was 
improved to an R2 of 0.97, which is higher than the R2 obtained for any of the in vitro assay 
alone. The yeast estrogen bioassay showed the most significant influence on the prediction 
value for the in vivo uterotrophic outcomes. In addition, combination of the yeast estrogen 
bioassay with either the coregulator binding assay or the MCF-7/BOS cell proliferation 
assay resulted in the highest correlations, i.e., R2 of 0.93 and 0.90, respectively for a 
combination of two assays. Combinations of any other two in vitro assays resulted in lower 
correlations. Combination of all the reporter gene assays resulted in an R2 of 0.87 with the in 
vivo uterotrophic assay which is the same as the R2 obtained when using the yeast estrogen 
bioassay alone. These findings indicate that combination of in vitro assays measuring the 
same endpoint, e.g., transcription activation may not further improve the predictivity of 
the in vitro test panel. Taken all these aspects together, i.e., predictivity, fastness, simplicity, 
reproducibility, and complementary nature of the selected in vitro assays, the yeast estrogen 
bioassay or the U2OS ERα-CALUX assay together with the coregulator binding assay 
appears to be the most promising combination of assays to be included in the ITS. This was 
further demonstrated in chapter 7, showing that the yeast estrogen bioassay and the U2OS 
ERα-CALUX assay accurately predict the estrogenicity of a series of newly tested model 
compounds and revealed 100% concordance with the in vivo uterotrophic assay.  
Although good in vitro - in vivo correlations were obtained in the studies described in 
this thesis, discrepancies do exist, and this is due, at least to some extent, to the multiple 
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biological effects of estrogens. The three in vitro assays that were recommended to be part 
of the ITS for estrogenicity testing, i.e., the coregulator binding assay, the yeast estrogen 
bioassay and the U2OS ERα-CALUX assay, only measure effects directly mediated by ERα 
and are therefore not able to detect chemicals that elicit their estrogenic effects through 
indirect mechanisms, e.g., alteration of hormone biosynthesis, metabolism or transport. In 
addition, the antiandrogenic compounds elicit in vivo effects by the androgen receptor (AR) 
that can hardly or not be distinguished from an estrogenic effect by an estrogen via the ER, and 
some compounds even have combined modes of action, e.g., several estrogenic compounds 
like 17α-ethinyl estradiol (EE2) and diethylstilbestrol (DES) are also antiandrogenic, and in 
this way may enhance the overall ‘estrogenic’ effect in vivo. 17, 18 This emphasises the need to 
extend the ITS initially established based on ERα responsive assays, by including androgen 
reporter gene assays and the H295R steroidogenesis assay. This was clearly demonstrated in 
chapter 7 which presents data on several model compounds that possess strong estrogenic 
activities and/or antiandrogenic activities, or effects on steroidogenesis, or combinations 
of those at the same time. These findings provided valuable information on the modes of 
action of the test compound, and this can help in the prioritization of chemicals for further 
screening in selected animal models.  
Thus, the in vitro assays used in the present thesis provide valuable insights on 
mechanisms of action of the compounds under investigation. However, these in vitro 
assays are restricted in their capacity to reflect the absorption, metabolism, distribution, 
and excretion (AMDE) processes of the intact animal. Poor metabolic capacity is one of 
the most frequently cited limitations of in vitro assays compared to in vivo assays. This was 
also demonstrated in the present thesis since, for example, tamoxifen is less potent than its 
metabolite 4-hydroxytamoxifen in in vitro proliferation assays, while these two compounds 
showed the same estrogenic potency in the in vivo uterotrophic assay. The same applies 
for the organochlorine insecticide methoxychlor: This compound is about 100 time less 
potent than its in vivo metabolite 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane (HPTE) 
in the U2OS ERα-CALUX assay, indicating the low metabolic capacity of the U2OS cells. 
In addition, steroid compounds can also be deactivated in vivo. In this case in vitro assays 
may lead to overestimation of the estrogenic potency of the test compound. To overcome 
these issues, several in vitro and ex vivo methods are currently being applied to study the 
metabolism of compounds. These methods range from the use of simple enzymatic reactions 
and cell fractions to the use of more complicated cell lines, primary cell cultures and tissue 
slices. Enzymatic hydrolysis and deconjugation methods are effective and easy to perform. 
Rijk et al. (2011), for example, reported that enzymatic deconjugation of genistin resulted 
in a significant increase in estrogenic activity due to the formation of the more potent 
genistein. 19 However, such enzymatic methods are suited for activation of only certain groups 
of compounds, e.g., hormone esters and glycoside derivatives. Liver cell lines, for example 
human HepG2 and HepaRG, primary hepatocytes and liver slices provide a more complete 
set of biotransformation enzymes including cytochromes P450 and Phase II enzymes and are 
therefore considered as more complete and representative models for in vivo metabolism. 
Due to the elaborated preparation procedures or limited availability of liver tissues, the latter 
162
8g
eN
eR
a
l D
IsC
U
ssIO
N
two methods are not suitable for high-throughput screening of chemicals. Liver S9 fractions 
are easier to prepare, contain major biotransformation enzyme activities, and can be used in 
combination with in vitro assays for endocrine disruption testing. 20-23 Although S9 is very 
useful, the major potential drawback is that S9 liver fractions need cofactors and it may not 
be known on forehand what cofactor is needed for the chemical under investigation. 24 In 
addition, co-incubation of liver S9 can lead to toxicity in mammalian cell-based reporter 
gene assays, in these cases the chemical should be pre-incubated with S9 first, extracted 
(mother compounds and metabolites formed) and then tested in the in vitro assay. A better 
option might be to combine the S9 with the more robust yeast-based reporter gene assays 
or with cell-free assays such as the coregulator binding assay. Another advantage of using 
combinations of S9 with in vitro assays that lack metabolism, such as the yeast based reporter 
gene assays and the coregulator binding assay, is that any change in estrogenic activity is 
most likely due the S9 treatment and thus due to metabolism, which allows important 
mechanistic information to be obtained. Although the mammalian reporter cells described 
in this thesis have a very limited metabolic capacity, compounds can be converted to more 
potent metabolites and lead to a false positive result. This was demonstrated in chapters 2, 3 
and 4, as testosterone induced a full dose response in the MCF-7/BOS proliferation assay, and 
it was shown that this was mainly due to the conversion of testosterone into the estrogenic 
metabolites E2, 4-androstenediol and 5-androstenediol. Therefore, cell models cannot be 
used as a black box, and it is necessary to characterize the cell line on the metabolic level in 
order to prevent misclassification of compounds. 
In addition to the use of in vitro tools for metabolism, methods that address in vivo 
digestion and absorption are also needed to further improve the in vitro prediction 
of in vivo effects. One of the in vitro models for digestion is the human gastrointestinal 
digestion model, which involves subsequent incubations of a test compound in saliva, 
and in gastric, duodenal and bile juice. Among others, this model has been applied for 
studying the bioavailability of compounds such as heavy metals, 25 mycotoxins 26 and silver 
nanoparticles. 27 The Caco-2 cell line, derived from a human colorectal carcinoma, is the 
most commonly used and well-established in vitro model for the prediction of intestinal 
absorption and transport of compounds. 28, 29 In this model, chemicals are typically added 
to the apical side of Caco-2 cell monolayers, and both their transport and metabolism can 
be measured upon a defined incubation time at the apical or basolateral side. Although 
the gastrointestinal digestion and the intestinal absorption models are routinely used in 
toxicology and pharmaceutical research, the utility of combining these and other ADME 
models with existing in vitro assays for high-throughput screening of estrogenicity should 
be further explored. In addition, the data obtained on absorption and metabolism can also 
contribute to building physiologically based kinetic (PBK) models that allow conversion of 
in vitro concentration-response curves to in vivo dose-response curves, in order to improve 
the impact and applicability of in vitro methods in risk assessment practice. 30, 31 
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fuTure PerSPecTiveS And concluSionS
The studies presented in this thesis provide further insight on developing an integrated 
testing strategy (ITS) based on existing and newly developed in vitro assays for estrogenicity. 
Although the proposed in vitro test panel cannot directly replace the in vivo uterotrophic 
assay, i.e., should be expanded with in vitro models for digestion, metabolism and 
absorption, it could be incorporated as part of a weight-of-evidence approach to reduce or 
eliminate the need for testing endocrine disruption effects in animal models. To this end, 
the information obtained from different in vitro endpoints should all be taken into account 
in reaching and supporting a conclusion concerning the endocrine disruption potential of a 
chemical. To date, most of the attention to endocrine disruption has focused on estrogenic 
and androgenic effects. 32, 33 Therefore, our knowledge on disruption of other hormone 
signaling pathways either directly through nuclear receptors (e.g., thyroid receptor, 
progesterone receptor and glucocorticoid receptor) or through indirect mechanisms (e.g., 
steroidogenesis) should be broadened.  
The current thesis can be used as a departure point towards defining an in vitro ITS for 
androgenic activity, thyroid hormone activity, progestagenic activity, or glucocorticoid activity. 
Similar as the in vivo uterotrophic assay, the golden standard for evaluating androgen agonists 
or antagonists, i.e., the Hershberger assay, is also based on the changes in tissue weight, 
more specifically, on five androgen-dependent tissues (i.e., ventral prostate, seminal vesicle, 
levator ani-bulbocavernosus muscle, paired Cowper’s glands and the glans penis) in castrated 
peripubertal male rat. 34 Various in vitro bioassays have been developed and applied for 
screening androgenic properties of chemicals, such as androgen receptor (AR) binding assays, 35 
yeast androgen reporter gene assays 36, 37 and several mammalian reporter gene assays. 38-41 As 
the Hershberger assay is already validated 34 and a substantial amount of chemicals have been 
tested, 42-44 the in vitro – in vivo correlation approach, as used in the current thesis, could also 
be applied in order to investigate the predictivity of the existing in vitro assays for in vivo (anti)
androgenic effects and to identify discrepancies between in vitro data and results from the in 
vivo Hershberger assay. Only a few studies explored the correlation between in vitro assays and 
the Hershberger assay. Sonneveld et al. (2004), for example, reported that the results obtained 
with the human U2OS AR-CALUX reporter gene assay resulted in a correlation coefficient of 
R2 = 0.46 with the Hershberger assay on a set of 34 steroids. 42 In a more recent study, Kolle et 
al. (2010) compared outcomes of a yeast androgen screen assay (YAS) with literature data from 
the Hershberger assay and showed that the YAS assay has a very high degree of concordance 
(95%) with androgenic effects in vivo. 7 Although several in vitro assays are developed for 
screening progestagenic activities, i.e., progesterone receptor (PR) binding assays, 45 yeast 
progesterone reporter gene screens 46 and mammalian cell-based reporter gene assays, 47-50 data 
on the in vivo endometrium differentiation assay (McPhail assay), an animal model for testing 
progestagenic activities in immature rabbits, are quite limited. Nevertheless, it has been shown 
that comparison between the U2OS PR-CALUX assay and the in vivo McPhail assay revealed 
a good correlation with R2 = 0.85 based on a set of 50 compounds. On the one hand, these data 
imply that in vitro assays measuring direct effects mediated by AR and PR could cover a major 
part of the androgenic and progestagenic activities, respectively, observed in vivo. On the other 
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hand, such a hypothesis may not apply to the thyroid system, as most of the thyroid effects 
are not mediated via the thyroid receptor, but through interference with thyroid hormone 
triiodothyronine (T3) and/or thyroxine (T4) synthesis and by disturbing the transport of T3 
and T4 in the bloodstream. This was demonstrated in a study by Jomaa et al. (2013), showing 
that among 11 thyroid-active compounds, known to affect pituitary and/or thyroid weights in 
vivo, only two compounds tested had an effect in the in vitro rat thyroid cell proliferation assay 
(TSH-screen). 51 Therefore, a broad range of in vitro assays that cover various modes of action 
of thyroid-active compounds are needed, for example, a thyroid peroxidase assay, or even more 
complex (vertebrate) “in vitro” models like zebrafish. 
The selected in vitro assays, covering different endocrine disruption endpoints, can also 
contribute to establish testing programs and strategies to predict potential toxicity, and to 
develop a cost-effective approach to prioritize the toxicity testing of chemicals. For example, 
these in vitro assays can be implemented in the U.S. Environmental Protection Agency (EPA) 
ToxCast program, which is currently evaluating over 1,000 chemicals in more than 600 in 
vitro assays. However, as strengthened above, to ultimately replace the short-term in vivo 
screening assays for specific endocrine disruption effects, the selected in vitro bioassays have 
to be combined with other types of in vitro assays, including at least the H295R steroidogenesis 
assay as an in vitro model for steroid metabolism, as well as for in vitro (cellular) models for 
digestion, absorption, and bioavailability of the compounds under investigation.
In conclusion, the present thesis provides proof-of-principle that combining in vitro 
assays measuring different steps in the estrogen receptor signaling pathway enables 
accurate prediction of the estrogenic effects in vivo. By including the androgen reporter 
gene assays as well as the H295R steroidogenesis assay, the extended testing panel even goes 
beyond estrogenicity testing, as it can detect possible (anti)androgenic effects and effects 
on steroidogenesis that are not covered by the in vivo uterotrophic assay. The integrated 
in vitro testing strategy presented in this thesis may therefore allow easy high-throughput 
screening and prioritization of chemicals, thereby contributing to refinement, reduction 
and to some extent even replacement of current animal testing for estrogenic effects.
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Testing chemicals for their endocrine-disrupting potential, including interference with 
estrogen receptor signaling, is an important aspect to assess the safety of currently used 
and newly developed chemicals. The standard test for disruption of normal estrogen 
function is the in vivo uterotrophic assay in immature or ovariectomised rodents with 
uterus weight as a crucial read-out parameter. Due to the high costs, ethical objections 
and labour intensiveness of the in vivo uterotrophic assay, the development of an in vitro 
test battery for in vivo estrogenicity has high priority. The aim of the present thesis was to 
develop an integrated testing strategy (ITS), based on existing and newly developed in vitro 
assays for estrogenicity testing, allowing easy high-throughput screening and prioritization 
of chemicals. An ITS preferentially based on in vitro assays would be a crucial step towards 
refinement, reduction, and ultimately replacement of current animal testing for estrogenic 
and other endocrine disrupting effects.
To reach this aim, several presently available and newly developed in vitro bioassays 
were selected and evaluated for optimal representation of the estrogenic effects occurring 
in the uterus/endometrium in vivo. In chapter 2 of the thesis the estrogenic potency of 
12 compounds was studied in four different estrogen-dependent cell proliferation assays 
in order to determine to what extent these in vitro tests provide alternatives for the in 
vivo uterotrophic assay. The cell lines used for proliferation assays were cell lines derived 
from three different female estrogen-sensitive tissues, i.e. breast (MCF-7/BOS and T47D), 
endometrial (ECC-1) and ovarian (BG-1) cells. These cell lines were characterised by 
investigating their relative estrogen receptor (ER) α and β levels, as the ERα/ERβ ratio is 
a known dominant factor determining the estrogen-dependent proliferative responses in 
estrogen sensitive cell lines. Results showed that all four cell lines clearly express the ERα 
type and a very low, yet detectable, amount of ERβ at both the mRNA and protein level, 
with the T47D cell line expressing the highest level of the ERβ type. Subsequently, a set 
of selected (estrogenic) reference compounds representing different modes of action and 
potency were used to investigate the proliferative response of the four cell lines. It was 
shown that the responses of all four cell lines towards the model compounds revealed a 
reasonable to good correlation with their in vivo uterotrophic effect, with the correlation 
being highest for the MCF-7/BOS cell line (R2 = 0.85). The main differences between the in 
vivo uterotrophic assay and the in vitro proliferation assays were observed for tamoxifen and 
testosterone. The proliferative response of the MCF-7/BOS cells to testosterone was shown 
to be partially caused by its conversion to estradiol by aromatase or via androstenedione to 
estrone. It was concluded that of the four cell lines tested, the best assay to include in an ITS 
for replacement of the in vivo uterotrophic assay is the proliferation assay with the human 
MCF-7/BOS breast cancer cell line.
In addition to proliferation assays, reporter gene assays based on either mammalian 
or yeast cells are also widely used for estrogenicity testing. In chapter 3 it was investigated 
which of these in vitro assays most accurately predict the in vivo uterotrophic effect and 
possible discrepancies between the in vitro assays and the in vivo uterotrophic assay were 
identified. To this end a larger set of 23 estrogenic reference compounds, most of which 
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were selected from the ICCVAM list of compounds defined for validation of in vitro tests 
for estrogenicity and representing diverse chemical classes, was tested in a series of in vitro 
reporter gene assays and in the MCF-7/BOS proliferation assay selected in a previous study 
(chapter 2). The reporter gene assays included two CALUX assays based on mammalian 
cell lines, i.e. the T47D ER-CALUX and U2OS ERα-CALUX, and a yeast based estrogen 
bioassay. Outcomes of these assays were compared with published results for ER binding 
assays and the OECD validated BG1Luc ER transcriptional activation (TA) assay, and then 
altogether compared with the outcomes of the in vivo uterotrophic assay in order to identify 
the in vitro assay(s) providing the best prediction of the in vivo uterotrophic response. 
All in vitro assays revealed a reasonable to good correlation (R2 = 0.62-0.87) with the in 
vivo uterotrophic assay. The best correlation was obtained with the yeast estrogen bioassay 
(R2 = 0.87), expressing a green fluorescent protein (yEGFP) in response to estrogens. The 
correlation with MCF-7/BOS cell proliferation assay in this study with 23 compounds was 
the same as obtained before in the study with the smaller set of 12 reference compounds 
(R2 = 0.85). However, compared to the reporter gene and ER binding assays (1-2 days) 
the MCF7/BOS takes too long (6 days) and is therefore regarded as less suited for the 
high-throughput screening of compounds for prediction of in vivo estrogenicity. The 
combination of the yeast estrogen bioassay with the U2OS ERα-CALUX assay seemed the 
most promising for an ITS for in vitro estrogenicity testing. The main outliers identified 
when correlating data from the different in vitro assays and the in vivo uterotrophic assay 
are 4-hydroxytamoxifen, testosterone and to a lesser extent apigenin, tamoxifen and kepone. 
Based on the modes of action possibly underlying these discrepancies it becomes evident 
that to further improve the ITS and ultimately replace animal testing for estrogenic effects, 
the selected bioassays have to be combined with other types of in vitro assays, including 
in vitro models for bioavailability as a result of adsorption, distribution, metabolism and 
excretion (ADME characteristics) of the compounds under investigation.
In an effort to also develop new, especially omics-based, in vitro assays for estrogenicity, 
chapter 4 describes a newly developed low-density DNA microchip for the detection of 
estrogenic compounds and their relative potencies. The low-density DNA microchip 
in array tube format contains probes for 11 different estrogen-responsive genes (marker 
genes) selected from a comprehensive gene expression study of estrogen-treated MCF-7/
BOS cells and was used to test a set of 12 selected reference compounds. The results showed 
that the seven most informative marker genes on the microchip resulted in fingerprints 
that correctly predicted the estrogenic activity of the model compounds, except that of the 
negative control testosterone. Two marker genes (i.e., myeloid leukemia factor 1-interacting 
protein and ubiquitin-conjugating enzyme E2C) were even capable of correctly predicting 
the estrogenic potency of all five ER agonists tested and correlated well with the potencies 
as determined in the MCF-7/BOS proliferation assay and the in vivo uterotrophic assay. 
In addition, it was demonstrated that the estrogenic responses of testosterone, both in 
the array tube assay and in the proliferation assay, were partially due to the conversion 
of testosterone into estradiol by aromatase, but also due to formation of other estrogenic 
metabolites, the presence and estrogenic potency of which were confirmed by GC-MS/
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MS analysis and a yeast-based reporter gene assay, respectively. The low-density DNA 
microchip-based analysis of marker gene expression fingerprints takes 3 days and is faster 
than the MCF-7/BOS cell proliferation assay which takes 6 days, but it is nevertheless quite 
laborious and requires highly skilled technicians; therefore, it is not ideal in its current 
format for the large-scale testing of chemicals as required by initiatives like REACH.
To further develop an in vitro ITS for refinement, reduction and ultimately replacement 
of in vivo tests for estrogenicity testing, chapter 5 describes a 155-plex high-throughput 
in vitro coregulator binding assay enabling the study of ligand-modulated interaction of 
coregulators with ERα. This assay uses a 96-well PamChip plate with a peptide microarray 
mounted in each well representing 155 different coregulator-nuclear receptor binding 
motifs. The relative estrogenic potencies of the tested compounds were determined based on 
ligand-induced ERα binding to 57 (out of 155) coregulator peptides on the PamChip peptide 
array that displayed a clear E2 dose-dependent response (goodness of fit of a logistic dose-
response model of 0.90 or higher). The estrogenic potencies thus obtained were compared 
to the relative estrogenic potencies as determined in the in vivo uterotrophic assay. It was 
shown that the estrogenic potencies predicted for 18 selected compounds based on induction 
of ERα-coregulator binding correlated well with their in vivo potencies in the uterotrophic 
assay, with coefficient of determination (R2) values for 30 coactivators even being higher 
than or equal to 0.85. Moreover, this coregulator binding assay was able to distinguish ER 
agonists from ER antagonists, as selective estrogen receptor modulators (SERMs), such as 
tamoxifen, showed distinct profiles for coregulator activation from pure ER agonists, such 
as dienestrol. It was concluded that combination of this coregulator binding assay with 
other types of in vitro assays, e.g., reporter gene assays and the H295R steroidogenesis assay, 
will provide an in vitro test panel suitable for screening and prioritization of chemicals, 
thereby contributing to reduce and ultimately replace animal testing for estrogenic effects.
With a view to practical application of the coregulator binding assay described in 
chapter 5, for example in a regulatory toxicology setting, chapter 6 presents the results on 
the technical characteristics of the assay, such as the reproducibility and robustness. A set 
of 14 model compounds recommended by the Office of Prevention, Pesticides and Toxic 
Substances (OPPTS) for testing laboratory proficiency in estrogen receptor transactivation 
assays were tested in the coregulator binding assay. With a median coefficient of variation 
of 5.0 % and excellent correlation (R2 = 0.993) between duplicate measurements, the 
reproducibility of the ERα-coregulator binding assay was better than the reproducibility of 
other commonly used in vitro ER functional assays. In addition, the coregulator binding 
assay is correctly predicting the estrogenicity for 13 out of 14 compounds tested. When the 
potency of the ER-agonists to induce ERα-coregulator binding was compared to their ER 
binding affinity, their ranking was similar, and the correlation between the respective EC50 
values was excellent (R2 = 0.96), as was the correlation with their potency in a transactivation 
assay (R2 = 0.94). Moreover, when the ERα-coregulator binding profiles were hierarchically 
clustered using Euclidian cluster distance, the structurally related compounds were found to 
cluster together, e.g., the steroid test compounds having an aromatic A-ring were separated 
from those with a cyclohexene A-ring. The results obtained in chapter 5 and 6 showed that 
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the coregulator binding assay is capable to distinguish ERα agonists from ERα antagonists 
and is even reflecting structural similarity of ERα agonists, indicating its potential to achieve 
identification and classification of ERα endocrine disruptors with high fidelity.
Further research, as described in Chapter 7, focused on the evaluation and extension 
of the previously established ITS for in vitro estrogenicity. Ten estrogenic compounds 
with modes of action in part different from ER binding were tested in the previously 
defined ITS, i.e., in a yeast estrogen reporter gene assay, a U2OS ERα-CALUX reporter 
gene assay and a cell-free coregulator binding assay. Results show that the two reporter 
gene assays in the ITS accurately predict the estrogenicity of the model compounds and 
revealed 100% concordance with the in vivo uterotrophic assay. Moreover, the coregulator 
binding profiles provided new mechanistic insights into estrogen receptor signaling of 
the model compounds tested. Moreover, by adding androgen reporter gene assays as well 
as the H295R steroidogenesis assay to the ITS, several model compounds also showed 
potent antiandrogenic properties and effects on steroidogenesis that might potentiate the 
estrogenic effects in vivo. By covering these additional mechanisms of estrogen-related 
endocrine disruption, this extended ITS will go beyond in vivo estrogenicity testing by the 
uterotrophic assay, thereby contributing to refinement, reduction and to some extent even 
a replacement of current animal testing for estrogenic effects.
Chapter 8 presents a discussion on the selection of the in vitro assays for the ITS based 
on the in vitro - in vivo correlation approach, taking also into account other aspects such as 
costs, fastness, simplicity, reproducibility and adaptability for high-throughput applications. 
Altogether, the results of the present thesis reveal that an ITS consisting of the U2OS ERα-
CALUX, yeast estrogen bioassay and ERα coregulator binding assay enables an accurate 
prediction of the estrogenic effects in vivo and provides mechanistic insights. By including 
the H295R steroidogenesis assay as well as an androgen reporter gene assay, the extended ITS 
will even go beyond in vivo estrogenicity testing as performed by the uterotrophic assay. The 
extended ITS presented in this thesis allows easy high-throughput screening and prioritization 
of chemicals, and was shown to be able to contribute to the refinement, reduction and to some 
extent even a replacement of current animal testing for estrogenic effects. 
176


Samenvatting 
Acknowledgements  
curriculum vitae
list of publications
overview of completed training activities A

asa
m
eN
v
a
T
TIN
g
 
SAmenvATTinG
Het testen van chemicaliën op hun hormoonverstorende werking is een belangrijk aspect 
bij de beoordeling van de veiligheid van reeds in gebruik zijnde en nieuw ontwikkelde 
chemicaliën. De verstoring van de signaaltransductie via de oestrogeenreceptor is hiervan 
een belangrijk onderdeel. De standaardtest voor het meten van verstoring van de normale 
hormoonfunctie van oestrogenen is de zogenaamde uterotrofe assay, een in vivo test die 
gebruik maakt van muizen of ratten, hetzij van juveniele dieren of van dieren waarvan de 
eierstokken zijn verwijderd, met uterusgewicht als de voornaamste meetwaarde. Vanwege de 
ernstige nadelen van de in vivo uterotrofe assay, zoals de hoge kosten, de ethische bezwaren 
en het arbeidsintensieve karakter, heeft de ontwikkeling van een in vitro testbatterij voor 
in vivo oestrogeniteit hoge prioriteit. Het doel van dit proefschrift was een integrale 
teststrategie (ITS) te ontwikkelen, gebaseerd op bestaande en nieuw-ontwikkelde in vitro 
testen voor oestrogene werking, die het onderzoeken van grote aantallen monsters (“high-
throughput screening”) en prioritering van chemicaliën mogelijk maakt en vereenvoudigt. 
Een ITS, bij voorkeur gebaseerd op in vitro testen, zou een cruciale stap zijn op de weg naar 
verfijning, vermindering en de uiteindelijk vervanging (3Vs) van de huidige dierproeven 
voor oestrogene en andere hormoonverstorende effecten.
Om dit doel te bereiken, werden meerdere reeds beschikbare- en nieuw ontwikkelde in 
vitro bioassays geselecteerd en werd geëvalueerd welke testen de oestrogene effecten op de 
uterus/het endometrium in vivo het beste weergeven. In hoofdstuk 2 van het proefschrift werd 
de oestrogene potentie van 12 stoffen bestudeerd in vier verschillende celproliferatietesten, 
testen gebaseerd op humane cellijnen die prolifereren in afhankelijkheid van oestrogenen, om 
te bepalen in welke mate deze in vitro testen een alternatief bieden voor de in vivo uterotrofe 
assay. De gebruikte cellijnen voor de proliferatietesten waren afkomstig uit drie verschillende 
vrouwelijke oestrogeengevoelige weefsels, t.w. borst- (MCF-7/BOS en T47D), endometrium- 
(ECC-1) en ovariumcellen (BG-1). Deze cellijnen werden gekarakteriseerd door hun 
relatieve oestrogeenreceptor (ER) α- en β-niveaus te bepalen, omdat de ERα/ERβ-ratio een 
dominante factor is die bepalend is voor de proliferatierespons. De resultaten toonden aan 
dat alle vier de cellijnen duidelijk ERα en een zeer lage, zij het detecteerbare, hoeveelheid 
ERβ tot expressie brengen (zowel op mRNA- als eiwitniveau). De T47D cellijn vertoonde 
nog de hoogste expressie van ERβ, maar ook daar was ERα dominant. Vervolgens werd 
voor een aantal geselecteerde referentiestoffen met verschillende werkingsmechanismen en 
oestrogene potentie de proliferatieve respons van de vier cellijnen onderzocht. Het bleek dat 
de respons van alle vier cellijnen op de modelstoffen een redelijk goede correlatie vertoonde 
met hun in vivo uterotrofe effect, waarbij de correlatie het hoogst was voor de MCF-7/
BOS-cellijn (R2 = 0.85). De belangrijkste verschillen tussen de in vivo uterotrofe assay en in 
vivo celproliferatie werden waargenomen voor tamoxifen en testosteron. De onverwachte 
proliferatieve respons van de MCF-7/BOS cellen na blootstelling aan testosteron bleek deels 
veroorzaakt te worden door de omzetting van testosteron in estradiol door aromatase of 
via androsteendion naar estron. Geconcludeerd werd dat van de vier geteste cellijnen, de 
proliferatietest met de humane MCF-7/BOS borstkankercellijn de beste is om mee te nemen 
in een ITS ter vervanging van de in vivo uterotrofe assay.
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Behalve proliferatietesten worden ook reportergen-assays, gebaseerd op hetzij 
zoogdiercellen, hetzij gistcellen, veelvuldig voor oestrogeniteitsonderzoek gebruikt. 
In hoofdstuk 3 werd onderzocht welke van deze in vitro assays het meest accuraat het 
uterotrofe effect in vivo voorspelt en mogelijke discrepanties tussen de in vitro assays en 
de in vivo uterotrofe assay werden geïdentificeerd. Hiervoor werd een grotere groep van 
23 oestrogene referentiestoffen getest in een serie in vitro reportergen-assays en in de 
al eerder geselecteerde MCF-7/BOS proliferatie-assay  (hoofdstuk 2). De meeste van 
deze stoffen waren geselecteerd uit de ICCVAM-lijst van stoffen die opgesteld is voor de 
validatie van in vitro oestrogeniteitstesten, en die verschillende chemische structuurklassen 
vertegenwoordigt. De reportergen-assays behelsden twee CALUX-assays gebaseerd op 
humane borstkankercellijnen, te weten de T47D ER-CALUX en U2OS ERα-CALUX, en 
een op gist gebaseerde bioassay voor oestrogenen. De resultaten van deze assays werden 
vergeleken met gepubliceerde resultaten van ER-receptorbindingstesten en de door de 
OECD-gevalideerde BG1Luc ER-transcriptie-activatie (TA) test, en vervolgens allemaal 
vergeleken met de uitkomsten van de in vivo uterotrofe assay om zo de in vitro assay(s) te 
identificeren met het beste voorspellend vermogen voor de in vivo uterotrofe respons. Alle 
in vitro assays lieten een redelijk goede tot goede correlatie zien (R2 = 0.62-0.87) met de 
in vivo uterotrofe assay. De bioassay gebaseerd op gist, die een groen fluorescerend eiwit 
(yEGFP) tot expressie brengt bij blootstelling aan oestrogenen, gaf de beste correlatie te zien 
(R2 = 0.87). De correlatie met de MCF-7/BOS celproliferatietest in deze studie met 23 stoffen 
was hetzelfde als eerder verkregen in de studie met de kleinere set van 12 referentiestoffen 
(R2 = 0.85). Vergeleken met de reportergen- en ER receptorbinding-assays (1-2 dagen) neemt 
de MCF7/BOS celproliferatietest te veel tijd in beslag (6 dagen) en wordt daarom beschouwd 
als minder geschikt voor het snel screenen van grote aantallen stoffen. De combinatie van de 
gistbioassay voor oestrogenen met de U2OS ERα-CALUX assay leek het meest veelbelovend 
in het kader van een ITS voor het testen van oestrogene activiteit in vitro. De belangrijkste 
afwijkende uitkomsten, na correleren van de data van de verschillende in vitro assays 
met de in vivo uterotrofe assay, werden gevonden voor 4-hydroxytamoxifen, testosteron 
en - in mindere mate – apigenine, tamoxifen en chloordecon (kepone). Gebaseerd op de 
werkingsmechanismen die mogelijk ten grondslag liggen aan deze afwijkende uitkomsten, 
wordt duidelijk, dat om de ITS verder te verbeteren en uiteindelijk een volledige vervanging 
van dierproeven voor het testen van oestrogene effecten te bereiken, de geselecteerde 
bioassays moeten worden gecombineerd met andere typen in vitro assays, inclusief in vitro 
modellen voor biobeschikbaarheid als gevolg van absorptie, distributie, metabolisme en 
excretie (ADME eigenschappen) van de onderzochte stoffen.
In een poging om ook nieuwe, in het bijzonder op omics gebaseerde in vitro assays voor 
oestrogeniteit te ontwikkelen en te testen, wordt in hoofdstuk 4 een nieuw ontwikkelde 
DNA microchip met lage probe-dichtheid beschreven voor de detectie van oestrogene 
stoffen en hun relatieve potenties. Deze “low-density” DNA-microchip in “array tube” 
format bevat probes voor 11 verschillende oestrogeen-responsieve genen (marker genen) 
die geselecteerd werden op basis van een genoomwijde gen-expressiestudie van met 
oestrogeen behandelde MCF-7/BOS-cellen. Deze microchip werd gebruikt om een groep 
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van 12 geselecteerde referentiestoffen te testen. De resultaten toonden aan dat de zeven 
meest informatieve genen op de microchip “vingerafdrukken” opleverden die de oestrogene 
activiteit van de modelstof correct voorspelden, met uitzondering van de negatieve controle 
testosteron. Twee marker genen (te weten myeloid leukemia factor 1-interacting protein 
en ubiquitin-conjugating enzym E2C) waren zelfs in staat de oestrogene potentie te 
voorspellen van alle vijf de geteste ER-agonisten, en correleerden dus goed met de potenties 
zoals gemeten in de MCF-7/BOS celproliferatietest en de in vivo uterotrofe assay. Daarnaast 
werd aangetoond dat de oestrogene respons van testosteron, zowel in de array tube assay 
als in de proliferatietest, gedeeltelijk veroorzaakt werd door de omzetting van testosteron in 
estradiol door aromatase, maar ook door de vorming van andere oestrogene metabolieten. 
De aanwezigheid en oestrogene potentie van die metabolieten werden bevestigd door 
respectievelijk een GC-MS/MS analyse en een op gist gebaseerde reportergen-assay. De 
analyse van deze “vingerafdrukken” gebaseerd op markergenexpressie gemeten door middel 
van de “low-density” DNA microchip duurt 3 dagen en is weliswaar sneller dan de MCF-7/
BOS celproliferatietest (6 dagen), maar is nogal arbeidsintensief, vereist een hoog technisch 
niveau en duurt langer dan de in vitro reportergen-assays en bindingsassays (hoofdstuk 3). 
Daarom is deze test in de huidige vorm niet ideaal voor het op grote schaal testen van 
chemicaliën zoals in het kader van REACH gewenst is.
Om een in vitro ITS te ontwikkelen voor verdere verfijning, reductie en uiteindelijk 
een volledige vervanging van in vivo proeven voor oestrogeniteitsonderzoek, beschrijft 
hoofdstuk 5 een in vitro coregulator-bindingstest, geschikt voor grote aantallen 
monsters (high-throughput), die de bestudering mogelijk maakt van door ligandbinding 
gemoduleerde interactie van ERα met 155 verschillende coregulatoren. Deze assay 
gebruikt een 96-well PamChip-plaat met in elke well een microarray met peptiden welke 
155 verschillende bindingsmotieven representeren voor binding van coregulatoren aan 
kernreceptoren. De relatieve oestrogene potenties van de onderzochte stoffen werden 
bepaald op basis van de binding, geïnduceerd door de desbetreffende ligand, tussen ERα 
en 57 (van de 155) coregulatorpeptiden op de PamChip peptide-array die een duidelijke, 
van de E2 dosis afhankelijke respons lieten zien (een goodness-of-fit van een logistisch 
dosis-responsmodel van 0.90 of hoger). De aldus gevonden oestrogene potenties werden 
vergeleken met de relatieve oestrogene potenties zoals bepaald in de in vivo uterotrofe 
assay. Daaruit bleek dat de oestrogene potenties die waren voorspeld voor 18 geselecteerde 
stoffen, goed correleerden met hun in vivo potenties in de uterotrofe assay, waarbij de 
correlatiecoëfficiënten (R2) voor 30 co-activatoren zelfs groter of gelijk waren aan 0.85. 
Bovendien was deze coregulator-bindingstest in staat ER agonisten te onderscheiden van ER 
antagonisten, aangezien selectieve modulatoren van de oestrogeenreceptor (SERMs), zoals 
tamoxifen, profielen vertoonden voor coregulator-activatie welke duidelijk verschilden van 
die van pure ER-agonisten, zoals dieenestrol. De conclusie was dat de combinatie van deze 
coregulator-bindingstest met andere typen in vitro testen, bijvoorbeeld reportergen-assays 
en de H295R steroidogenese assay, een in vitro test panel kunnen opleveren dat geschikt 
is voor het screenen en prioriteren van stoffen, en zo bijdragen aan het verminderen en 
uiteindelijk vervangen van dierproeven voor het onderzoeken van oestrogene effecten.
183
asa
m
eN
v
a
T
TIN
g
 
Met het oog op de praktische toepassing van de coregulator-bindingstest, zoals beschreven 
in hoofdstuk 5, bijvoorbeeld in de toxicologische regelgeving, laat hoofdstuk 6 de resultaten 
zien van de technische karakterisering van de assay, zoals de reproduceerbaarheid en de 
robuustheid. Een groep van 14 modelstoffen, aanbevolen door het Office of Prevention, 
Pesticides and Toxic Substances (OPPTS) voor het onderzoeken van de bekwaamheid 
van onderzoekslaboratoria in het uitvoeren van transactivatie-assays, werden getest in 
de coregulator-bindingstest. Met een mediaan van 5% voor de variatiecoëfficiënt en een 
excellente correlatie (R2 = 0.933) tussen duplometingen was de reproduceerbaarheid van 
de ERα-coregulator-bindingstest beter dan de reproduceerbaarheid van andere, standaard 
in vitro functionele ER-testen. Bovendien voorspelt de coregulator-bindingstest de 
oestrogeniteit van 13 van de 14 onderzochte stoffen op correcte wijze. Bij vergelijking van 
de potentie van deze ER-agonisten om ERα-coregulatorbinding te induceren met hun ER 
bindingsaffiniteit, bleek hun rangorde overeenkomstig te zijn, en de correlatie tussen de 
respectievelijke EC50-waarden was uitstekend (R2 = 0.96), evenals de correlatie met hun 
potentie in een transactivatie-assay (R2 = 0.94). Bovendien bleken de structureel verwante 
stoffen samen te clusteren wanneer de ERα-coregulator bindingsprofielen hiërarchisch 
werden geclusterd op basis van Euclidische afstand, bijvoorbeeld de geteste steroïden met 
een aromatische A-ring werden gescheiden van de teststoffen met een cyclohexeenring. 
De resultaten die in hoofdstuk 5 en 6 werden verkregen, tonen aan dat de coregulator-
bindingstest in staat is onderscheid te maken tussen ERα-agonisten en ERα-antagonisten en 
zelfs structurele gelijkenis weergeeft van ERα-agonisten, hetgeen zijn vermogen aantoont 
om een betrouwbare identificatie en classificatie van endocriene verstoorders (endocrine 
disruptors) van ERα tot stand te brengen.
Verder onderzoek, zoals beschreven in hoofdstuk 7, richtte zich op de evaluatie van 
de eerder ontwikkelde ITS voor in vitro oestrogeniteit. Tien oestrogene stoffen, deels met 
werkingsmechanismen verschillend van ER binding, werden getest in de eerder gedefinieerde 
ITS, te weten de gist reportergen-assay voor oestrogenen, de U2OS ERα-CALUX 
reportergen-assay en de celvrije coregulator-bindingstest (dedicated peptide microarray). De 
resultaten tonen aan dat de twee reportergen-assays in de ITS nauwkeurig de oestrogeniteit 
voorspelden van de modelstoffen met 100% overeenkomst met de in vivo uterotrofe assay. 
Daarenboven geven de coregulator-bindingsprofielen nieuwe mechanistische inzichten in 
de signaaltransductie via de oestrogeenreceptor geïnduceerd door de geteste modelstof. 
Door zowel reportergen-assays voor androgenen als de H295R steroidogenese assay aan 
de ITS toe te voegen, kwamen bij verschillende modelstoffen tevens potente antiandrogene 
eigenschappen en effecten op de steroidogenese aan het licht, welke zouden kunnen leiden 
tot potentiering van de oestrogene effecten in vivo . Door deze additionele mechanismen van 
aan oestrogenen gerelateerde endocriene verstoring mee te nemen, gaat deze uitgebreide ITS 
verder dan in vivo oestrogeniteitsonderzoek door middel van de uterotrofe assay.
Hoofdstuk 8 geeft een discussie betreffende de selectie van in vitro testen voor de ITS, 
gebaseerd op de in vitro – in vivo correlatie, en ook rekening houdend met andere aspecten 
zoals kosten, snelheid, eenvoud, reproduceerbaarheid en toepasbaarheid bij grote aantallen 
monsters (“high-throughput” toepassingen). Concluderend laten de resultaten van dit 
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proefschrift zien dat een ITS die bestaat uit de U2OS ERα-CALUX, de gist bioassay voor 
oestrogenen en de ERα coregulator-bindingstest, een nauwkeurige voorspelling mogelijk 
maakt van de oestrogene effecten in vivo en mechanistisch inzicht verschaft. Door zowel de 
H295R steroidogenesetest als een reportergen-assay voor androgenen toe te voegen, stijgt 
de ITS zelfs uit boven in vivo oestrogeniteitsonderzoek, zoals uitgevoerd in de uterotrofe 
assay. De uitgebreide ITS, zoals gepresenteerd in dit proefschrift, maakt “high-throughput” 
screening en prioritering van chemicaliën op eenvoudige wijze mogelijk en blijkt ook in 
staat te zijn bij te dragen aan de verfijning, reductie en tot op zekere hoogte zelfs vervanging 
van het huidige proefdieronderzoek naar oestrogene effecten.
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